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Summary 
The work carried out in this thesis comprises two main sections: i) characterisation of the 
role of ICP34.5 and ORF P in HSV -1 replication; and ii) identification of cellular and 
viral proteins which interact with ORF P. 
A complication in the analysis of the role of ICP34.5 in the HSV -1 lifecycle is the 
presence of overlapping antisense genes, ORF OIP, which are also deleted in ICP34.5 
negative mutants. In 1991, MacLean, A. et ai, isolated 1716, a HSV -1 17+ ICP34.510RF 
OIP deletion mutant. This mutant has been demonstrated to have specific characteristics 
both in vitro and in vivo. To attribute characteristics which were originally attributed 
solely to ICP34.5 to each of the genes, a number of HSV -1 recombinant viruses that 
express ICP34.5 and ORF OIP independently were constructed, purified and 
characterised. In all recombinant viruses an expression cassette was inserted into the 
1716 UL431UL43.510cus containing the gene of interest under the control of the HSV-l 
gD promoter and f3 galactosidase in the opposite orientation. Recombinants 1622 and 
1625 express ICP34.5 and in both 1624 and 1624.5 ORF P is inserted in UL43 and 
UL43.5, respectively. Additionally, in 1625 ORF P is inserted in the non essential US5 
gene. 
Western blotting analysis of 1622 and 1625 infected BHK cells demonstrated at least an 
eight-fold increase in ICP34.5 levels compared to wild type 17+. In the recombinants 
1624, 1624.5 and 1625 no ORF P was detected, suggesting that these recombinants 
express low levels of ORF P, as the rabbit polyclonal sera used exhibited problems of 
detection with low amounts of ORF P from 17+ but not from the overproducing ts 
mutant in ICP4, tsK. Also, it is possible that the recombinants do not express ORF P. 
Summary 
As we were not able to detect ORF P from our recombinant viruses, we proceeded to 
look for its RNA. A band with the size expected for ORF P RNA of about 700 bp was 
detected in 1624, 1624.5, and 1625. The 700 bp ICP34.5 transcript was also detected in 
1622. 
Multicycle replication kinetics of the recombinants was analysed in three cell lines: 
BRK, 3T6 and SK-N-SH cells. In BHK cells all recombinant viruses with the exception 
of 1624 exhibited a similar growth pattern to 17+. In stationary state 3 T6 cells, 17+ grew 
well whereas 1716, 1624 and 1624.5 failed to grow. 1622 and 1625 also grew, although 
platauing at a maximum titre of 101 to 102 fold lower than 17+ with 1625 slightly more 
impaired than 1622. In SK-N-SH cells, 17+ grew well. This cell line is semi permissive 
for 1716 and 1624.5, exhibiting limited growth with a maximum titre 104 fold lower than 
17+. In agreement with its impaired growth in BHK cells, 1624 grew consistently 10 fold 
poorer than 1716 andI624.5. Both 1622 and 1625 grew similarly to wild type virus. 
Restoration of ICP34.5 function in both 1622 and 1625 was confirmed in vitro by the 
prevention of host cell protein synthesis shutoff in SK-N-SH cells. However, restoration 
of ORF P fails to prevent host cell protein synthesis shutoff. ICP34.5 seems to confer two 
functions of growth and maintenance of protein synthesis, with no apparent function in 
the in vitro viral lifecycle for ORF OIP. 
An alternative way to analyse the function of ORF OIP is to identify those cellular and 
viral proteins with which they interact. This was carried out for ORF P using GST 
pulldowns. A major problem faced in carrying out pUlldown experiments was the lack of 
expression of full length GST -ORF P fusion protein despite attempts to try and optimise 
this. A number of specific interacting proteins were detected. These proteins include at 
Summary 
least two viral and possibly one cellular protein with sizes of 27, 40 (viral) and 47 KDa 
(cellular). We then tried to identify these interacting cellular and viral gene proteins. Due 
to the previous association of ORF P with proteins involved in posttranscriptional control 
and its suggested role in HSV splicing, the pull downs were screened with ten available 
antibodies against cellular proteins with a role in posttranscriptional regulation of an 
approximate molecular weight to those identified and antibodies against HSV ICP27 and 
thymidine kinase. Of these, only SC35 was demonstrated to interact specifically with 
ORF P. We demonstrated that both SC35 and ORF P are located in the nucleus and tried 
to determine if ORF P interacts with SC35 in vivo by carrying out immunoprecipitation 
of infected BHK cell extracts. Unfortunately, SC35 was non-specifically 
coimmunoprecipitated by the ORF P antisera and we were unable to 
immmunoprecipitate SC35 with the SC35 antibody. Thus we were unable to determine 
by coimmunoprecipitation ifSC35 and ORF P interact in vivo. 
ORF P insertion into the virus has not been conclusively proven and there is no evidence 
of expression at all. Therefore the conclusions made with regard to growth curves etc 
may be incorrect. 1625 may be (are) unstable due to multiple insertion of the gD 
promoter. The recombinants need to be properly characterised to conclude if the actually 
contain/express ORF P by using purified ORF P fragment as a probe. 
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Chapter 1 Introduction 
1.1 The Herpesviridae family 
This family are double stranded linear DNA enveloped viruses which are widely distributed 
in nature. So far, 112 herpesviruses have been identified which infect mainly vertebrates 
especially mammals, including cattle, pigs and man (Comps and Cochennec, 1993; Roizman 
and Sears, 1993). 
1.2 Biological properties 
The following biological properties are shared by all herpesviuses. (i) They encode a large 
array of enzymes involved in nucleic acid metabolism, DNA synthesis and possibly 
processing of proteins. (ii) They encode several transacting factors which regulate the 
temporal expression of viral genes controlling the phase of infection (Cann, 1993). (iii) Both 
the synthesis of viral DNAs and the assembly of capsids occur in the nucleus. (iv) 
Production of infectious progeny virus invariably leads to cell death. (v) Infection leads to 
establishment of a latent infection in their natural host (Roizman and Sears, 1996). 
1.3 Classification: 
The current classification of herpesviridae is on the basis of their biological properties and 
divides them into three subfamilies, the aiphaherpesvirinae, the betaherpesvirinae and the 
gamaherpesvirinae (Roizman et al., 1981). 
1.3.1 Alphaherpesvirinae 
Members of this subfamily have a variable host range, relatively short replication cycle, 
rapid spread in culture, efficient destruction of infected cells and capacity to establish latent 
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infections primarily, but not exclusively, in sensory ganglia ofthe peripheral nervous system 
(PNS). Members of this subfamily include herpes simplex virus types 1 and 2 (HSV-1I2) 
and varicella zoster virus (VZV). 
1.3.2 Betaherpesv;r;nae 
These viruses are slow growing and may be cytomegalic (massive enlargment of infected 
cells), have a variable host range, a long reproductive cycle and infect cells slowly in culture 
and become latent in secretory glands and kidneys. Examples include human 
cytomegalovirus (HCMV). 
1.3.3 Gammaherpesv;r;nae 
These viruses infect and become latent in lymphoid cells. Viruses have tropism for either B 
or T lymphocytes where lytic or latent infection is frequently found without production of 
infectious progeny. Epstein-Barr virus (HHV5) infects B cells and is classified in the 
lyptocryptovirus genus. Human herpes virus 8, Kaposi's sarcoma-associated herpesvirus, 
infects T cells and is classified in the rhadinovirus genus (Greens ill et aI., 2000). 
1.4 Morphology 
The virion has a similar morphology in all herpesviruses which led to their classification into 
one family. The size of the virion is variable ranging from 120 nm to 300 nm in diameter. 
(Fig. I. I ). The virion consists of a core containing a double stranded linear DNA genome 
encased in an icosohedral capsid (Wildy ef al., 1960). An amorphous, sometimes 
asymmetric, tegument surrounds the icosohedral capsid (Roizman and Furlong, 1974). 
2 
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Glycoprotein --------... 
Membrane 
Tegument 
Capsid 
DNA 
Figure 1.1 Structure of HSV-1 virion 
Representation of virion morphology of herpesviridae, showing the outer 
envelope layer containing glycoprotein molecules, the tegument and icosahedral 
capsid surrounding the central core of double stranded DNA (Adapted from 
Rixon, 1993). 
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Surrounding the tegument is an envelope containing viral glycoprotein spikes on its surface 
(Spear and Roizman, 1972). The virion structure is reviewed in Rixon (1993). 
1.4.1 Core 
Herpesvirus DNAs are double stranded linear molecules, which can circularise immediately 
upon release into the host cell nuclei. DNA size and base composition are variable between 
different herpesviruses. DNA size ranges between 120 kbp and 230 kbp and base 
composition varies from 31 % to 75% G+C. Genomic size varies within all herpes viruses to a 
minimal but significant extent. Both variation in the copy number of terminal and internal 
repeated sequences and spontaneous deletions contribute to this variation (Roizman, 1996). 
Based on the presence and location of reiterated sequences, herpesviruses have been split 
into the six groups A-F (Davison, 1993; Roizman, 1996) (Fig. 1.2). 
1.4.2 Capsid 
The icosohedral capsid consists of 150 hexameric and 12 pentameric capsomeres. The 
hexomers occupy the faces and the edges of the capsid, while the pentamers are positioned 
at the vertices (Wildy et al., 1960; Zhou et al., 1994). The hexomer consists of six molecules 
of VP5, the major capsid protein, and the pentomer VP5 and 80-100 copies of VP26. A 
triplex structure made up ofVPI9 and VP23 co-ordinates the hexons in 3-fold symmetry and 
a fifth capsid protein VP24 projects into the interior (Rixon, 1993; Zhou et ai., 1994). 
Studies of HSV -1 capsid assembly have become more amenable with the development of an 
in vitro assembly system (Newcomb et al., 1994) and a recombinant baculovirus assembly 
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system in insect cells (Tatman et al., 1994). Three types of capsids A, B, and C can be 
isolated from HSV-l infected cells. A and C capsids are similar in protein content but only C 
capsids contain a genomic equivalent of DNA. The B capsid is composed of seven proteins 
VP5, VP19c, VP22a, VP21, VP23, VP24, and VP26 (Gibson and Roizman, 1972). A and C 
capsids have a similar protein content to B capsids but lack the scafolding proteins VP21 and 
VP22a (Rixon, 1993). 
1.4.3 Tegument 
The virion tegument is an electron dense material located between the capsid and the 
envelope and is composed of at least 20 distinct viral proteins (Aurelian et al., 1989). Its 
structure and the process by which it is acquired is poorly understood. Viral structural 
proteins known not to be a component of the capsid or envelope are assigned to the 
tegument (Rixon, 1993). Certain tegument proteins such as a-trans inducing factor (a-TIF, 
VP16 or UL48) and the virion associated host shut-off (vhs or UL41) are involved in 
initiation of infection (Batterson and Roizman, 1983; Read and Frenkel, 1983). 
1.4.4 Envelope 
The virion envelope has a trilaminar appearance in electron micrographs (Epstein, 1962) and 
is acquired from host cell membranes probabely the golgi or golgi derived membranes (van 
Genderen et al., 1994). The glycoprotein spikes contained in the envelope are approximately 
8 nm long and vary in number and relative amount between the different herpesviruses. HSV 
encodes 12 glycoproteins of which all but gL are found in the viral envelope (McGeoch et 
ai., 1988; Barnett et al., 1992). 
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The glycoproteins are named gB, gC, gD, gE, gG, gH, gI, gJ, gK, gL, gM and gN (McGeoch 
et ai., 1988; Spears, 1993). Glycoprotein B, gD, gH, gK and gL, are essential for virus 
replication in vitro (Cai et ai., 1988; Ligas and Johnson, 1988; Roop et ai., 1993; Hutchinson 
and Johnson, 1995). Six HSV-l glycoproteins are known to form stable complexes: gB and 
ge form homo-oligomers and gE, gH; gI and gL form the hetero-oligomers gE/gI and gH/gL 
(Claesson-Welsh and Spear, 1986; Johnson and Feenstra, 1987; Hutchinson et al., 1992; 
Handler et ai., 1996). In addition, gM and gN form a complex in several herpesviruses (Jons 
et ai., 1998). These glycoproteins playa role in several parts of the viral life cycle namely 
attachment, penetration, cell to cell spread, cell fusion, envelopment and egress and also in 
immune invasion. Both gB and gC are thought to have a role in viral adsorption (Herold et 
ai., 1994). Glycoprotein B (Cai et al., 1988), gD (Ligas and Johnson, 1988) and gH/gL 
(Roop et ai., 1993) have been shown to be essential for virus penetration. Glycoprotein K 
may play a role in both envelopment and subsequent egress of infectious particles 
(Hutchinson and Johnson, 1995). Glycoprotein B, gD, gH/gL and gE/gI have also shown to 
be involved in cell-cell spread. 
1.5 Human herpesviruses 
Eight herpesviruses infect humans as their primary host and cause a wide variety of diseases 
ranging from minor lesions to viral encephalitis. These viruses may cause severe infections 
in immunocompromised individuals (Whitley, 1996). The human herpesviruses and the 
diseases caused are shown in table 1.1. 
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Herpesvirus Class Illness 
Herpes simplex Causes 80-95% of oral lesions (cold sores), 
virus-l ex 30- 50% of genital lesions, and rarely: conjunctivitis, 
(HSV-l) (HHV-l) herpetic whitelaw, keratitis, and encephalitis. 
Herpes simplex Causes 5-20% of oral lesions (cold sores), 
virus 50- 70% of genital lesions (life threatening for infected 
(HSV-2) (HHV-2) ex neonates) and rarely: conjunctivitis, herpetic whitelaw, 
keratitis, and encephalitis. 
Varicella zoster Primary infection: chicken pox (rash) appears 14-15 days 
virus (VZV) post-infection, accompanied by fever. Reactivation: 
(HHV-3) ex shingles; lesions appear at the relevant dermatone often 
accompanied by extreme pain which can last for months 
after lesions have healed. 
Epstein Barr virus Primary infection in children is often asymptomatic. In 
(EBV) (HHV -4) older children and adults is infectious mononucleosis 
y (glandular fever). Associated with Burkitt's lymphoma 
and nasopharyngal carcinoma. 
Human Primary infection: enlargement and fusion of 
cytomegalovirus macrophages. Often asymptomatic though can be fatal 
(HCMV)(HHV -5) ~ especially in new borns. Infection is problematic in 
immunocompromised individuals where symptoms 
include gastro-enteritis and retinitis. A major cause of 
congenital birth defects. 
Human Infants rash, exanthem subitum. 
herpesvirus 6 ~ 
(HHV-6) 
Human Febrile illness. 
herpesvirus 7 13 
(HHV-7) 
Kaposi's sarcoma Associated with Kaposi's sarcoma, a vasculated nodular 
associated y skin lesion. 
herpesvirus 
(KSHV) (HHV -8) 
Table 1.1 Human herpesviruses. The eight herpesviruses known to infect humans, 
classification and the diseases associated with them. 
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1.6 Herpes simplex virus (HSV) 
Both HSV-l and HSV-2 belong to the subfamily alphaherpesvirinae and the genus 
simplexvirus. HSV-l and HSV-2 have 47%-50% sequence homology and their genetic maps 
are co-linear. Their differences are in restriction endonuclease (RE) cleavage sites, apparent 
size of viral proteins, antigenic determinants, plaque size and growth in cultured cells 
(Roizman and Sears, 1996; Roizman et aI., 1984). Work in this thesis considers infection 
with the HSV -1 Glasgow strain 17+ (Brown et al., 1973). 
1.7 Clinical features 
This virus is predominantly associated with oral lesions (cold sores) and also with some 
cases of genital herpes lesions (Kinghorn, 1993). Lifelong latency is established in the 
sensory ganglion of the PNS. HSV-l occasionally causes serious diseases such as herpetic 
whitelaw, eczema, keratoconjunctivitis and encephalitis (Whitley, 1996). 
1.8 Genome 
The HSV -1 genome is 152 kbp in size, encodes about 84 polypeptides, and has an unusually 
high G+C content (McGeoch ef al., 1985, 1986, 1988; Perry and McGeoch, 1988). It 
consists of two covalently linked unique regions, the unique long (Ud and unique short 
(Us). The UL region is 107.9 kbp and the Us region 13 kbp long. The unique sequences are 
flanked by inverted repeats, RL (9 kbp) and Rs (6.5 kbp) (McGeoch et al., 1988). RL and Rs 
are not related in sequence apart from the "a" sequence (400 bp) located at the genome 
termini. One copy of the "a" sequence is located at the S terminus, whereas the L terminus 
may have more than one copy. The "a" sequence is also present at the L-S junction as an 
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inverted repeat and again can be present as more than one copy (Wagner and Summers, 
1978). The two unique sequences can invert relative to each other via the repeats such that a 
population ofHSV DNA molecules consists of four equimolar isomers (Fig. 1.3). 
1.9 Lifecycle 
The HSV-l lifecycle consists of both lytic and latent phases. 
1.10 Lytic replication 
Here the virus enters a host cell, replicates in it and eventually releases progeny virions into 
the surrounding medium (Roizman and Sears, 1996). This cycle consists of attachment, 
entry, gene expression, DNA replication, capsid assembly, maturation and egress, 
respectively, resulting in the death of the host cell. The viral lifecycle is approximately 18-
20 h in fully permissive tissue culture cells (Roizman and Sears, 1996). Two types of HSV 
related particles are produced in infected cells: (i) the infectious virion; and (ii) L-particles 
which lack the nucleocapsid and viral DNA and are non infectious (Szilagyi and 
Cunningham, 1991). 
1.10.1 Adsorption/penetration 
Attachment/entry are the most important stages of viral infection. During attachment, 
glycoproteins on the virion envelope (1.4.4) interact with specific cellular receptors which 
leads to binding to the cell surface. 
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Figure 1.3 Schematic diagram of HSV-l genome 
The unique DNA elements, UL and Us are covalently linked and flanked by inverted 
repeats (boxes). The "a" sequence is represented by a white box and is present at each 
end of the genome and in an inverted orientation at the L-S junction. The Land S regions 
can invert relative to each other forming four isomers (Hayward et al., 1975). The 
orientation of the 4 isomers is shown by the arrows. 
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1.10.2 Gene expression 
Gene expression occurs in a highly regulated order in three phases. The mRNAs produced 
during each of these phases corresponds to three classes of polypeptides: immediately early 
(IE), early (E), and late (L) (Roizman et al., 1978; Clements et al., 1977). 
1.10.3 IE genes 
Expression of IE genes can proceed without de novo viral protein synthesis, and is 
stimulated by the action of the virion protein a. -TIF (also known as Vmw 65 or VP16). Four 
of the five IE genes products are responsible for the regulated expression of E and L gene. 
These are ICP22, ICP4, ICPO and ICP27. The last 3 in particular are key regulators. The 
fifth IE gene, ICP47 is involved in regulating the host immune response (1.11.3). 
(i) ICP4 
ICP4 is an essential regulator and transactivator gene and is required for expression of E and 
L genes. It binds to DNA through a strong consensus binding site (Faber and Wilcox, 1986), 
but subsequent reports have revealed numerous HSV-I binding sites which do not 
correspond to the previously identified consensus sequences (Michael and Roizman, 1989). 
The various forms of ICP4 differ in their affinity of DNA binding (Michael et al., 1988). 
Dephosphorylated ICP4 is reported to bind to IE promoters, while the phosphorylated form 
binds to E and L promoters (Papavassiliou et a/., 1991). Interaction of ICP4 with TAT A 
binding protein and the transcription complex is further evidence of ICP4 involvement in 
transactivation of HSV -1 genes (Smith et al., 1993). Binding of ICP4 at its own transcription 
initiation site leads to autoregulation (Roberts et al., 1988). As consensus ICP4 binding sites 
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are also found in the promoter of ICPO, ICP4 may also downregulate expression of ICPO by 
binding to its promoter (Faber and Wilcox, 1986). 
(ii) ICPO 
ICPO is a non-essential protein but defects in this protein delay expression of E and L genes 
and impair viral replication (Chen and Silverstein, 1992). From transient expression 
experiments, ICPO is thought to enhance the activity of ICP4, ~s well as possibly 
transactivating gene expression in its own right (Everett, 1984; O'Hare and Hayward, 1985; 
_. ___ .", __ .. _n ._~ __ ~ __ ' ... ~_,_~. ___ ~. _.~"' 
Quinlan and Knipe, 1985). 
(iii) ICP22 
This gene appears to be nonessential for HSV-l infection. Deletion oflCP22 has no effect 
on viral DNA synthesis. Viral mutants in this gene replicate in Vero and Hep-2 cells as 
effectively as the parent virus. However in BHK, RAT -1 cell lines and human embryonic 
lung cells the plating efficiency is reduced and yield is multiplicity dependent. Moreover in 
these cells E protein synthesis is delayed and the expression of L proteins and the number of 
capsids detected in the infected cells is reduced (Sears et al., 1985). 
(iv) ICP27 
ICP27 is an essential IE protein which is required for HSV-1 late gene expression at both the 
transcriptional and posttranscriptionallevel. 
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At the transcriptional level, ICP27 up or down regulates both viral and cellular mRNA 
transcription either in conjunction with ICP4 or by acting upon it and a physical interaction 
of these two proteins occurs (Pangiotidis et al., 1997). Other evidence suggests that ICP27 
can inhibit the action of proteins which are involved in transcription (Birney et al., 1993). 
At the posttranscriptional level, ICP27 has a role in the processing of pre-mRNA and 
nucleocytoplasmic transport of viral intronless transcripts. ICP27 cause unspliced pre-
mRNAs to accumulate in the nucleus and reduces cellular mRNA levels (Hibbard and 
Sandri-Goldin, 1995). ICP27 shuttles from the nucleus to the cytoplasm (Phelan and 
Clements, 1997) and has a role in the export of viral mRNAs. Sandri-Goldin (1998) 
suggested that ICP27 binds and shuttles with all classes of intronless HSV-l transcripts. 
Recent evidence suggests that ICP27-mediated viral RNA export requires cellular mRNA 
export factor, REF and TAPINXFI (Koffa et al., 2001). 
Co-localization suggests that ICP27 interacts with one or more of the components of the 
splicing machinery. This is evidenced by immunoprecipitation of ICP27 by anti-SM 
antibody (Sandri-Goldin and Hibbard, 1996). Recently, it has been demonstrated that ICP27 
interacts with the essential splicing factor SAP 145 which leads to inhibition of splicing. This 
inhibition could facilitate the nuclear export of viral mRNA and contribute to host cell 
shuttoff (Hardwicke and Sandri-Goldin, 1994; Hardy and Sandri-Goldin, 1994; Bryant et aI., 
2001). 
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(v) ICP47 
This non-essential protein is not involved in the regulation of viral gene expression but down 
regulates the host immune response (1.11.3). 
1.10.4 Induction of E genes 
The sequence elements for expression of E genes consist of a TAT A box, a cap site 
(McKnight and Tijan, 1986), and binding sites for cellular factors. For example, the HSV-I 
thymidine kinase (TK) gene contains binding sites for SP I and CCAA T binding protein 
(CBP), clustered upstream of the TA TA box (Pande et aI., 1998). ICP4 is almost certainly 
involved in transactivation of E genes but the mechanism is not clear Viral mutants in ICP4 
do not produce any E genes (Dixon and Schaffer, 1980; Watson and Clements, 1980). The 
binding of ICP4 to E gene promoters requires cellular factors and is determined by both its 
1.10.5 Induction of L genes 
The control of L gene expression is the least well understood and is likely to vary from gene 
to gene. Analyses of several genes have suggested that sequences required for efficient 
expression include the TAT A box, and extend into the 5' transcribed non-coding domain 
(Dennis and Smiley, 1984; Everett and Dunlop, 1984; Johnson et al., 1986; Guzowski and 
Wagner, 1993; Wagner et aI., 1998). Additional sequences downstream from the TAT A box 
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appear to be required for expression of L genes (Greaves and O'Hare, 1989; Wagner et el., 
1998). 
Embedded in both the promoter and 5' non-coding regions are ICP4 binding sites (Michael 
et al., 1988). The role of these sites and ICP4 involvement is unclear. In infected cells, ICP4 
is required but not sufficient for efficient and correctly regulated expression of L genes. A 
key observation in understanding expression of L genes has been the observation that 
deletions in the 5' transcribed non-coding domain of a L gene may cause it to be expressed 
as an IE gene (Roizman and Sears, 1996). This can be explained in two ways; either the 
non-coding domain contains a site that allows binding of a transactivating repressor or the 
region may form a secondary structure which affects expression of L genes. Either way, the 
data suggests that the 5' transcribed region binds a repressor of some sort. This repressor 
must preclude expression of L genes under conditions which allow expression of IE and E 
genes and bind an activator which allows their expression in the absence of the repressor. As 
L gene expression cannot occur in the absence of viral DNA synthesis, it has been suggested 
that replication removes the block and/or produces/modifies the transactivating factor. 
Alternatively removal of the block may be essential to DNA replication. 
1.10.6 DNA replication 
DNA circulizes in the nucleus and undergoes initial theta replication, then DNA replication 
occurs by a rolling circle mechanism leading to the accumulation of head to tail DNA 
concatemers at specific sites, termed viral replication sites, in the nucleus which are defined 
by host cell nuclear architecture (de Bruyn Kops and Knipe., 1994). The DNA replication 
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mechanism is conserved in all alphaherpesviruses. In HSV-l a set of seven viral genes are 
necessary and sufficient for replication (Challberg, 1991). 
Viral replication typically starts at about 2 h pj and peaks between 8-10 h post infection. It 
is initiated from one of three origins (ori) of replication, one in the middle ofUL and the two 
others in TRs and IRs, via binding of the ori binding protein UL9. The helicase/primase 
complex (UL5, UL8 and UL52 gene products) subsequently associates with the UL9/ori 
complex and the hydrolysis of ATP creates an initiation bubble which permits association of 
the DNA polymerase and DNA binding protein complex (UL30IUL42). DNA synthesis is 
continuous along one strand and discontinuous along the lagging strand with the major DNA 
binding protein UL29 maintaining the growing forks. 
Other virally encoded enzymes are also involved in nucleic acid metabolism; e.g. thymidine 
kinase (TK), ribonucleotide reductase (RR), uracil-DNA glycosylase and dUTPase 
(Roizman and Sears, 1996). None of these are essential as they can be complemented by 
host cell factors except in non dividing cells such as neurons (1.13). 
1.10.7 Transcription 
HSV-l genes are transcribed by the host cell RNA polymerase II (RNA Pol II) (Costanzo et 
al., 1977). Like the cellular mRNAs, viral mRNAs are capped, methylated and 
polyadenylated. Methylation is more common in E transcripts than Lones (Hann et al., 
1998). Use of alternative polyadenylation sites may be a mechanism of regulating gene 
expression (McGregor et al., 1996). Unlike cellular mRNAs, most genes lack introns with 
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only four viral transcripts ICPO, ICP27, ICP47 and UL15 being spliced. Transcripts sharing 
5' and particularly 3' termini have been described (Wagner, 1985) and several genes appear 
to have multiple transcription initiation sites (Murchie and McGeoch, 1982). 
1.10.8 Capsid assembly 
Following DNA replication, late gene expression and the production of all the necessary 
components, capsid assembly begins in the cytoplasm and is completed within the nuclear 
compartment. In the cytoplasm a number of interactions occur. VP5 interacts with preVP22a 
and VP26 whilst VP19C interacts with VP23 (Homa and Brown, 1997). Protein-protein 
interactions occur between the viral structural and scaffold proteins leading to the assembly 
of spherical procapsids (Newcomb et al., 200 I). The viral DNA is packaged and cleaved 
into genome length units directed by signals in the terminal "a" sequence (Stow et al., 1983; 
Hodge and Stow, 2001). VP22a is expelled and simultaneously the capsid undergoes a 
structural transition to an icosahedral shape (Rixon, 1993). Infected cells contain three forms 
of capsids, A, B, and C which can be resolved via sucrose density gradient 
ultracentrifugation. The mature infectious virion is produced from the C-capsid which 
contains viral DNA. B-capsids do not contain DNA and are the precursor of C-capsids. 
VP22a occupies the inner space of the B capsid and functions as a scaffold for assembly of 
the icosahedral capsid shell. A-capsids do not contain DNA and cannot form infectious 
particles (Gibson and Roizman, 1972; Rixon, 1993). 
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1.10.9 Maturation/release 
Budding through the inner nuclear membrane and acquiring an envelope, the capsid is 
released into the perinuclear space (Granzow et ai., 2001). Until recently, it was not known 
whether the virion retains this envelope or acquires a fresh envelope from a cytoplasmic 
compartment during maturation and egression. In other alphaherpesviruses such as 
pseudorabies virus (PRV) , the final envelope is acquired in a cytoplasmic compartment, 
probably the golgi. Recent evidence suggests a similar situation occurs with HSV. 
Envelopment occurs as the capsid buds through the outer nuclear membrane, followed by re-
envelopment in a post-golgi compartment (Van Genderen et ai., 1994; Skepper et al., 2001). 
The virion is thought to exit via the secretory pathway (Rixon, 1993). 
1.11 HSV factors involved in immune modulation 
Different viruses have evolved a variety of strategies to modulate the host immune response. 
HSV -I has evolved several mechanisms to evade or counteract both the innate and specific 
host immune response. HSV-I glycoproteins gC, gE and gI and ICP47 act to protect virions 
and virus infected cells from several host-immune attack mechanisms. 
1.11.1 gC 
gC acts as a receptor for complement component C3b and hence is though to protect the 
virus from complement mediated lysis (Friedman et al., 1984). 
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1.11.2 gEII 
Glycoprotein E can act as a receptor for the Fc receptor of IgG (Baucke and Spear, 1979). In 
addition, a complex of gElgI can also act as a high affinity receptor for the Fc region of IgG. 
gE forms a heterodimer with gI and both of them are co-precipitated from infected cell 
extracts using nonimmune rabbit or human serum, or purified nonimmune IgG (Johnson and 
Feenstra, 1987; Johnson et al., 1988). It has been postulated that HSV gEII prevents 
activation of the classical complement pathway by binding to the Fc region of antiviral IgG 
(Frank and Friedman, 1989). 
1.11.3 ICP47 
At least one HSV-l gene, ICP47 acts to disrupt the presentation of antigenic peptides by 
MHC class I molecules on the surface of infected cells and this is thought to prevent 
recognition and lysis by cytotoxic T-cells (CTLs). ICP47 binds to a human protein transport 
associated with antigen processing (TAP) and prevents peptide translocation into the 
endoplasmic reticulum (York et al., 1994; Fruh et al., 1995; Hill et al., 1995). 
Recent work has suggested that HSV-I has also evolved a mechanism to inhibit or reduce 
the amount of MHC class II on the surface of infected cells. Preliminary evidence suggests 
that both the virion host shutoff protein (vhs) and ICP34.5 act to block MHC class II 
presentation on the surface of infected cells (Trgovcich et al., 2002). 
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1.12 Latency 
HSV-l and -2 cause two types of infections in humans and experimental animals, lytic 
(1.10) and latent (reviewed in Roizman, 1996). Replicating in epithelial tissue at the site of 
primary infection, HSV infects innervating axonal termini of sensory neurons and is 
transported retrogradly to the nueronal cell body (Stevens and Cook, 1971; Stevens et al., 
1987), where it establishes a latent infection in the sensory ganglia that innervate the initial 
replication site. At least some of the initially infected neurons support virus replication. 
However, within a few days, no free virus can be detected within the ganglia and latency has 
been established (Stevens and Cook, 1971). The precise sequence of events is unclear. It 
seems that in some neurons the virus replicates and destroys the neurons whereas in others 
the virus undergoes an abortive infection and establishes latency (Stevens et al., 1987). 
Occular infection leads to latent infection in the trigeminal ganglia (TG) (Kristensson et al., 
1978). Latency is established in the appropriate dorsal root ganglia (DRG) following ear, 
flank, and footpad infection, (Stevens and Cook, 1971; Hill et al., 1975; Harbour et al., 
1981). Latency can be separated into three stages: establishment, maintenance and 
reactivation. 
1.12.1 In vivo latency models 
Experimental HSV-l infection in the mouse is apparently similar to that in humans. During 
primary infection, viral replication at the surface is detectable for a 10-12 day period. Within 
24 hpj. virus is transported to the innervating sensory ganglia, where peak titres are 
achieved around 3 to 4 days pj, and infectious virus becomes undetectable within the 
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ganglia by 7 to 9 days p.i. The establishment of latent infections occurs during this 
replicative phase (Stevens et al., 1987). To investigate latency in vivo, mouse footpad 
(Stevens and Cook, 1971), mouse eye (Kristensson et 'al., 1978), mouse ear (Harbour et al., 
1981), rabbit eye (Nesbum et al., 1977) and guinea pig vagina (Scriba, 1975) models have 
been developed and utilised. 
1.12.2 Establishment 
Little is known of the establishment phase since the neurons in which the virus replicates 
during the first several days after infection obscure the events taking place in the neurons 
where latency is being established (Stevens et ai., 1987). It has been suggested that HSV-l 
latency can be established without detectable lytic gene expression (Lachmann et ai., 1999) 
and during latency transcription of the genome, with one exception, is prevented in neurons. 
In a lytic infection, transcription of IE genes is stimulated by the action of VP16, a major 
component of the HSV tegument (reviewed by O'Hare, 1993). VP16 acts through the target 
sequence T AA TGART which is present in at least one copy in all HSV IE promoters. 
TAATGART is a binding site for a cellular protein, OCT1 (Sturm et al., 1988). VPl6 and an 
additional cellular protein, HCF, bind to the Oct-II TAA TGARA T complex and stimulate 
transcription of IE genes. During the establishment of latency it has been suggested that the 
blockage in virus replication occurs at the level of expression of IE gene products. This 
hypothesis is supported by the behaviour of in 1814, a HSV -1 mutant with a mutation in 
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VP16 that abolishes its interaction with OCT-l and HCF, resulting in significantly reduced 
IE gene expression (Ace et at., 1989). Although, this mutant replicates poorly both in tissue 
culture cells and at the site of inoculation in mice, it establishes latency in at least as many 
cells as found with wild type HSV-l (Steiner et at., 1990; Valyi-Nagi et at., 1991, 1992; 
Ecob-Prince et at., 1993). This suggests that a blockage in IE gene expression causes a 
predisposition for the virus to establish latency and is in agreement with the hypothesis that 
the natural block is at the IE expression level. In a wild type infection, failure of 
transactivation of IE transcription in neurons could result either from a lack of VP 16 or from 
a lack of cellular factors Oct-l and HCF. One hypothesis is that the virus does not carry 
VP16 in the tegument into some neuronal nuclei during transport along the axon (Roizman 
and Sears, 1987; Kristie and Roizman, 1988). Alternatively, it has been proposed that other 
members of the Oct family, rather than Oct-I, are present in some sensory neurons (He et 
at., 1989). These proteins can bind to the TAATGART elements but do not interact with 
VP16. Thus these other Oct proteins might compete with Oct-l for TAATGART binding 
and prevent formation of the VPI6/0ct-1IHCF complex and thus repress IE transcription. 
1.12.3 Maintenance 
No replicating virus can be detected in the neuron during the maintenance state. Viral DNA 
is maintained in an episomal form (Rock and Fraser, 1983; Mellerick and Fraser, 1987) and 
only a small region of the genome is transcribed to produce LA Ts (Stevens et at., 1987). 
Within an individual latently infected neuron the viral gene copy number is variable ranging 
between 10-1000 per cell. The higher the viral input titre, the more neurons in which latency 
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is established. and the greater the number of viral genome copies per cell (Sawtell, 1997). 
Typically, by in situ PCR 4.8% of neurons harbour latent HSV DNA. However, only 1.6% 
of neurons are LAT positive, suggesting that not all latently infected neurons express LA T 
(Mehta et al., 1995). 
1.12.4 Latency associated transcripts (LA Ts) 
A major focus of investigation into genes controlling the establishment, maintenance and 
reactivation from latency has been the LA Ts, a family of transcripts arising from the HSV 
inverted repeats flanking the UL sequence and therefore present in 2 copies per viral genome 
(Pemg et al., 1996, Stevens et al., 1987) (Fig. 1.4 ). The LAT transcripts overlap the ICPO 
and ICP34.5 genes in an antisense direction. These transcripts are the only viral transcripts 
detectable during a HSV latent infection (Stevens et al., 1987; Rock et a/., 1987). The LATs 
consist of abundant 2 and 1.5 kbp transcripts and a less abundant 8.3 kbp transcript. The 8.3 
kbp LA T is a cytoplasmic polyadenylated precursor RNA. Derived from the 8.3 kbp 
product, the 2 11.5 kbp LATs are nuclear, nonpolyadenylated, stable introns that overlap 
ICPO. (Fraser et al., 1992; Farrell et at., 1991). The HSV-l 2 kb LAT contains three ORFs 
(Wechsler et al., 1989). These ORFs are conserved both positionally and in sequence in all 
HSV-l strains but in HSV-2 only positionally with no sequence conservation (Coffin et al., 
1998; Krause et al., 1991). No protein expression from these ORFs has yet been detected in 
HSV -1 latently infected neurons (Thomas et al., 1999a). In contrast, in the related 
alphaherpesvirus bovine herpes virus-I, (BHV -I), LA T expresses a 41 KDa protein in 
neurons (Hossain et ai., 1995). 
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However, recent work has demonstrated that constitutive expression of the largest LAT ORF 
aHows replication of wild type HSV -1 in semi permissive neuronal cell lines, complements 
lacks of ICPO (Thomas et al., 1999a) and overcomes repression of exogenous promoters 
introduced into the HSV-l genome which normaHy occurs in the absence of IE gene 
expression (Thomas et al., 2002). When an epitope tagged LAT ORF, LATmycHis, is 
expressed it forms punctuate structures in the infected cell nucleus reminiscent of the 
structures formed by ICPO. These are associated with the appearance of a phosphorylated 
form of the protein and are formed adjacent to, or around the edges of, viral replication 
compartments (Thomas et al., 2002). These properties suggest that the HSV-l LAT ORF 
protein is biologically functional and that the tightly regulated expression of this protein may 
be important in vivo, possibly during reactivation (Thomas et al., 2002). 
Two LA T promoters have been identified LAP 1 and LAP2 (Fig. 1.4 ). LAP 1 is a TAT A box 
containing promoter situated at the 5' end of the 8.3 kb LAT 700 bp upstream of the 2 kb 
intron. In vitro the LAP 1 TAT A box plays an essential role in transcription initiation (Soares 
et al., 1996; Farrell et al., 1991 ) and is required for short term expression in latently 
infected neurons (Margolis et al., 1993). LAP2 is located between LAP1 and the 5' end of 
the 2 kb LAT (Soares et al., 1996; Goins et al., 1994). LAP2 is required for maintenance of 
long term expression in neuronal cells (Lachmann and Efstathiou, 1997; Dobson et al., 
1995). 
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The role of the LA Ts in latency is not known. As the 2 kb LA T is complementary to a part 
of the ICPO mRNA, it has been suggested that it influences and maintains latency by down 
regulating ICPO through an antisense mechanism (Farrell et al., 1991; Stevens et al., 1987). 
In dual transfection assays, expression of the 2 kb LA T has been shown to reduce ICPO 
transactivation (Farrell et al., 1991). This hypothesis was strenghtened when it was found 
that ICPO mRNA levels were elevated in BHK cells infected with viruses unable to make 
the 2 kb LAT (Arthur et al., 1998). However, in contrast Chen et al (2002) found that in 
mouse ganglia latently infected with a LAT deletion mutant the level of ICPO transcripts 
was not increased. Alternatively transcription of the LA T locus may keep the genome in a 
transcriptionally competent state during latency such that reactivation is possible (Spivack et 
al., 1991). Although LATs transcription is not detectable in all latently infected sensory 
neurons during latency, it is probable that not all neurons reactivate and it may be that LAT 
negative neurons do not (Preston, 2000). LATs may have a role in efficient establishment of 
latency (Sawtell and Thompson, 1992; Thompson and Sawtell, 1997). 
Although reactivation does not absolutely depend on the presence of LA Ts (Preston, 2000), 
in some cases deletion of LA Ts reduces the capacity of the virus to reactivate following 
explantation of neurons. Thus LA T may be required for high level reactivation from latency. 
(Block et al., 1993; Hill et al., 1990; Bloom et al., 1996). The region of LAT associated with 
decreased reactivation has been mapped to a sequence in the 5' end of LA T (Bloom et al., 
1996; Hill et al .,1996; Thompson and Sawtell, 1997). Some reports indicate that sequences 
containing the 2 kbp LA T can protect neurons from apoptosis. This antiapoptotic function of 
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LA T may be a mechanism to enhance survival of latently infected neurons and hence 
enhance reactivation (Pemg et ai, 2000, 2002; Inman et al., 200 I; Thompson and Sawtell., 
2001). Thus, at least one function of LA T may be to promote neuronal survival during the 
maintenance of a latent infection. Other studies have suggested that viral functions that 
repress lytic gene expression in vivo reside within the LA T domain, although the effectors of 
these functions have not been identified (Garber et at., 1997; Chen et al., 1997). 
Although the exact function of LATs are not known, is not absolutely required for the 
establishment of latency or reactivation. However, it may be required for optimum 
establishment of latency and reactivation. 
1.12.5 Reactivation 
Once HSV latent infection is established in neurons of sensory ganglia, recurrent disease can 
occur as a consequence of reactivation of latent virus from these cellular reservoirs (Stevens 
and Cook, 1971). Reactivation occurrs in only a small fraction of the viral DNA containing 
neurons (Preston, 2000). ICPO is required for both efficient establishment of and 
reactivation from latency (Halford and Schaffer, 2000) and latent genome copy number 
strongly correlates with the ability to reactivate in vivo (Sawtell et al., 1998). 
To investigate the mechanism of reactivation, several in vitro and in vivo models have been 
developed. In the most widely used in vitro reactivation model, explantation of the HSV 
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latently infected ganglia leads to reactivation of the virus in culture. This method is more 
probably a measure of the amount of latent virus than reactivation per se (Trousdale et aI., 
1991). Using several animal models, in vivo reactivation models have been developed. These 
models give a more comprehensive analysis of virus reactivation. Once latency is 
established, the latent virus can either spontaneously reactivate or be induced to reactivate. 
(i) Spontaneous reactivation 
Periodic spontaneous shedding of virus occurs after infection of rabbits and guinea pigs. 
After vaginal inoculation with HSV, spontaneous reactivation periodically occurs in guinea 
pigs (reviewed by Wagner and Bloom, 1997). Spontaneous reactivation had been reported 
following HSV ocular infection of rabbits (reviewed by Wagner and Bloom, 1997; Pemg et 
al., 2002). Spontaneous shedding does not occur in mice. 
(ii) Induced reactivation 
Several different methods have been developed to induce reactivation. In the mouse model, 
Sawtell and Thompson (1992) have developed a hyperthermic based induced in vivo 
reactivation model. Reactivation has been induced in HSV-I infected mice following 
injection of cadmium (Fawl et al., 1996). Reactivation in both rabbit and mouse eye models 
has been induced by UV light (Coen et al., 1989) or iontophoresis of adrenalin (Willey et 
al., 1984; Trousdale et al., 1991). 
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1.12.6 In vitro latency models 
To attempt to understand the molecular mechanisms of latent HSV infection, several in vitro 
cell culture systems have been developed and utilized. In general, latency is established by 
infecting cells with virus in the presence of inhibitors of virus replication or at a 
supraoptimal temperature (O'Neill et al., 1972; Wigdahl et al., 1981, 1982, 1983). Removal 
of the replication inhibitor or transfer to a lower temperature may result in spontaneous 
reactivation. Alternatively, superinfection of cells with viruses that express ICPO (Harris et 
al., 1989) or with HSV-l temperature sensitive mutants at 38.50C (Russell et al., 1986) has 
resulted in reactivation. 
An in vitro latency system for HSV -2 had been developed. In this system, to suppress viral 
replication, human foetal lung (HFL) cells were infected with virus at a supraoptimal 
temperature, 42°C, followed by transfer of the cells to 37°C. Reactivation occurred following 
superinfection of cells with HSV-l temperature sensitive mutants at 38.SoC (Russell and 
Preston, 1986). Using the in vitro latency model described above, mutant virus in 1814 
(1.12.2) was retained in HFL cells following infection at low multiplicity of infection (m.o.i) 
after incubation at 42°C. It was proposed that lack of VP16 function predisposses HSV to 
latency, resulting in the retention of the genome similar to that found in vivo (Harris and 
Preston, 1991). Reactivation occurred by superinfection of the mono layers with viruses that 
express ICPO (Harris et aI., 1989). 
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1.13 HSV pathogenicity 
HSV-1 and HSV-2 cause a variety of diseases ranging from benign superficial cutaneous 
lesions to life threatening encephalitis (Whitley, 1985). A number of genes control HSV-1 
pathogenicity. Any alteration in a virus gene which impairs replication in vitro will also 
affect the performance of the virus in vivo and so all essential genes could be considered 
virulence genes. However, here I am only dealing with genes whose deletion can abolish 
virulence in vivo but has a minimal effect in tissue culture. Identification of these genes is 
important in understanding the fundamental mechanism by which HSV causes disease in 
humans. The genes involved in HSV -1 pathogenicity can be classified into several broad 
categories. 
One group is glycoproteins which play an important role at the early stages of the virus 
lifecycle (i.e. adsorption and penetration) and might be expected to also be relevant in vivo. 
However, HSV-l (and HSV-2) gC mutants have been shown to be highly virulent following 
peripheral or intracerebral inoculation (Dix et al., 1983; Sunstrum et al., 1988). Both HSV-l 
strains (Ang) and (KOS) are completely non-neurovirulent following inoculation via the 
mouse footpad (Kumel et ai., 1982; Kaemer et al., 1983; Thompson et ai., 1986), but are 
neurovirulent following intracranial inoculation. Thus there appears to be a defect in 
neuroinvasiveness. Following passage in the mouse brain, variants of HSV-l (Ang) were 
isolated which were neurovirulent following footpad inoculation. The neuroinvasiveness of 
these isolates was associated with a single base change in gD (Izumi and Stevens, 1990). In 
HSV-l (KOS) 2 loci are required for complete restoration of a neuroinvasive phenotype. 
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One of these is a single base change in gB which significantly affects neurovirulence 
(Yuhasz and Stevens, 1993). 
Although gEl! are non essential for HSV replication in tissue culture cells such as BHK-21, 
they are required for neuroinvasiveness in mice following peripheral inoculation (Balan et 
al., 1994) and the gEl! heteroligomer is required for efficient neuron-to-neuron transmission 
in rats (Dingwell et al., 1995). Meigner et al (1988) demonstrated that a gE- mutant was not 
significantly impaired in neurovirulence following intracerebral inoculation of mice. 
Glycoproteins Ell are also important in the pathogenicity of the closely related 
alphaherpesvirus PrV. Deletion ofgE and gI impairs spread ofPrV compared to the parental 
strain by affecting transneuronal transfer of PrV (Kritas et al., 1994; Babic et aI., 1996). 
Another group of genes with a role in pathogenicity are those involved in DNA replication. 
These genes are essential with their deletion abolishing replication in vitro. However, there 
are some point mutants in these genes which have little effect in vitro but abolish replication 
in vivo. Using 3 distinct DNA polymerase mutants in a mouse ear model, Field and Coen 
(1986) showed that although these mutants exhibited no significant difference in replication 
kinetics compared to the wild type virus at peripheral sites (ear pinna and flanks), no 
neurological involvement was observed. Following intracerebral inoculation these DNA 
polymerase mutants were highly attenuated for pathogenicity (Larder et al., 1986). 
Another group is genes involved in nucleotide metabolism e.g TK and ribonucleotide 
reductase (RR). None of these genes are essential in tissue culture (Cameron et al., 1988; 
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Efstathiou et al., 1989; Goldstein and Weller, 1988a, b) with cellular enzymes substituting 
for the virus enzymes in dividing cells. HSV-l TK- mutants are less virulent than wild type 
virus and do not replicate in the TG (Field and WiIdy, 1978; Tenser et al., 1979, 1981). 
Their lack of virulence is due to an inability to replicate in non dividing neuronal cells where 
there is no pool of nucleotide precursors. However, they can establish latency, but are not 
able to reactivate indicating TK may be required for reactivation from latency (Coen et al., 
1989; Efstathiou et al., 1989). 
Similarly to TK, RR is non essential in dividing cells but important in virus virulence. A 
deletion variant of HSV-l (KOS), ICP6~, lacking 90% of the Rl coding sequences showed 
only a slightly reduced ability to grow on BHKlC13 cells (Goldstein and Weller, 1988a, b). 
However, this RR mutant showed extreme growth impairment following inoculation in the 
mouse eye. The mutant replicated poorly in the cornea, did not cause severe ocular disease 
compared to the wild type and rescuant and only established a low level of virulence (Brandt 
etal., 1991). 
1.14 USH 
The US 11 gene is located in the Us region of the HSV -1 genome (McGeoch et al., 1985). It 
is expressed as a y2 gene (Johnson et al., 1986) and its mRNA is 3' co-terminal with US 10 
and US12 sharing a common polyadenylation signal (Rixon and McGeoch, 1984, 1985; 
McGeoch et al., 1985). The protein 21K encoded by this gene is a small basic 
phosphoprotein that localizes to the nucleolus of infected cells (Puvion-Dultilleul, 1987). It 
is non essential for virus growth in vitro and in vivo and the function of US 11 during the 
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HSV-l lytic cycle is unclear (Longnecker and Roizman, 1986; Nishiyasm et at., 1993). The 
major properties associated with US 11 are RNA binding and the antagonism of the 
interferon induced, double stranded RNA dependent protein kinase. US 11 binds several 
RNA transcripts separately both in vitro and in vivo (Roller and Roizman, 1990, 1991; 
McCormick., et al 1999). This protein is incorporated into the virion tegument and is 
therefore delivered to the host cell upon infection (Roller and Roizman, 1992). 
Ultrastructure studies have revealed that early in infection 21K co-localizes with viral DNA 
in the nucleus and perinuclear region which is rich in ribosomes (Puvion-Dultilleul, 1987). 
Expression of US 11 early in infection was found to be responsible for the suppression of 
host mediated protein synthesis shutoff in ICP34.5 null mutants (Cassady et ai., 1998a; 
Mulvey et at., 1999) (1.15.3). Inhibition of ds RNA dependent protein kinase R (PKR) 
autophosphorylation/activation or block of eIF-2a phosphorylation have been suggested to 
be potential candidates for .the mode of US 11 action (Cassady et al., 1998a, b; Mulvey et ai., 
1999; Popper et at., 2000). Several hypotheses have been proposed for the mechanism by 
which US 11 inhibits PKR activation and eIF2a phosphorylation. PKR is activated by 
dsRNA although the actual sequence of the substrate is unknown (Gunnery and Mathews, 
1998). As US II is a RNA binding protein it has been proposed that US 11 binds both PKR 
and the activating ds RNA thereby preventing PKR dimerization and activation. An 
alternative hypothesis is that as US 11 appears to act upstream of PKR activation it may 
compete with PKR for binding of dsRNA (Poppers et at., 2000). 
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Recent evidence suggests that US 11 can also inhibit PACT-mediated activation of PKR both 
in vitro and in vivo. Binding of the C-terminus domain of US 11 to PKR (and not to PACT) 
is required for inhibition of activation. This domain is the same domain that binds to dsRNA 
(Peters et al., 2002). 
1.15 
1.15.1 
ICP34.5 
Identification: 
ICP34.5 has been identified as a HSV virulence gene. Originally, Thompson et al. (1983) 
mapped a neurovirolence locus to the long repeat region of the HSV-I genome. 
Subsequently, a gene, ICP34.5, was identified in the long repeat sequence between ICPO 
and the "a" sequence in HSV -1 strain F (Chou and Roizman, 1986, 1990), in HSV -I strain 
17+ (Dolan et al., 1992), and in HSV -2 strain HG52 (McGeoch et al., 1991) whose promoter 
is located in the "a" sequence (Ackermann et al., 1986). As ICP34.5 is located in the long 
repeat, it is present in two copies per viral genome (Fig.I.5) (Chou and Roizman, 1986, 
1990). The virulence function originally identified by Thompson et al (1983) was 
subsequently mapped to ICP34.5 (Taha et al., 1989; Thompson et al., 1989; Chou et al., 
1990; MacLean, A. et al., 1991). 
1.15.2 Characterization 
The ICP34.5 promoter is contained entirely within the terminal "a" sequence, lacks a TAT A 
box and, unlike most HSV-I genes, contains numerous repetitive G+C rich elements (Chou 
and Roizman, 1986). Transcription of the ICP34.5 gene is initiated in the DR 1 element of 
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the "a" sequence. It is a YI gene and its expression is reduced but not abolished by inhibitors 
of DNA synthesis (McKay et ai., 1993). 
The ICP34.5 gene consists of a basic amino acid terminus and a 63 amino acid region with 
83% homology to HSV-2 and homology to cellular genes (1.15.3) separated by a DNA 
repeat encoding a PAT trimer (Proline, Alanine, Threonine) which varies in number between 
strains being present 10 times in HSV -1 (F) giving a protein of 263 amino acids with a Mr of 
39 KDa (Chou and Roizman, 1990) but only five times in HSV-l(17+) giving a protein of 
248 amino acids with a Mr of 37 KDa (Dolan et al., 1992; McKay et al., 1993) (Fig.1.5). 
Unlike HSV-l, the gene in HSV-2 does not contain the sequence containing the PAT trimer 
repeat but does contain an intron (McGeoch et al., 1991). 
ICP34.5 is distributed in the nucleus, nucleolus, and cytoplasm in transfected or 
superinfected cells. Deletion analysis revealed that the Arg-rich cluster from amino acids 1 
to 16 in ICP34.5 functions as a nucleolar localization signal. The region from amino acids 
208 to 236, containing a bipartite basic amino acid cluster, is able to mediate nuclear 
localization. These results suggest that the ICP34.5 protein continuously shuttles between 
the nucleus, nucleolus, and cytoplasm, which may be a requirement for the different 
activities of the ICP34.5 protein in virus infected cells (Cheng et al., 2002). 
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1.15.3 Function: 
ICP34.5 is non essential in most cell types in vitro but essential in vivo (Chou et 01., 1990). 
Two functions have been attributed to HSV-l ICP34.5: (i) virulence; and (ii) the prevention 
of the shut-off of host cell protein synthesis. These two phenotypes will be discussed 
individually and then correlated. 
(i) In vivo phenotype 
In vivo a number of phenotypes have been attributed to ICP34.5. Following intracranial 
inoculation, ICP34.5 null mutants are unable to replicate in the CNS of mice and are totally 
avirulent with a LDso of 106 pfu/mouse higher than wild type or rescued virus (Chou et 01., 
1990; MacLean, A. et 01., 1991; McKie et 01., 1994). Detailed analysis of replication 
characteristics in the CNS have revealed that while some cells allow limited gene 
expression, the only cell type which allows productive replication are ependymal cells and 
this terminates after 14 days (Markovitz et al., 1997; Kesari et al., 1998). 
ICP34.5 negative mutants establish latency in the CNS as determined by the presence of 
LAT positive neurons (Kesari et 01., 1996, 1998). Following peripheral inoculation in the 
eye, the virus does not appear to replicate in the cornea or TO and although establishing 
latency in TO does so at a significantly lower frequency than wild type. Based on the level 
of LAT expression in the TO, the number of LAT+ve cells and the absence of detectable 
HSV DNA by PCR, the decrease in amount of latent virus is 10 and possibly 100 fold. This 
is probably due to lack of replication in both the cornea and TO (Spivack et of., 1995). 
Virus can be reactivated either in vitro following explantation or in vivo for example 
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following ionotrophesis of adrenalin (Perng et al., 1995, 1996). Following footpad or 
vaginal inoculation, virus may undergo limited replication at the initial site of inoculation 
(Roberston et al.,1992; Whitely et al., 1993; Spivack et al., 1995). No replication takes 
place in the DRG and latency is established inefficiently although not as inefficiently as in 
the TG and can be reactivated in vitro following explantation (Spivack et al., 1995). Initial 
work suggested that ICP34.5 is a neurovirulence gene (Chou et al., 1990; MacLean, A. et 
al., 1991). However, the lack of replication in the cornea, the possible lack of replication in 
the footpad, and lack of pathogenicity in SCID mice, suggested that the defect may be a 
lack of replication in vivo per se (Valyi-Nagy et al., 1994; Randazzo et al., 1996). Thus 
ICP34.5 should be regarded as a virulence gene. 
One anomalous result is an ICP34.5 null mutant called 17termA which is a mutant in HSV-
1 (17+) with a stop codon after the N-terminal 30 amino acids (Bolovan et al., 1994) and is 
essentially ICP34.5 null. However this mutant instead of being avirulent, showed only a 25-
100 fold reduction in virulence compared to wild type (Bolovan et al., 1994). This might 
suggest a partial function mapping to the N-terminus of ICP34.5. However the HSV-l (F) 
mutant, R4009, with an identical mutation was completely avirulent (Chou et al., 1990) as 
was a strain 17+ mutant, 1771, with a stop codon immediately after the initiating methionine 
codon (McKie et ai, 1994; Spivack et ai., 1995). The anomaly of 17termA still retaining 
some virulence has yet to be resolved .. 
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(ii) In vitro phenotype 
In tissue culture, ICP34.5 null mutants replicate normally in many non neuronal cell types 
such as Vero and BHK 211C13 cells, but are restricted in SK-N-SH neuroblastoma cells, 
human foreskin fibroblast (HFF), murine lOT1I2 cells, stationary phase primary mouse 
embryo and mouse embryo fibroblast (3T6) cells (Chou et al., 1990, 1994; Chou and 
Roizman, 1992; Bolovan et al., 1994; Brown et al., 1994a ). In general, in nonpermissive 
cells the growth defect of ICP34.5 null mutants is greater when they are in a stationary phase 
(Brown et al., 1994a). One explanation is that nonpermissive cells infected with ICP34.5 
null mutants undergo a total shutoff of protein synthesis. Therefore in these cells ICP34.5 
provides a mechanism for cell survival which enables the virus to sustain its replication 
cycle and produce infectious virus (Chou and Roizman, 1992; Chou et al., 1995; He et al., 
1997a) (see below). 
Another explanation for the role of ICP34.5 in vitro is that failure to express ICP34.5 results 
in a defect in virus maturation and egress from the nuclei of infected,cells. Brown et al. 
(1994a) demonstrated that the growth of ICP34.5 null mutants was impaired in 3T6 cells 
with the impairment amplified in the stationary state. These workers demonstrated that the 
impairment in growth was due to a defect in envelopment and egress of virus particles with 
an accumulation of unenvelopped capsids in the nucleus of infected 3T6 cells with little or 
no effect on the behaviour of the virus in BHK cells (Brown et al., 1994b). 
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(iii) Shutoff of host protein synthesis 
The cellular response to virus infection is a complex process and includes induction of 
interferons (IFNs). IFNs are key components of the host innate immunity to virus infection 
and act through several pathways to block virus growth and virulence (Stark et at., 1998). 
Cells infected with a variety of both DNA and RNA viruses synthesize double stranded 
RNA which induces an IFN response (Katze, 1995). PKR is induced by IFNs and is a major 
mediator of the cellular response to stress such as virus infection (Fig 1.6). PKR becomes 
activated through autophophorylation and dimerization (Merrick, 1992; Wu et at., 1998) and 
phosphorylates eIF-2a. This leads to the loss of functional elF-2a which results in inhibition 
of protein synthesis (Katze, 1993). This is the primary mechanism by which PKR prevents 
viral replication by total shuttoff of protein synthesis (Mathews, 1996). 
In HSV -1 infected cells, transcription of the complementary DNA strands results in the 
formation of double stranded RNA, induction of IFN and activation of the PKR pathway 
which should result in premature shutoff of host protein synthesis. However, HSV encodes a 
gene ICP34.5 which blocks the shutoff of host protein synthesis (Chou and Roizman, 1994). 
It has been suggested that some cell lines such as Vero cells might be defective in the IFN-
induced mechanism targeted by ICP34.5 (Mossman and Smiley, 2002), explaining their 
ability to support replication of ICP34.5 negative viruses. 
In HSV-l infected cells PKR is activated and eIF-2a is phosphorylated. However, a 
cytoplasmic complex containing protein phosphatase la (PPla) and ICP34.5 is formed and 
PPla is redirected to dephosphorylate eIF-2a (He et ai., 1997a, 1998) and thus prevent 
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Figure 1.6 IFN-mediated induction of the antiviral state through independent 
pathways by RNase Land PKR 
IFN binds to its receptor and activates two pathways. On the left the RNase L pathway 
and on the right the PKR pathway. In right side panel, IFN induces expression of PKR 
which is activated through double stranded RNA binding. 
One of the activities of PKR is to phosphorylate eIF-2ex. leading to cessation of protein 
synthesis and blocking of viral replication. To evade this antiviral mechanism, HSV-l 
ICP34.5 binds to protein phosphatasel ex. and dephosphorylates eIF-2a, lifting the block 
on viral replication. 
In left side panel, IFNs interacting with their receptors lead to expression of 2-SA 
synthetase, which, after double-stranded RNA binding, produces 2', 5'-oligodenylates 
that lead to RNase L activation and blockage of viral replication (Leib et at., 2000) 
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premature shutoff of host protein synthesis induced after the onset of viral DNA synthesis 
(Chou et al., 1995). In cells infected with ICP34.5 null mutants, PKR is activated, eIF-2a. is 
phosphorylated and protein synthesis is shutoff (Chou et al., 1995). The ability of ICP34.5 to 
prevent protein synthesis shutoff maps to the C-terminus of the protein as deletions in this 
region preclude shutoff of host protein synthesis whereas deletions in the N-terminal have no 
effect on this phenotype (Chou and Roizman, 1992, 1994). The binding site for PPla. has 
been mapped to amino acids 190-203 in the carboxy terminus of ICP34.5 (He et al., 1998). 
In addition, for a functional high molecular weight complex an intact Ala-Arg motif from 
the carboxy terminus ofICP34.5 is required (Cheng et al., 2001). 
The carboxy terminus of ICP34.5 has homology to cellular genes involved in response to 
cellular stress and DNA damage These are MyD 116 (Lord et al., 1990; Barnett and 
McGeoch, 1991) and GADD34 (Fornace et al., 1989). The carboxy terminus of MyD1I6 
also interacts with protein phosphatase la (PPla.) both in vitro and in the yeast-2-hybrid 
system (Chou and Roizman, 1994; He et al., 1997a). It is likely that GADD34 will also have 
a similar function to interact with and redirect PPla. to dephosphorylate eIF-2a. to enable 
continued protein synthesis in conditions of cellular stress (He et al., 1997a). Substitution of 
the ICP34.5 carboxy terminus by the corresponding domain ofMyDl16 in the context of the 
viral genome restored the ability of an ICP34.5 null mutant to preclude host protein 
synthesis shutoff in both neuroblastoma cells and human foreskin fibroblasts (He et al., 
1996). 
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Both ICP34.5 and MyDI16 interact with proliferating cell nuclear antigen through the 63-
amino acid conserved domain (Brown et al., 1997). The carboxy terminal domain of 
ICP34.5 also shows significant homology to an African swine fever virus (ASF) gene 23-NL 
(NL-S) which has been shown to have a role in ASF virulence (Sussman et ai., 1992; Zsak et 
al., 1996). 
Second-site compensatory ICP34.5 null mutants have been isolated by Mohr and Gluzman 
(1996) which exhibit restored ability to prevent host shutoff of protein synthesis and to 
grow in some neoplastic neuronal cell lines. In these mutants the deletions were present in 
the a gene USI2 such that the y2 gene USII (Johnson et al., 1986) was now expressed as 
an a gene (Fig. I. 7). This was confirmed by the construction of targeted deletion mutants 
where US II was expressed under the USI2 a promoter (1.14) (Cassady et al., I998a, b; He 
et ai., 1997b). However, these mutants are still nonneurovirulent (Mohr et ai., 2001). 
Interestingly, although US II is a structural tegument protein (Roller and Roizman, 1992) 
and therefore will be delivered early in infection, de novo expression is required to prevent 
protein synthesis shutoff. Thus either there is not enough US II in the virion or it is not in 
the correct processed form to prevent shutoff of protein synthesis (Mulvey et al., 1999; 
Mohr et ai., 200 I; Cassady et al., 1998a, b). 
In these revertants the US II RNA binding protein prevents shutoff of host protein synthesis 
by inactivating the PKR pathway. The 68 amino acid carboxy terminus fragment of US II 
contains a novel proline rich basic RNA binding domain which is sufficient to inhibit 
activation of the kinase activity of the cellular PKR (Poppers et al., 2000). A 30 amino acid 
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Figure 1.7 Map of the junction region where Us joins the terminal repeat (TRs) 
A diagram illustrating the Us/TRs junction region (dashed line). The US 10, 11 and 12 
ORFs in Us are shown. ORFs are denoted as heavy boxes. The 3' terminal mRNAs 
appear as arrows terminating at their common polyadenylation site. The cis-elements 
which direct transcription of the various open reading frames are denoted as solid circles 
C. ) above their respective transcript. The region deleted in the suppressor viruses is 
shown below C" ). 
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domain within this carboxy terminus of US II interacts with PKR in the ribosomes of 
infected cell (Cassady and Gross, 2002). 
Recently a second class of second site compensatory ICP34.5 null mutants has been isolated 
which also prevents the PKR induced shutoff of protein synthesis. In these mutants, the 
mutation although shown to occur outside the USlO-12 domain, has not yet been mapped. 
In this class of mutants neurovirulence is partially restored (Cassady et al., 2002). 
(iv) Relevance of shutoff of host protein synthesis to virulence 
ICP34.5 clearly has two functions: a role in allowing replication in vivo; and preventing host 
protein synthesis shutoff in some cell types in vitro. The question arises as to whether the 
lack of replication and hence avirulence in vivo is due to the host protein synthesis shutoff 
phenotype. There is evidence both in favour and against this hypothesis. 
Against is the fact that the second site US 11 revertants whilst regaining the host shutoff 
phenotype do not regain any virulence (Mohr et al., 2001). In addition, the recombinant 
virus where the MyDI16 carboxy terminus has been substituted for the ICP34.5 carboxy 
terminus whilst being fully functional for the host shutoff phenotype, is completely avirulent 
(Andreansky et al., 1996). 
However, in favour of the linkage is the observation that second site revertants outside US I I 
do regain some virulence (Cassady et al., 2002). Most importantly is transgenic mice data 
which strongly suggest that there is linkage between inhibition of PKR function and 
virulence. A HSV -1 ICP34.5 mutant grows to normal levels and shows wild type virulence 
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in mice lacking both type 1 and type 2 IFN receptors whereas the same mutant has a 104 
reduction in replication and neurovirulence in normal mice (Leib et at., 1999). This was 
shown to be due to the PKR response as an ICP34.5 deletion mutant had wild type 
replication characteristics and virulence in transgenic mice from which PKR had been 
deleted (Leib et at., 2000). 
1.16 
1.16.1 
LISTs, ORFs 0 and P 
LISTs 
A set of LIS junction-spanning transcripts (LISTs) with their upstream regulatory sequences 
has been described by two groups (Bohenzky et at., 1993; Yeh and Schaffer, 1993). The 
LISTs are a series of 5'-coterminal polyadenylated RNAs ranging in size from 2.3 to >9.0 
kb, are transcribed from the same DNA strand as the latency-associated transcripts (LATs) 
and overlap the 3' terminal 2.3 kb of the 8.3 kb LAT (Fig. 1.8) (Yeh and Schaffer,1993). The 
LISTs exhibit a novel pattern of regulation since they are not detected during normal 
infection but are overproduced during infection with a virus in which ICP4 is inactive. A 
strong binding site for ICP4 is found at the 5' end of the LISTs (Yeh and Schaffer, 1993; 
Lagunoff and Roizman, 1995; Randall et al., 1997). Mutagenesis of this site also results in 
overproduction of LISTs during normal infection, indicating that ICP4 represses 
transcription of LISTs (Yeh and Schaffer, 1993, Lagunoff and Roizman, 1995; Yeh and 
Schaffer, 1998). 
The HSV -1 unspliced 8.3 kb LA T has been shown to contain at least 16 ORFs greater than 
50 amino acids in length (Lagunoff and Roizman, 1994). These ORFs have been designated 
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(A) Diagram of the HSV-l genome. (B) Expanded inverted repeat sequence b'-a'-c ' lying 
between n.p.117,OOO-134, lOOO on the HSV-J genome. The map shows the locations of 
sequences specifying the transcripts encoding ICPO, ICP34.5 and ICP4 and sequences 
specifying the LA Ts. ORFs including ORF 0 and ORF P are hatched boxes. LISTs 
transcripts are indicated as arrows (--. ). 
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by the letters A through P (Lagunoff and Roizman, 1994). At least two of these 16 ORFs, 
ORF 0 and ORF P, are expressed (Lagunoff and Roizman, 1994, 1995; Randall and 
Roizman, 1997). ORF 0 and ORF P are located in the 3' domain of LAT, almost entirely 
antisense to the ICP34.5 gene and are also contained at 5' end of the LISTs. Both ORFs 0 
and P are expressed from LISTs and not from the LAT (Bohenzky et aI., 1993; Yeh and 
Schaffer, 1993; Lagunoffand Roizman, 1994, 1995; Randall and Roizman, 1997). 
1.16.2 ORFO 
It was originally proposed that in strain 17+, ORF 0 is approximately 300 codons in length, 
whilst in strains KOS, F, MHIO, and CVG2, a single base pair substitution terminates ORF 
o after approximately 160 codons (Yeh and Schaffer, 1998). ORF 0 overlaps ORF P but in 
a different reading frame. These workers assumed that the initiating methionine codon of 
ORF 0 is located in the TATA box of the LISTs. However, for a number of reasons, 
Randall et al (1997) suggested that this methionine is not the initiating methionine. Firstly 
ORF 0 appears to be expressed from the LISTs and secondly mutation of the ORF P 
initiating methionine also prevents ORF 0 protein expression in strain F infected cells at 
39.5°C, the nonpermissive temperature for ICP4. Thus ORF 0, like ORF P, is 
downregulated by ICP4 (Randall et al., 1997). Analysis of cells infected with a derepressed 
ORF P failed to detect a separate RNA corresponding to ORF 0 (Randall et al., 1997). 
Detailed analyses of the products encoded by the ORFs showed that the translation of ORF 
o begins at the ORF P initiating methionine codon and then shifts into the ORF 0 reading 
frame before amino acid 35 of ORF P. Based on this information, ORF 0 actually consists 
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of 245 amino acids in strain 17+ and 105 amino acids in strains KOS, F, MHlO and CVG2 
(Randall et ai., 1997). 
In vitro, ORF 0 protein specifically binds to ICP4 inhibiting its binding to its cognate site 
(Randall et ai., 1997). 
1.16.3 ORFP 
The first identified and largest ORF in the LISTs is ORF P, which encodes the ORF P 
protein. ORF P is expressed at detectable levels only under conditions which allows 
expression of the LISTs (Lagunoff and Roizman, 1994; Yeh and Schaffer, 1993). The most 
striking feature of ORF P is that it is nearly completely antisense to ICP34.5. Only 8 codons 
of ORF P are not antisense to ICP34.5, and only 23 codons of ICP34.5 are not antisense to 
ORF P (Lagunoff and Roizman, 1994). ORF P expressed by HSV-l (F) is predicted to 
contain 248 amino acids. It contains a short amino terminal domain followed by an amino 
acid trimer of Ala-Gly-Val repeated 10 times and a long carboxy terminal domain. The 
protein in HSV-l (17+) contains 233 amino acids with the amino acid trimer of Ala·Gly-Val 
repeated only 5 times. Similarly to ICP34.5, the variation in the length of the protein 
between different strains is because of the variation in the number of repeats of this trimer 
(Lagunoff and Roizman, 1994). 
Expression of LISTs and their protein products, ORF P and ORF 0 has not been detected 
during productive infection by Lagunoff et al. (1996). However, it has been demonstrated in 
our laboratory (McKie and MacLean, personal communication) that in BHKlCl3 cells RLl 
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and LIST transcripts and ICP34.5 and ORF P are simultaneously expressed in the presence 
of functional ICP4 during a productive infection by HSV-l (17+). Work in this thesis 
confirms simultaneous expression of ICP34.5 and ORF P during productive infection. 
As most ICP34.5 null mutants also affect ORF P due to the extensive overlap of their 
sequences, it was difficult to assign a role to ORF P. Therefore, to investigate the role of 
ORF P in the HSV-l lifecycle and any possible effects of ORF P on the ICP34.5 gene, a 
number of mutants have been constructed and characterized. The following mutants are 
ORF P derepressed mutants which produce LISTs and ORF P during productive infection. 
Lagunoff et al. (1996) constructed a HSV-l(F) ORF P derepressed mutant, ORF P++, in 
which the ICP4 binding site in the LIST promoter was mutagenized to allow expression of 
the LISTs and the ORF P gene throughout the lytic cycle of the mutant virus. ICP34.5 was 
not detected and the level of its RNA was decreased in infected cells. This mutant was 
highly attenuated upon inoculation into mice by the intracerebral or ocular route. It could 
not be recovered following explantation from the TG. However, protein synthesis was not 
prematurely shutoff, possibly as only a low level of ICP34.5 is necessary for this phenotype 
(Chou and Roizman, 1994). It had been suggested that, in the ORF P++ mutant, either 
overproduction of ORF P blocks the expression of ICP34.5 or derepression of LISTs 
transcription has a negative effect on the transcription of the antisense ICP34.5 RNA 
(Lagunoff et al., 1996). 
A second HSV-I (F) mutant R7546 suggested that the reduction in the accumulation of 
ICP34.5 mRNA and protein in cells infected with ORF P++ is due to the effect of LISTs 
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antisense transcription rather than a function of the ORF P protein (Randall and Roizman 
1997). In R 7546, LISTs transcription was again derepressed but the initiating ORF P 
methionine codon was mutagenized and ORF P protein was not produced. The phenotype of 
R7546 was identical to ORF P++. 
A similar mutant to ORF P++, LlST4BS with the ICP4 binding site mutated was 
constructed in HSV -1 strain KOS by Yeh and Schaffer (1998). In LlST4BS, LISTs and ORF 
P were expressed during a productive infection. Similar to ORF P++, this mutant was also 
highly attenuated following intracranial inoculation of juvenile mice. However, replication 
of this mutant was efficient in the mouse eye and TO. In Vero cells as well as the LISTs, 
both ICP34.5 and LATs transcripts were abundant. However, in mouse neuroblastoma cells 
(NB4IA3) ICP34.5 and LAT transcripts were barely detected. In contrast to ORF P++ in 
SK-N-SH cells, LlST4BS induced premature shutoff of protein synthesis in NB41A3 cells. 
The reason for the difference in results between these two mutants is unclear but might 
reflect either the slightly different mutation in the ICP4 binding site or a strain difference. 
Both Yeh and Schaffer (1998) and Randall et al (2000) have constructed mutants which do 
not express ORF P but have no effect on the ICP34.5 coding sequence. A HSV -1 strain 
KOS mutant containing a single base pair alteration in ORF P at codon 38 results in 
termination of ORF P translation and expression of a truncated ORF P protein (Yeh and 
Schaffer, 1998). LlST-n38 exhibited no premature shutoff of infected cell proteins and had 
no observable phenotype relative to wild type virus in vitro and in vivo. This mutation 
induced an Arg-to-Thr change at amino acid of 38 of ORF O. If ORF 0 protein is involved 
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in any of the functions measured, this substitution had no detectable effect on these 
functions (Yeh and Schaffer, 1998). 
Similarly, Randall et al. (2000) constructed an HSV-l (F) mutant, R7538(P-IO-), in which 
the ORF P initiating methionine codon, which also serves as the initiating methionine codon 
for ORF 0, was mutated. The R7538 (P-IO-) mutant failed to express ORF 0 and ORF P 
proteins but expressed a wild-type ICP34.5 protein. Similar to LlSTn-38, the R7538 (P-IO-) 
showed similar behaviour to that of the wild type following infection of SK-N-SH and Vera 
cells, and infection of mice by the intracerebral or ocular routes. 
The ability of LISTs, ORF 0 and ORF P to be expressed in the absence of viral protein 
synthesis and the complete repression of this gene by ICP4 suggested that ORF 0 and Pare 
pre-a genes, i.e. expressed under condition in which the a. genes are not expressed 
(Bohenzkey et aI., 1993; Lagunoff and Roizman, 1995). Their ability to be expressed in the 
absence of protein synthesis is disputed by Yeh and Schaffer (1993). 
Interaction of ORF P with a number of proteins involved in splicing has been demonstrated. 
Using immunoflourescense microscopy, ORF P has been shown to colocalise with SM 
antigens and SC35 in the nuclei of infected cells, interact with SM components by GST 
pull down assay and interact with P32 in a yeast-two hybrid screen (Brunei and Roizman, 
1996). In cells infected with a virus carrying a derepressed ORF P, it is rapidly 
posttranslationally modified and ORF P appear to inhibit the synthesis of the spliced 
immediate early transcripts of the ICPO and 22 genes early (8 h) but not late (18 h) in 
44 
Chapter 1 Introduction 
infection, while the levels of two immediate early proteins synthesized from intronless 
mRNAs, ICP4 and ICP27, are unchanged (Brunei and Roizman, 1996; Randall and 
Roizman, 1997). However, in Vero and NB41A3 cells infected with the ORF P null mutant 
LlST- n38 no difference has been detected in the levels of ICPO transcripts at early times 
(6 h) p.i. compared with wild-type virus-infected cells (Yeh and Schaffer, 1998). 
ORF 0 protein inhibits the function of ICP4 (Randall et ai., 1997). ORF P protein reduces 
the accumulation of ICPO and ICP22 (Randall and Roizman, 1997). Thus ORF ° and P 
appear to inhibit the synthesis or function of three key immediate early proteins, ICPO, 
ICP22, and ICP4 which are required for viral replication and lytic gene expression. The 
LISTs and ORF P derepressed mutants ORF P++ and LlST-4BS establish latency. However, 
although LlST-n38 and R7538(P-IO-) reactivate from latency, the amount of latent R7538 
(P-IO-) DNA is eightfold less than that of its rescuant. Thus ORF ° and ORF P whilst not 
essential for the establishment of latency in mice may playa role in determining the quantity 
of latent virus maintained in sensory neurons (Randall et al., 2000). In contrast, Yeh and 
Schaffer (1998) suggest that ORF P plays no major role in neurovirulence or in latency and 
reactivation in mice. To date, there is no evidence of expression of ORFs 0 and P in neurons 
harbouring latent HSV genomes (Preston, 2000). Thus, the function of ORF OIP remains to 
be determined. 
45 
Chapter 1 Introduction 
1.17 Gene therapy/delivery 
The introduction of genes into cells for a theraputic purpose such as treatment of many 
inherited genetic diseases and other diseases and use of a gene instead of ordinary drugs is 
referred to as gene therapy. The gene has to be efficiently delivered to the appropriate cells 
and gene expression must be at the right level. The ideal vector would be non toxic, 
immunogenic or mutagenic in the patient, and easily produced in high concentration and 
purity at a low price. To date, two approaches viral and non-viral vectors have been 
developed to deliver genes. For the advantages and disadvantages of each approach see table 
1.2. 
1.18 Viral vectors 
Some of the characteristics important in viruses for gene delivery are: delivery of the gene of 
interest (GI) into cells, often of a very specific cell type; easy removal of a viral gene/genes; 
and later replacement by the GI(s). The recombinant vectors are packaged into virus 
particles and infection of cells by the particles leads to expression of the OI. To date, the 
following virus vectors have been used for gene therapy: retroviruses, adenoviruses, 
adenoassociated viruses (AAV) and herpes simplex virus-l (HSV). 
1.18.1 Retroviruses 
Effective retroviral vectors have been created by deleting essential genes. All essential genes 
(gag, pol, and env) are removed and a foreign gene and selectable marker are inserted into 
the vector which retains the packaging signals. Retroviruses are 7-9 kb in length and at most 
9 kb can be packaged into these vectors. This plasmid is transfected into a packaging cell 
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Vectors Advantages Disadvantages 
Retroviruses -Integrate into the genome -Random integration 
-All viral genes removed -Only dividing cells transduced 
-Relatively safe -Low titres obtained in vitro 
-Size limitation 
Adenovirus -Large insert (35 kbp) -Toxicity 
-High titres obtained in vitro -Immunological response 
-Efficient transduction into -Transient expression 
different cell types -Prior exposure 
-Transduce dividing/ non-
dividing cells 
Adeno -Non pathogenic -Small genome 
associated -Transduce dividing! non- -High multiplicity of virus for 
virus dividing cells transducing some cell types 
-Long term expression -Toxicity associated with helper virus 
-Safe 
-Stable expression 
-Integrates into known location 
Herpes -Large insert -Hard to obtain long term expression 
simplex -Lifelong latent state -Amplicon: Low titres obtained in 
virus -Transduce dividing/non- vitro 
dividing cells Hard to separate from 
-Amplicon: Efficient delivery helper virus 
Low toxicity Low packing efficiency 
-Defective: Infects neurones -Recombinant: Toxicity 
High titres in Transient expression 
vitro 
Non-viral -Easy to manipulate -Rely on cellular transport into nucleus 
vectors -Lack of viral components -Lack tissue targeting 
-Size -Transient gene expression 
-Stable on storage -Inefficient delivery 
-Safe, lack of immune 
recognition 
Table 1.2 Advantages and disadvantages of different vectors in gene therapy (Kay et 
al., 1997). 
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line which contains and expresses a recombinant retroviral backbone expressing gag, pol, 
and env proteins which are essential for retroviral replication but does not contain the 
packaging signal. It is essential that the retroviral backbone and vector do not have any 
homology to prevent the production of wild type retroviruses (Logg et al., 2002). The 
packaged vector is able to enter the nucleus and recombine into the chromosome of dividing 
cells (Miller, 1992). These vectors are not able to infect nondividing cells and hence are 
inappropriate for gene transfer to neuronal tissue in vivo. However, newer retrovirus vectors 
based on lentiviruses have been developed which also infect non dividing cells (Chang et 
aI., 1999). 
1.18.2 Adenoviruses 
Adenoviruses have a large 35 kbp DNA genome and have been studied for their potential 
use in gene therapy. These viruses usually replicate as an episomal element in the nucleus 
and rarely, if ever, integrate into the host genome (Danthinne and Imperiale, 2000; Shalev et 
aI., 2001). Deletion of EI-E4 creates a adenovirus vector with a large capacity for foreign 
genes. The major limitation in the development of adenovirus is that despite the deletion of 
El, leaky expression of late genes occurs leading to a host immune response (Yang et aI., 
1994). However, these vectors can potentially be used for cancer therapy and vaccination 
where avoiding an immune response is not so important (Danthinne and Imperiale, 2000). 
1.18.3 Adenoassociated viruses (AA V) 
AA V is a small ssDNA defective parvovirus (Fink et al., 1996). The AA V genome 
integrates site specifically into the short arm of chromosome 19 and as the vector does not 
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contain any wild type viral genes, is less immunogenic (Dong et at., 1996). This virus will 
reside latently in the host genome until the cell is superinfected by a helper virus 
(Ponnazhagan et at., 2001). However, due to its small genome size, only 1-2 kb can be 
inserted (Dong et ai., 1996). Integration can lead to prolonged expression from an AA V 
vector (Xiao et aI., 1996). 
1.18.4 HSV-l 
Two different types of HSV -1 vectors, defective and amp Ii con based have been developed. 
Amplicon based vectors consists of a bacterial plasmid that contains a copy of a HSV 
replication origin, a HSV packing sequence and the GI. The amplicon is transfected into 
suitable cells with helper virus which provides the required genes in trans for amplification 
and packaging of the amplicon genome. The amplicon containing viral particles are in fact 
defective virions, containing mUltiple copies of the amplicon sequences and are able to 
infect mammalian cells (Table1.2) (Wang et at., 2002). One problem is the difficulty in 
removing the helper virus. 
Defective HSV -1 vectors are constructed by flanking the 01 and usually a reporter gene with 
HSV -1 DNA sequences and recombining them back into the mutant virus at the desired site 
(Latchman, 2001). Such viruses are replication defective as they are deleted in an essential 
gene and are therefore produced in a complementing cell line. However, due to the toxicity 
of the remaining genes such viruses could not be used for gene therapy. To overcome this 
and create vectors with minimal toxicity, several genes, especially IE genes, are removed. 
For example deletion of IE genes ICP4, ICP27, ICP22, and ICPO will create a vector with 
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minimum toxicity (Krisky et al., 1998; Lilley et al., 2001). However, such a vector may be 
difficult to grow. An alternative approach is to delete only the essential ICP4 and ICP27 and 
mutagenise Vmw65 to downregulate expression of the other IE genes (see section 1.10.3; 
Thomas et al., 1999b). 
1.19 Non viral vectors 
Non viral vectors, either naked plasmid DNA or packaged in liposomes can be used for 
transferring genes into cells. These vectors can be manipulated easily with standard 
molecular biology techniques and contain no packaging sequences required for viral vectors 
(Smith et al., 1996). Foreign genes up to 48 kbp can be inserted into these vectors and hence 
it is possible to transfer large genes/regulatory sequences or a few smaller genes at the same 
time into the cell (Cotten et al., 1990). Non viral vectors are also less immunogenic (Wells et 
al., 2000). However, non viral vectors use the cellular machinery to transfer DNA into the 
cell and the nucleus which is possibly why transfection efficiency and hence protein 
expression are low (Smith et al., 1996). 
1.20 Cancer therapy using viral vectors 
Although advances have been made in the treatment of many cancers by conventional means 
such as surgery, radiation and chemotherapy, this is not true for all tumour types. For 
example, in the case of malignant glioma, the lifespan of patients has not been significantly 
enhanced (Kim et al., 2001). The resistance of many cancers to conventional therapies has 
led to the search for novel strategies. One approach is based upon gene therapy with the 
introduction of "tumour killing" genes into tumour cells by means of disabled (usually 
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retroviral) vectors (Walther and Stein, 2000). Alternatively, the inherent cytotoxicity, spread 
from cell to cell and inherent tumour selectively of some viruses led to the hypothesis that 
replication competent viruses could be used for cancer treatment. Originally a number of 
wild type viruses such as vesicular stomatitis virus (VSV), Newcastle disease virus (NDV) 
and reovirus (Ahlert and Schirrmacher, 1990; Hashiro et ai., 1977; Stojdi et ai., 2000) were 
used to treat cancer but this approach was abandoned due to lack of tumour selective toxicity 
(Southam et al., 1960). 
More recently, recombinant DNA technology has led to the use of genetically engineered 
viruses for this anti tumour approach. This is achieved by deleting viral genes necessary for 
efficient replication in normal cells but which are expendable in tumour cells, to generate 
tumour specific replication competent viruses. The use of tumour specific promoters and 
modification of the viral envelope to lead to selective uptake by tumour cells may ultimately 
increase the specifity of such replication competent viruses. Replication competent viruses 
can also be used to deliver "cytotoxic genes" to cells to increase their tumour killing 
potential. The first selectively replication competent genetically engineered virus for cancer 
therapy was tested in animal models in the early 1990s (Martuza et al., 1991). Two viruses, 
HSV and adenovirus have been extensively used in this approach and several mutants are in 
clinical trials. 
1.20.1 Adenoviruses 
In normal cells both the adenovirus ElA and ElB 55K proteins are involved in binding and 
inactivating the cellular proteins pRB and p53, respectively, and thus allowing virus 
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replication to take place by forcing cells into S phase (Nevins and Vogt, 1996). Hence, in 
normal cells mutants in these viral genes will be unable to replicate. However, due to the 
defect in the control of cell proliferation, these two viral proteins are not required for 
adenovirus replication in many tumour cells. An E1A deletion mutant has been shown to 
replicate to wild type level in all cancer cells tested (Heise et al., 2000) and one such mutant 
is now in phase I clinical trials. An E1B 55 K deletion mutant (ONYX-OIS) is able to 
replicate in p53 negative tumour cells (Bischoff et al., 1996) and is now undergoing phase 
III clinical trials for head and neck tumours and phase I trials for several other tumour types 
(Nemunaitis et al., 2000). ONYX-O 15 appears especially effective when given in 
combination with the chemotherapeutic agent cisplatin (Khuri et al., 2000). 
1.20.2 HSV 
HSV encodes a large number of genes such as those involved in nucleotide metabolism, 
necessary for replication in nondividing neuronal cells but not in dividing cells including 
tumours. Mutants in these genes are usually highly attenuated (Efstathiou et al., 1989). Early 
HSV tumour studies deleted genes involved in nucleotide metabolism, for example TK and 
\ 
RR (Cameron et al., 1988). However, these mutants still exhibit some residual 
neuropathogenicity and although succesful at killing the implanted tumours in animal 
models would not be suitable for use in humans (Martuza et al., 1991). Currently, research is 
based upon the development of viruses deleted in ICP34.5 which seem unable to replicate in 
any normal tissues in vivo (1.15.3) but retain the ability to replicate in tumour cells. Two 
HSV mutants 0207 (Markert et al., 2000) and 1716 (Ramp ling, 2000) are in phase I clinical 
trials for cancer therapy in patients with malignant glioma. In 1716, both copies of ICP34.5 
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are deleted whereas in 0207 as well as both copies of ICP34.5 being deleted, RR has also 
been inactivated by the insertion of lacZ (Mineta et al., 1995). No toxicity has been 
attributed to either of these viruses. 
Several new HSV deletion mutants based upon ICP34.5 negative viruses are approaching the 
stage of clinical trials. The most promising candidate as well as having a direct cytopathic 
effect on the tumour will also invoke an antitumour immune response by expressing the IL-
12 gene. In animal models, such an ICP34.5 negative mutant expressing murine IL-12 led to 
significantly longer survival times compared to treatment with the parental virus lacking the 
IL-12 gene (Parker et al., 2000). 
1.20.3 Aims 
This project consisted of two main aims: i) in vitro characterization of the role of two HSV-l 
overlapping antisense genes ORF P and ICP34.5; and ii) identification of both cellular and 
viral proteins which interact with ORF P. 
i) To investigate the role ofICP34.5 and ORF P in the HSV-l lifecycle, a number ofHSV-l 
recombinants were constructed and characterized in vitro. All recombinants were made in 
the background of the HSV -1 ICP34.5/0RF P null mutant, 1716 and express ICP34.5 or 
ORF P separately in nonessentialloci. 
ii) To investigate both cellular and viral proteins which interact with ORF P, GST pulldowns 
were carried out with a GST -ORF P fusion protein against infected cell extracts. 
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2.1 
2.1.1 
Materials 
Bacteria 
Materials and methods 
The E.coli strains used in this thesis were: i) BL21 [BF" dcm ompT hsds (rB·mB·) gal] 
(Stratagene); ii) C+ [ BF" dcm ompT hsds (rB·mB-) gal] (Stratagene); iii) C41 [BF" dcm 
ompT hsds (rB-mB-) gal] (Stratagene); iv) Novablue [recAendALacIq] (Novagen); and 
v) XL-2blue, [recAl end Al gyrA96thi-1 hsdR17 supE44 relAllac [F'proAB 
lacIQZ.1M15 Tn10 (Td) Amy Camr]] (Stratagene). 
2.1.2 Bacteriophage 
CE6 A phage (Novagen) was used to express T7 RNA polymerase and induce expression 
of GST -ORF P in the Novablue E. coli strain (Studier and Moffatt, 1986). 
2.1.3 Bacterial culture media 
All strains were grown in L-broth (170mM NaCl, 109/L bactopeptone, 5g/L yeast 
extract) or 2YT broth (85rnM NaCl, 16g/L bactopeptone, 10gIL yeast extract). L-brothl 
agar plates were made with 1.5% (w/v) agar in L-broth. Where necessary, media and 
L-brothlagar plates were supplemented with the appropriate antibiotic, e.g. 100ug/ml 
ampicillin. 
2.1.4 Plasmids 
The plasmids used in this thesis were: i) p35-0RF P (Holman, 2000), in which gD/ORF 
P was inserted into the HSV-l UL43/43.5 genes in p35 (n.p. 91610-96751, MacLean, C. 
et ai., 1991) at the Nsil site (n.p. 94711) in both orientations; ii) pATS. 1 which contains a 
HSV-1 BamHIIEcoRV fragment (n.p. 136289-139258) spanning the US5 gene cloned 
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into pAT153 (supplied by Dr A. MacLean); iii) GST (Pharmacia); GST-ORF P (supplied 
by Dr. A. MacLean) in which ORF P was inserted in frame at the 3' end of GST; v) GST-
ICP27 (Bryant, 2000) in which ICP27 was inserted in frame at the 3' end ofGST. 
2.1.S Tissue culture media 
The following tissue culture media were used throughout this thesis. 
ETC 10: Eagle's medium (Life technology) supplemented with 10% (v/v) newborn calf 
serum (Life technology), 10% (v/v) tryptose phosphate broth (Busby et al., 1964), 100 
ulml penicillin and 100mglml streptomycin (Life technology). 
DMEMIO: Dulbecco's modified Eagle's medium (Life technology) supplemented with 
10% (v/v) foetal calf serum, 100 ulml penicillin and 100mglml streptomycin (Life 
technology). 
EmetJ5C2: Eagle's medium containing one-fifth the normal concentration of methionine 
and 2% (v/v) newborn calf serum was used for radiolabelling cells. 
EMCIO: Eagle's medium containing 1.5% (w/v) carboxymethyl cellulose and 10% (v/v) 
newborn calf serum was used to overlay titrations to stop virus spread. If the cells were 
confluent, the percentage of calf serum was reduced to 5% (v/v) or 2% (v/v). 
2.1.6 Cells 
Baby hamster kidney 21 clone 13 (BRK) cells (Macpherson and Stoker, 1962) were 
grown in ETCIO medium. Human neuroblastoma (SK-N-SH) cells and mouse embryo 
fibroblast 3T6 cells (European Tissue Culture Collection) were grown in DMEMlO. 
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2.1.7 Viruses 
The wild type virus used was HSV -1 strain 17+ (Brown et al., 1973). The HSV -1 strain 
17+ deletion variant 1716 (MacLean, A. et al., 1991) was used as the parental virus for 
making recombinant viruses and as an ICP34.5 negative control in many experiments. 
TsK, a HSV -1 (17+) mutant with a ts lesion in ICP4 (Preston, 1979) which results in 
overproduction ofORF P at the NPT was also used. 
2.1.8 Antisera 
The following antisera were used throughout this thesis: a polyclonal antiserum, 137, 
against a GST-ICP34.5 fusion protein (Brown et al., 1997); two rabbit polyclonal 
antisera, 128 and 129, against a GST -ORF P fusion protein (provided by Dr. A. 
MacLean); an antipeptide serum against US11 (Johnson et al., 1986); and a monoclonal 
antibody against GST (Sigma). Protein A-HRP (Sigma) and anti mouse IgG HRP 
(Sigma) congugated sera were used as secondary antibodies. Antibodies used to detect 
ORF P interactions with both cellular and viral proteins are shown in table 2.1. 
2.1.9 Radiochemicals 
All radioisotopes were supplied by Amersham International pIc. They had the following 
activities: 
eSS]-methionine 
e2p]-dCTP 
[> 1 000 Ci/mmoI] 
[3000 Ci/mmoI] 
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Primary Type Function References 
antibody 
a CPSF (25 KDa) Mouse 3' cleavage and (Mane ley, 1995) 
polyadenylation of mRNA 
hnRNPK Rabbit Interacts with a number of (Bustello et al., 
cellular proteins involved in 1995) 
transcription, translation and 
signal transduction 
CK II ~ sununit Mouse phosphorylates and modulates (Sanz-Ezquerro et 
the function of a number of al., 1998) 
viral proteins 
Thymidine kinase Mouse Deoxypyrimidine kinase (Evans et al., 
(phosphorylation of thimidint!) 1998 
P32 Mouse Involved in splicing (Krainer, 1990) 
SC35 I Mouse Splicing factor (Sandri-Goldin 
et aI., 1995) 
hnRNP J Mouse Multifunctional protein (Bustello et ai., 
involved in posttranscriptional 1995) 
regulation 
aASF Mouse Recognition and cleavage of 5' (Krainer et ai., 
splice sites 1991) 
ICP27 Rabbit Multifunctional protein (Bryant et al., 
involved in posttranscriptional 2000 
r~ulation 
a CFI (25 KDa) Rabbit 3' cleavage and (Takagaki et al., 
polyadenylation of mRNA 1989) 
a CFI (68 KDa) Rabbit 3' cleavage and (Takagaki et al., 
polyadenylation of mRNA 1989) 
a CPSF (30 KDa) Rabbit 3' cleavage and (Maneley, 1995) 
polyadenylation ofmRNA 
Table 2.1: Cellular and viral proteins whose in vitro interaction with ORF P was 
investigated. Identified proteins interacting with ORF P indicated I. 
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2.1.10 Enzymes 
Restriction enzymes were purchased from Boehringer Mannheim and New England 
Laboratories. 
2.1.11 Membranes 
Hybond-N (Amersham) was used for Southern and Northern blotting. Either Hybond-
ECL (Amersham) or Immobilin-P (Millipore) was used for Western blotting. 
2.1.12 Plasmid harvesting reagents 
TE buffer: 10mM Tris HCI, ImM EDTA, pH 7.S 
Solution I SOmM glucose, 10mM EDT A, 2SmM Tris HCI, pH 8 and 
lysozyme (4 mg/ml) 
Solution II O.2M NaOH and 1 % (w/v) SDS 
Solution III 3M KAc, pH 4.8 
2.1.13 Tissue Culture Reagents 
HEBS: 130mM NaCI, 4.9mM KCl, 1.6mM NaHP04, 
5.SmM D-glucose, 21mM HEPES, pH 7.05 
NTE buffer: 10mM Tris HCl, 10mM NaCI, ImM EDTA, HCI pH 7.0S 
RSB 10mM KCI, 1.SmM MgCh, 10mM Tris, pH 7.6 
PBS A 170mM NaCl, 3.4mM KCI, 10mM Na2HP04, 1.8mM 
KH2P04, pH 7.2 
Trypsin 
Versene 
0.25% (w/v) trypsin in tris/saline containing (0.002%) 
phenol red, adjusted to pH 7.S with NaHC03 
0.6mM EDT A in PBS A, 0.002% phenol red 
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2.1.14 
TBE: 
Agarose gel reagents 
RE stop: 
89mM Tris, 89mM boric acid, 2mM EDT A. 
100mM EDTA, 10% (w/v) Ficoll 400, 0.25% (w/v) 
bromophenol blue in 5x TBE 
2.1.15 Southern blotting reagents 
Gel Soak I: 
Gel Soak II: 
20xSSC: 
Hybridization buffer: 
Washing solution: 
200mM NaOH, 600mM NaCI 
1M Tris HCI, 600mM NaCl, pH 8 
O.3M Na3 citrate, 3M NaCI 
O.5M NaP, 7% (w/v) SDS, pH 7.4 
2x SSC, 0.1% (w/v) SDS 
2.1.16 Northern blotting reagents 
lOX MOPS 
Denhardt's solution 
0.2M MOPS, 80mM sodium acetate, 10mM EDTA, 
pH8 
1% (w/v) BSA, 1% (w/v) Ficoll, 1% (w/v) PVP 
Northern blot prehybridization solution: 
50% (v/v) formamide, 5X SSC, 5X Denhardt's, 50mM 
Na2HP04, 0.1 % (w/v) SDS, 100 Ilg/ml salmon sperm 
DNA, pH 7.0 
Northern blot hybridization solution: 
50% (v/v) formamide, 5X SSC, 2X Oenhardt's, 5% (w/v) 
dextran sulphate, 0.5% (w/v) SDS, 250 Ilg/ml salmon 
sperm DNA, pH 7.0 
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15% (w/v) Ficoll, 10mM Sodium phosphate, ImM EOTA, 
0.25% (w/v) bromophenol blue, pH 7.0 
2.1.17 
Buffer A 
Buffer B 
Small scale nuclear and cytoplasmic extracts 
Hypotonic lysis buffer 
50mM Tris HCl, SmM MgCh, 10% (v/v) NP40, pH 7.S 
20mM Tris HCI, 420mM NaCl, 1.5mM MgCh, 0.5mM 
PMSF, (v/v) 25% glycerol 0.1% (v/v) smM ~­
mercaotoethanol, NP40, pH 8 
lOmM Tris HCI, lOmM KCl, 2.5mM MgCh, pH 7.5 
2.1.18 SDS-PAGE and Western blot reagents 
BM: 3xBM: 1 ml SGB, 25% (w/v) SOS, 0.5 ml ~­
mercaptoethanol, 1ml glycerol, 0.25% (w/v) bromo 
phenolblue 
ROB: 
SOB: 
Acrylamide (single) 
Acrylamide (gradient) 
Coomassie stain 
Destain 
HEPES extraction buffer 
375mM Tris HCl, 0.1 % (w/v) SOS, pH 8.9 
O.lM Tris HCl, 0.1% (w/v) SOS, pH 6.7 
30% (w/v) acrylamide [29.25% (w/v) acrylamide, 0.75% 
(w/v) N,N'-methyllene bisacrylamide] 
30% (w/v) acrylamide [28.5% (w/v) acrylamide, 1.5% 
(w/v) N,N'-methyllene bisacrylamide] 
50% (v/v) methanol, 7% (v/v) acetic acid, 0.02% (w/v) 
Coomassie brilliant blue 
5% (v/v) methanol, 7% (v/v) acetic acid 
50mM Hepes, 50mM NaCI, 0.1 % (v/v) NP40, pH 7.5 
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20% (w/v) methanol, 25mM Tris HCl, I 92mM glycine, pH 
8.3 
Protein gel running buffer 0.05M Tris, 0.05M glycine, 0.1 % (w/v) SDS 
2.1.19 
2.1.20 
Immunoprecipitation buffer (Zweig's buffer) 
O.lM Tris HCI, 10% (w/v) glycerol, 0.5% (w/v) NP40, 
0.5% (w/v) deoxycholate, pH 8.0 
Pull-down reagents 
50mM Tris HCI, 0.5mM NaCI, ImM EDTA, 0.5% (v/v) 
NP40 and Boehringer Mannheim protease inhibitors, pH 
8.0 
2.1.21 Chemicals 
Chemicals used were analytical grade and mostly supplied from BDH chemicals, U.K 
or Sigma Chemicals Co. APS and TEMED were supplied from Bio-Rad Laboratories. 
Ampicillin (penbritin) was supplied from Beecham Research. 
2.1.22 Autoradiography 
Autoradiograph grade XS-I film was supplied by Kodak. Autoradiographs were 
exposed for the appropriate time and developed in a Kodak-X-omat model ME-3. 
2.1.23 Miscellaneous equipment 
DNA was crosslinked to nitrocellulose membrane using a Stratagene UV Stralinker 
1800. 
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2.2 Methods 
2.2.1 Small scale isolation of plasmid DNA 
A single plasmid containing bacterial colony from a L-broth agar petri dish containing 
100 llglml ampicillin was picked with an autoclaved toothpick and placed in a universal 
bottle containing 5 ml L-broth and IOOllg/ml ampicillin. The bottle was placed in a 37° C 
shaker overnight. 1.5 ml of the culture was centrifuged at low speed for 1 min. The cell 
pellet was resuspended in 100 III of solution I by vortexing and incubated at RT for 5 
min. 200 III of solution II was added, mixed by inversion several times and incubated at 
RT for 5 min. 150 III of solution III was added, mixed by inversion, incubated at RT for 5 
min and centrifuged at high speed for 5 min. The supernatant containing plasmid DNA 
was transferred to a fresh tube and mixed with 450 III of phenol:chloroform (l: 1). The 
samples were vortexed and centrifuged at 13,000 rpm for 3 min at RT. The aqueous layer 
was transferred into a fresh tube, mixed with 1 ml EtOH and centrifuged at 13,000 rpm 
for 5 min at RT. The DNA pellet was washed with 70% EtOH, dried for 1 h at RT, 
resuspended in 100 III dH20 containing 50 ug/ul RNase A and stored at -20°C. 
2.2.2 Large scale isolation of plasmid DNA 
A 500 ml plasmid containing E. coli culture was grown in a 37°C shaker overnight in L-
broth containing 100 llg/m 1 ampicillin. Cells were pelleted by centrifugation at 7,000 
rpm for 10 min at RT. The supernatant was discarded and the pellet resuspended in IO 
ml Solution I by vortexing and incubated at RT for 5 min. 15 ml of solution II was 
added, mixed by inverting several times and incubated at RT for 5 min. 20 ml of solution 
III was added, mixed by inversion, incubated at RT for 5 min and centrifuged at 3,000 
rpm for 15 min. The pellet was discarded and the supernatant containing plasmid DNA 
was transferred to a fresh Falcon tube, mixed with 45 ml of phenol and centrifuged at 
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3,000 rpm for 15 min. The aqueous layer was transferred into a fresh Falcon tube and the 
phenol extraction repeated followed by a chloroform extraction. The aqueous layer was 
transferred into a fresh tube, mixed with two volumes of EtOH by vortexing and 
centrifuged at 3,000 rpm for 20 min at RT. The pellet was washed with 70% EtOH and 
dried overnight at RT. The pellet was resuspended in Iml dH20 containing 50 ug/ul 
RNase A. This solution was considered as plasmid DNA and kept at -20°C. 
2.2.3 Restriction endonuclease digestion 
Plasmid and viral DNA was routinely digested by different restriction endonucleases, 
using the buffer and temperature (usually 37°C) recommended by the manufacturer. 
Enzyme activity was stopped either by phenol extraction or by adding RE stop to the 
mixture. Digestion was visualized by electrophoresis through an agarose gel. 
2.2.4 Agarose gel electrophoresis 
Agarose gels (0.6-1.5% (w/v) agarose) were prepared by boiling the appropriate quantity 
ofagarose in Ix THE. Ethidium bromide at a concentration ofO.5/lg/ml was added to the 
gel prior to pouring. The solution was poured into a sealed tray which held a comb and 
placed in an electrophoresis kit. Once the agar was cool, the comb was removed and the 
samples pipetted into individual wells. Electrophoresis of the samples was carried out by 
running the gel overnight and the gel visualized and photographed under shortwave V.V 
light. 
2.2.5 Purification of restriction enzyme fragments from agarose gels 
DNA was digested with the appropriate restriction enzyme and electrophoresed through 
an agarose gel contanining 0.5 /lg/ml ethidium bromide until the fragment to be isolated 
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was well resolved. The gel was visualised under long wave UV light and the desired 
fragment excised using a sterile scapel. The gel slice was added to a filter tube (Costar) 
and centrifuged at 13,000 rpm for 15 min to elute the DNA. Residual DNA was eluted by 
adding an equal volume of 0.3M NaAc and recentrifuging. DNA was then 
phenol:cloroform extracted and EtOH precipitated. 
2.2.6 Phenol:chloroform extraction and precipitation of plasmid DNA 
An equal volume of phenol:chloroform was added to the DNA, mixed by vortexing and 
subjected to centrifugation for 2 min at 13,000 rpm at RT. The upper aqueous layer 
containing DNA was pipetted into a fresh tube and two volumes EtOH and 0.1 volume 
3M NaAc added, vortexed and placed on dry ice for 20 min. The solution was 
centrifuged for 5 min at 13,000 rpm at RT. The supernatant was discarded, the DNA 
pellet left to dry and the pellet resuspended in dH20 containing 50Ilg/ml RNase A. 
2.2.7 Ligation of plasmid DNA 
Different molar ratios of plasmid DNA to vector were added to a total volume of 14 Ill. 
4 III 5x ligation buffer was added, the solution mixed and centrifuged to collect at the 
bottom of the tube. Lastly 2,.11 T4 DNA ligase (3uJJll) was added to the solution which 
was mixed well and placed in a water bath at 16°C overnight. The following day this was 
used in a transformation reaction. 
2.2.8 Transformation of bacterial cells 
5 ml L-broth or 2YT broth were inoculated with E.coli and grown overnight at 37°C in a 
shaking incubator. 100 ml of fresh media were inoculated with 1 ml of the overnight 
culture and grown for approximately 3 h until an OD6oo of 0.6-1.0 had been reached. The 
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cells were pelleted by centrifugation at 2,000 rpm for 15 min at 4°C and the bacterial 
pellet resuspended in 50 ml 50mM CaCho The bacteria were pelleted as before, 
resuspended in 10 ml 50mM CaCh and incubated on ice for 30 min-24 h and used for 
transformation. 
Alternatively, Ultracompetent E. coli (Strategene) were thawed on ice from -70°C and 20 
J.lI ali quoted into an eppendorf tube. I J.lg of plasmid DNA or 1 J.ll of plasmid DNA 
solution was added, mixed and the tube placed on ice for 30 min followed by heat 
shocking in a 42°C water bath for exactly 90 sec followed by placing on ice for 2 min. 80 
J.ll 2YT broth was added and the reaction tube incubated for 1 h at 37°C. After I h the 
mixture was pipetted and spread onto a L-broth agar plate containing the appropriate 
antibiotic (usually amp at 100 J.lg/m1). The 100 J.lI mixture was adsorbed on the agar for 
15 min at RT before the plates were inverted and incubated in a 37°C incubator for 16 h. 
2.2.9 Growth and passaging of cells 
T -175 flasks or roller bottles with confluent mono layers were opened in a category 2 
microbiological safety hood, the supernatant decanted and 10 mi or 20 mI, respectively, 
of a trypsin/EDTA (0.25% v/v) solution poured over the monolayer and decanted. This 
was repeated and the flask or roller bottle left for 2 to 3 min. The cells were shaken into 
10 or 20 mls media for further use. For use in experiments the cells were plated onto 130 
mm (2xl08 cells), 60 mm (5x106 cells) and 35 mm (2xl06 cells) petridishes or Linbro 
wells (5x105 cells). 
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For passage, BHK cells, seeded at a 1 in 10 dilution, were grown in 100 ml ETClO in 
850 cm2 roller bottles with 5% C02 at 37°C for 3 to 4 days. Confluent cells (lxl08/roller 
bottle) were harvested as described previously. 
3T6 cells seeded at a 1 in 4 dilution, were grown in 50 ml DMEMlO in large flasks (T-
175) with 5% C02 at 37°C for 3 to 4 days. Confluent cells (3xl07/T-175 flask) were 
harvested as described previously. 
Human neuroblastoma (SK-N-SH) cells at a 1 in 4 dilution were grown in 50 ml 
DMEMlO in large flasks (T-175) with 5% C02 at 37°C for 3 to 4 days. Confluent cells 
(3xl07/T-175 flask) were harvested as described previously. 
2.2.10 Cryopreservation of cells 
Confluent cell monolayers of SK-N-SH and 3T6 cells were harvested from T175 flasks 
as described above, resuspended in 15 ml media and pelleted in Falcon tubes at 3,000 
rpm at 4°C for 10 min. Cells were resuspended in 5 ml of DMEMI0 containing 10% 
(v/v) DMSO, aliquoted into 1 ml, frozen overnight at _70°C and moved to a liquid 
nitrogen freezer (-140°C) for long term storage. 
2.2.11 Growth of HSV stocks 
Roller bottles containing a fresh monolayer of BHK cell (1 x 1 08 cellslbottle) were 
infected with 0.01 pfu/cell of HSV -1 in 20 m I of ETC 10 and incubated at 31°C for 4 
days or until c.p.e. was complete, when the cells were shaken into the medium and the 
cell suspension poured into a 250 ml plastic Falcon tube and the cells pelleted by 
centrifugation at 2,000 rpm for 10 min at 4°C. The supernatant and cell pellet were 
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divided into 2 individual stocks. The cell pellet was resuspended in 5 ml medium/roller 
bottle, pipetted into a sterile universal bottle, thoroughly sonicated for 5 min in a sonibath 
and centrifuged at 2,000 rpm for 10 min at 4°C. The process was repeated, the pellet 
discarded and the two supernatants combined and aliquoted into 1.5 m 1 sterile cryovials, 
stored at -70°C and considered as cell associated virus (CA). The supernatant was poured 
into a 250 ml sterile centrifuge bottle and spun at 12,000 rpm for 2 h at 4°C. The 
supernatant was discarded and the virus pellet resuspended in 5 ml fresh ETCIO lroller 
bottle and sonicated until homogeneous. This was aliquoted into 1.5 ml sterile cryovials, 
stored at -70°C and considered as supernatant virus (SV). 
2.2.12 Sterility checks on virus stocks 
BHI plates containing 10% (v/v) horse blood (blood agar) were used to check for yeast or 
bacterial contamination in viral stocks. A small aliquot of a viral stock was streaked onto 
the medium plates which were sealed with parafilm and incubated at 37°C for 24-48 h. If 
there was no growth by 48 h, stocks were considered sterile. 
2.2.13 Multicycle replication kinetics 
35 mm petri dishes were seeded with 2x106 cells/plate in 2 ml ETCIO and grown 
overnight at 37°C. Growth media was poured off and 100 ul of virus (0.0001 pfu/cell) 
added. The plates were returned to 37°C for I h. After 1 h the petri dishes were washed 
with 2 ml PBSNI0% CS and overlaid with 2 ml ETC 10. This was regarded as 
timepoint "0" h. Petri dishes were incubated at the appropriate temperature and harvested 
at the designated time points (usually 0, 6, 12, 24, 48, 72 and 96 h) by scraping the cell 
monolayer into the medium and transferring the suspension to a sterile bijou bottle 
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(Harland and Brown, 1985). The samples were sonicated and stored at -70°C until the 
experiment was complete. Titration of samples was carried out as described below. 
2.2.14 Virus titration 
Virus stocks were serially diluted lO-fold in PBS 10% CS and 0.1 m! aliquots added to 
fresh mono layers of BHK cells on 60 mm petridishes from which the media had been 
removed. The petri dishes were incubated at 37°C for 1 h to allow adsorption to the 
cells, before overlaying with 4 ml EMCIO. The petridishes were incubated at 37°C for 
48 to 72 h. The EMCIO was poured off each petri dish and the monolayer fixed and 
stained with Giemsa stain at RT for 1 h. After rinsing the petridishes with tap water and 
allowing them to dry, plaques were counted using a dissection microscope and virus 
titres calculated as pfuJml. 
2.2.15 Preparation of HSV virion DNA 
Ten roller bottles containing a fresh monolayer of BHK cells (lx108 cellslbottle) were 
infected with 0.01 pfuJcell of HSV-1 in 20 ml ETC 10. These were incubated at 31°C 
until c.p.e. was complete, when the cells were shaken into the medium. The cell 
suspension was poured into a 250 m1 plastic Falcon tube and pelleted by centrifugation 
at 2,000 rpm for 10 min at 4°C. The supernatant was kept on ice while nuclei were 
extracted from the cell pellet by treatment with 0.5% (v/v) NP40 in RSB buffer followed 
by centrifugation at 2,000 rpm for 10 min at 4°C. The supernatant was kept on ice and 
the above process repeated before pooling the three supernatants and centrifuging at 
12,000 rpm for 2 h at 4°C. The supernatant was discarded and the virus pellet lysed by 
resuspension in NTE buffer and the addition of EDT A and SDS to a final concentration 
of 10 mM and 2% (w/v), respectively. Viral DNA was extracted 3 times with saturated 
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phenol and once with chloroform, prior to precipitating with 2 volumes of EtOH by 
gentle inversion. The DNA was pelleted by centrifugation in a Fison's coolspin 
centrifuge at 2,000 rpm for 10 min at RT. The DNA pellet was washed with 0.67 tube 
volume 70% (v/v) EtOH by gentle inversion and centrifuged as described above. The 
supernatant was discarded and the pellet air dried for 15 min at R T before redissoving in 
dH20 containing 50 llg/m1 RNase A. 
2.2.16 Transfection of viral DNA 
The growth medium was removed from 60 mm petri dishes containing 4xl06 cells and a 
solution containing HEBS (with 10Ilg/ml calf thymus DNA), 130mM CaCh and HSV 
DNA (ranging from 0.2 to 2.0 Ilg) was added to each monolayer and incubated at 37°C 
for 40 min, overlayed with ETCI0 and incubated at 37°C for 4 h. The medium was 
removed, the mono layers washed Ix with ETClO and 1 ml HEBS (25% (v/v) DMSO) 
was added and incubated again at RT for 4 min. The medium was removed quickly, 
washed 2x with ETC I 0, overlayed with 4 ml ETC 1 0 and incubated for 3 days at 37°C 
until c.p.e was complete. The amount of HSV DNA giving the maximum level of c.p.e, 
was used to determine the amount ofHSV DNA for use in marker rescue. 
For marker rescue the same procedure was carried out but with a linearized cloned HSV 
fragment containing the desired mutation present in the transfection mixture at varying 
molar ratios, usually I: 1 to 50: 1. Again when c.p.e was complete, after 3-4 days, infected 
plates were harvested and titrated. 
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2.2.17 Plaque purification 
Serial IO-fold dilutions from either a transfection mixture or semipurified virus were 
made in PBS AlIO%CS. 100 III from each of the 102 to 106 dilutions were plated onto 
fresh BHK monolayers in 60 mm petri dishes from which the media had been removed. 
After I h adsorption at 37°C, the petri dishes were overlayed with 5 ml EMCIO and 
incubation continued at 37°C for a further 48 to 72 h. Using a 100 III Gilson pipette, 
plaques from the monolayer with the fewest well separated plaques were picked, 
resuspended in 500 III PBS AlIO%CS and sonicated in a sonibath until homogeneous. 
This procedure was either repeated or a Southern blot performed to check the purity of 
the recombinant virus. 
Occasionally, after plaque purification, recombinant viruses were further purified by 
limited dilution cloning. Here virus was 10 fold serialy diluted and each dilution was 
plated onto a 96 multi well dish (5x104 cells). Wells from a plate where less than 33% of 
wells were infected were regarded as originating from a single particle and virus stocks 
prepared and the DNA profile analysed. 
2.2.18 X-gal staining. 
Recombinant viruses expressing B-galactosidase were plaque purified by staining with X-
gal. BHK cell mono layers were infected with virus and overlayed as described 
previously using EMC2 containing 150 Ilg/ml X-gal. Recombinant plaques were isolated 
on the basis of their blue staining 
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2.2.19 Infected cell DNA preparation 
Linbro plates with BHK cell mono layers were infected at a moi of 5 pfulcell at 31°C. 
After 48 h the supernatant was removed and cells lysed by incubating with 2 m 1 lysis 
buffer (0.6% (w/v) SDS, 10 mM EDTA and 10 mM Tris HCI, pH 7.4) containig 
500,...g/ml protease for 4 h at 37°C. Infected cell DNA was extracted twice with an equal 
volume of phenol and once with chloroform, precipitated by the addition of 2 volumes of 
EtOH, the pellet washed with 70% EtOH and air dried for 30 min before redissolving in 
dH20 containing 50 Jlglml RNase A. 
2.2.20 Southern blotting and hybridization 
Purified DNA was digested with appropriate restriction enzymes before electrophoresing 
on a 1% (w/v) agarose gel. The gel was visualised under a short wave UV light to 
confirm DNA digestion then placed in a bath containing Gel Soak I for 1 hat RT. After 
rinsing with dH20 the gel was incubated in Gel Soak II for 1 h at R T and rinsed as above. 
Finally, the gel was incubated in 20x SSC for 1 hat RT. 
A pack of 'Hi-dri' towels was stacked on the bench followed by 3 sheets of dry Watmann 
3 MM paper. On top were 3 sheets of pre-soaked 3 MM paper and 1 sheet of nitro 
cellulose membrane (Hybond N) in 20 x SSC. The gel was placed on top, a glass plate 
and heavy weight placed over the top and left overnight to transfer DNA. To transfer 
DNA to two membranes this procedure was repeated on top of the gel. A UV crosslinker 
was used to crosslink the DNA to the membrane. The membrane was allowed to dry, 
placed in a glass bottle and hybridization buffer and radiolabelled probe DNA added. The 
membrane was incubated in a BioRad oven at 65°C overnight. The membrane was 
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washed twice in wash solution at 65°C for 30 min, air dried, covered with cling film and 
exposed to XS 1 film. 
2.2.21 Radiolabelling DNA 
Approximately, twenty five ng template DNA was made up to a final volume of II ul 
with dH20, placed in a tube and denatured by heating in a boiling water bath for 10 min 
followed by chilling quickly in an ice bath. The DNA was placed on ice while 4 J,ll of 5x 
High Prime reaction buffer containing the appropriate amount of enzyme (Boehringer 
Mannheim) and 2 J,ll (20J,lCi) [a.32p]dCTP] were added and the tube incubated for 30 min 
at 37°C. The reaction was stopped by placing the tube in a boiling water bath for 5 min. 
After boiling, the radio labelled probe was used with the blot as described in the previous 
section. 
For Northern blotting, the radiolabelled probe was purified from the unincorporated 
nucleotides by adding to a Mini quick spin RNA column (Roche) and spinning at 6 K for 
4 min. The eluate was the purified probe. 
2.2.22 Isolation of total RNA 
Total cellular RNA was prepared by Trizol (Life technology) extraction according to the 
manufacturer's protocol. The cell monolayer was washed twice with PBS A and 
harvested in 5 ml Trizol by passing the cell lysate several times using a plastic pipette. 
The lysate was incubated 5 min at RT in a 10 ml Starsted tube. 1 ml chloroform was 
added, incubated 2-3 min at RT, spun at 2000 rpm for IS min and the RNA containing 
aqueous upper layer transfered to a fresh tube. 2.5 ml of isopropanol was added and 
incubated 10 min at RT, followed by centrifugation at 2,000 rpm for 15 min. The 
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supernatant was discarded and pellet was kept in 75% EtOH at -70°C until use. At this 
time the EtOH was removed by spinning at 2,000 rpm for 15 min. The pellet was air 
dried for 5-10 min at RT, dissolved in 100 ,.d dH20 containing 0.5% (w/v) SDS at 60°C 
for 10 min and stored at -20°C. 
For Northern blotting, the sample was further purified. 100 J.lI ofphenol:chloroform (5:1) 
was added to the sample, shaken and spun at 2,000 rpm for 10 min. The top layer was 
transfered into a fresh tube, mixed with chloroform and spun again as before. The top 
layer was transfered into a fresh tube and treated with DNase solution (22 j..ll DEPEC 
dH20,3 J.lI DNase I, 10 j..lllOxbuffer) at 37°C for 1 h. The sample was mixed with 100 j..ll 
of phenol:chloroform and precipitated at 12,000 for 10 min, kept at -70°C and checked 
by loading on a gel containing 2.2% (v/v) formaldehyde, Ix MOPS, 1.2% (w/v) agarose 
and electrophoresised in Ix MOPS buffer at 140 mV until the dye front had migrated two 
thirds of the gel. 
2.2.23 Northern blotting 
10 ug of total RNA was dried under vacuum and resuspended in 15 ul of a buffer 
containing 50% (v/v) formamide, 16.6% (v/v) formaldehyde and Ix MOPS and 
incubated at 37°C for 10 min. 3 ul RNA loading buffer was added, the sample boiled for 
2 min and chilled on ice. The RNA samples were electrophoresed as described 
previously. The marker lane was removed and stained in 5 ug/ml ethidium bromide for 
20 min, washed twice in dH20 and left to destain overnight in 500 ml dH20. 
The gel was washed three times with 2x SSC and the transfer set up. For this, a 14 x 9 cm 
horizontal gel slab tray to be used as a support was placed upside down in about 2 cm of 
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2x SSC in a tray. To form the wick to allow the 2x SSC to travel into the tower, two 
pieces of 14 x 18 cm 3 MM Whatman filter paper were pre-wet in 2 x SSC and laid over 
the support so the overhanging edges dipped into 2 x SSC. This was overlayed by four 14 
x 9 cm 3 MM papers prewet in 2 x SSC. The gel slab was placed on the filter paper and a 
Hybond-N membrane, cut to the same size as the gel, placed on top. The tower was 
completed by the addition of 2 pieces of 3 MM papper cut to the same size as the gel and 
a stack of paper towels. A glass plate was placed on the top and the tower weighted 
down. At all times care was taken to ensure the removal of air bubbles. Transfer was left 
to occur overnight at RT. 
To prepare the membrane for probing, the tower was disassembled and the nitrocellulose 
membrane left to air dry. The RNA was crosslinked to the membrane for 2 min in a UV 
cross linker. To probe the blot for specific RNAs, a column purified random primed 
probe was used. For this, the membrane was prehybridized for 4 h at 42°C in 5ml of pre-
hybridization buffer and at the end replaced by 2 ml hybridization buffer. The e2PJ-
labelled ONA probe was denatured for 5 min at 100°C, chilled on ice, added to the 
hybridization buffer and incubated with the membrane overnight at 42°C. The blot was 
washed at 6SoC, Ix with 2 x SSC/O.1% (w/v) SOS and Ix with 1 x SSC/O.l% (w/v) SOS 
and monitored for radioactivity. If the blot was still fairly radioactive it was washed a 
further Ix with 0.5 x SSC/O.l % (w/v) SOS and Ix with 0.1 x SSC/O.l % (w/v) SOS at 
6SoC. The blot was sealed in a heat sealable bag and exposed to X-Omat XSI film at 
least overnight at -70°C. 
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2.2.24 Extraction of infected cell proteins 
60 mm plates containing 4xl06 cells were infected with 20 pfu/cell and incubated for the 
appropriate time (usually overnight) at 37°C. Samples were harvested by removing the 
media, washing the infected cell monolayers twice with cold PBS A and the monolayers 
extracted in 500 f.11 boiling mixture (BM/3). For immunoprecipitation experiments, the 
same procedure was carried out but the mono layers were harvested with 500 ul Zweig's 
buffer. 
2.2.25 SDS-polyacrylamide gel electrophoresis 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) was used to analyse both viral and 
cellular proteins. Slab gels were cast vertically in a sandwich consisting of 2 glass plates 
separated by 1.5 mm perspex spacers. Either a single concentration gel ranging from 
7.5% to 12.5% (w/v) acrylamide or a 5-12.5% (w/v) acrylamide gradient gel was used. 
The resolving gel was prepared using RGB with 0.05% (w/v) APS and 0.04% (v/v) 
TEMED. A 1 ml layer of butan-2-01 was poured on top to exclude air and enable 
polymerisation of the gel. Prior· to adding the stacking gel, the butan-2-0 1 was removed 
by rinsing the surface of the running gel with dH20. The stacking gel was composed of 
5% (w/v) acrylamide crosslinked with the same ratio of N,N-methylene-bisacrylamide 
used in the resolving gel, mixed with SGB, 0.05% (w/v) APS and 0.04% (v/v) TEMED. 
This was poured on top of the resolving gel, a comb installed and allowed to solidify for 
30 min. Gels were electrophoresed either for 3 to 4 h at 50 rnA, or overnight at 10 rnA 
(Marsden et al., 1978) and if appropriate prepared for Western blotting. 
In addition to Western blotting, gels were used for analysis of protein expression both by 
Commassie blue staining and autoradiography. Gels were stained for 1 hat RT, de stained 
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3x for 30 min, and if appropriate enhanced in 50 ml ofEn3Hance (New England Nuclear) 
for 15-30 min, dried under a vacuum for 1.5 h at 80°C and exposed to X-omat film at-
70°C. 
2.2.26 Western blotting 
Samples were separated by SDS-PAGE as described above. Hybond-ECL membrane 
(Amersham) or Immunoblot (Millipore) and two 3 MM sheets were cut to the same size 
as the gel and presoaked in Towbin buffer. The proteins in the gel were transferred to the 
membrane for at least 3 h at 250 mAo After transfer, the membrane was blocked in PBS 
AfT (PBS A and 0.05% (v/v) Tween 20) containing 5% (w/v) Marvel milk for 1 h at RT. 
The primary antibody was diluted to the desired concentration in 25 m 1 PBS AfT !Marvel 
and incubated at either 37°C for 2 h, RT for 2 h or 4°C overnight. The membrane was 
washed 3 times in PBS AIT for 10 min at RT. The membrane was incubated in the 
appropriate HRP conjugated secondary antibody, diluted 1:1000 in PBS AfT!Marvel at 
RT for 1 h followed by 3 washes in PBS AIT for 10 min. A detection reagent (ECL) was 
added to the membrane for 1 min and the membrane exposed to XS-l film for the 
appropriate amount of time. 
2.2.27 Immunoprecipitation 
Cell monolayers in 60 mm plates were infected with virus at a moi of 20. At the 
appropriate time(s) mono layers were harvested by washing with PBS A twice, adding 
500 J..I.I Zweig's buffer to each plate and incubating for 60 min at 4°C. The extract from 
each plate was transferred into a bijou, sonicated for 3 min and spun for 3 min at 13,000 
rpm. The supernatant was pipetted into a fresh eppendorf tube and either used 
immediately or stored at -70°C. 200-500 u1 of the supernatant (cell extract) was mixed 
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with the appropriate volume of antibody and incubated at either 4°C overnight or 37°C 
for 2 h. 75 ~1 50% (v/v), protein-A-sepharose in Zweig's buffer was added and the 
sample incubated on an end-oyer-end mixer for 45 min at 4°C. After that, the sample was 
centrifuged at 7,000 rpm for 1 min, the supernatant discarded and the pellet washed 3-4 
times with Zweig's buffer. After the final wash, the pellet was harvested in 50 ~ I boiling 
mixture and analysed by SDS-PAGE. 
2.2.28 Nuclear and cytoplasmic fractionation 
Initially, the same method was used to extract nuclear and cytoplasmic fractions. 
However, due to contamination of nuclear with cytoplasmic material, different methods 
were subsequently used. Confluent monolayers in either 60, 90 or 130 mm plates were 
infected with virus at a m.o.i. of 20 pfu/cell at 37°C for 16 h. Cells were washed twice 
with PBS A and harvested by scraping the monolayer into PBS A. 
To extract the cytoplasmic fraction, the monolayer was scraped into I ml PBS A. The 
cell suspension was poured into an eppendorf tube, briefly vortexed and spun at 6,000 
rpm for 1 min at 4°C. The cell pellet was resuspended in 100J.11 buffer A containing 0.5% 
(v/v) NP40, incubated on ice for 15 min and homogenized on ice in a Dounce 
homogenizer. After incubation the samples were centrifuged at 6,000 rpm for 15 sec at 
4°C. The supernatant was kept on ice while the pellet was resuspended with 100 ~1 
buffer A containing 0.5% (v/v) NP40, incubated on ice for 2-3 min, spun at 6,000 rpm 
for 15 sec and the supernatant mixed with previous one and used as the cytoplasmic 
fraction. 
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To extract the nuclear fraction, the monolayer was scraped into 10 ml PBS A. The cell 
suspension was poured into a 15 ml Falcon tube, briefly vortexed and spun at 3,000 rpm 
for 5 min at 4°C. The cell pellet was resuspended in 4 ml hypotonic lysis buffer (HLB) 
and incubated on ice for 15 min. After incubation the samples were centrifuged at 3,000 
rpm for 5 min at 4°C. The supernatant was left on ice while the pellet was resuspended 
with I ml supernatant and homogenized on ice in a Oounce homogenizer. The 
homogenized solution was mixed with the rest of supernatant in a 15 ml Falcon tube, 
underlayed with I ml HLB+IO% (w/v) sucrose and respun at 3600 rpm for 5 min at 4°C. 
The supernatant was discarded and the pellet containing the nuclei resuspended in 100 III 
boiling mix. Samples were boiled for 10 min, analysed by SOS-PAGE and Western 
blotted. 
2.2.29 Analysis of virus and host cell protein synthesis shutoff 
Cells were either mock infected or exposed to 20 pfu/ml virus for I h at 37°C. Growth 
media was added and petridishes incubated for 14 h at 37°C. At 14 h pi, the media was 
poured off, the cells washed twice with 2 ml Emetl5C2 and overlayed with Emetl5C2 
containing 50 uCii ml eSS]-methionine for 2 h. At 16 h pi cells were washed twice with 
PBS A, harvested in boiling mixture, analysed by SOS-PAGE and autoradiography. 
2.2.30 GST fusion protein growth and purification 
A single freshly transformed colony was grown overnight in 5 m 1 2YT containing 
100uglml ampicillin. This culture was diluted 11100 in 2YT containing lOOuglml 
ampicillin and grown in a shaking 37°C incubator to reach an 00600 of 0.6-0.1. To induce 
expression of the GST fusion protein, O.2mM IPTG was added and the cultures placed 
back in the incubator for either 2 h at 37°C, 4 h at 31°C or overnight at RT. After 
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induction, the culture was centrifuged at 13,000 rpm at 4°C for 5 min, the supernatant 
discarded and the pellet resuspended in 300 ).11 ice cold PBS A. Cells were lysed using a 
soniprobe and centrifuged at 13,000 rpm for 5 min at 4°C to remove the cell debris. The 
supernatant was transferred to a fresh ependorf tube, 50 ).11 of 50% (v/v) glutathione 
agarose beads added to the supernatant and mixed end-oyer-end for 1-3 h at 4°C. 
Samples were centrifuged at 13,000 rpm for 1 min at 4°C, the supernatant discarded and 
1 ml of PBS A added to the pellet, vortexed, and centrifuged for 1 min at RT. Washing 
was repeated 3 times and the pellet harvested in boiling mixture and analysed by SDS-
PAGE or stored at 4°C for use in a pull down assay (2.2.32). 
To induce expression of GST fusion proteins in Novablue strain, bacterial cultures were 
grown as described above but after reaching an OD600 of 0.6 to 1.0, superinfected with 2-
4x109 pfu/ml (5-10 moi) of ACE6 phage at 37°C for 3 h. After induction, the same 
procedure as above was carried out to harvest expressed protein. 
2.2.31 Cell extract preparation for GST pulldown 
For pull down assays, soluble protein extracts were prepared from either labelled or 
unlabelled infected or mock infected cell extracts. For labelled extracts, proteins were 
labelled with 100).1Cilml eSS]-methionine in E-metl5. Cell mono layers were washed 
twice with PBS A, 1.3 ml HEBS extraction buffer added for 30-60 min at 4°C and cells 
harvested by scraping. The cells were lysed by sonication for 2 min in a sonibath and cell 
debris pelleted by centrifugation at 13,000 rpm for 2 min. The pellet was discarded and 
soluble protein extracts were stored at -70°C. 
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2.2.32 Pulldown assay 
Freshly prepared glutathione agarose beads with bound GST fusion proteins were mixed 
with 300 or 400 ul labelled or unlabelled cell protein extract and incubated for at least 3 
h at 4°C with continuous end-over-end mixing. The beads were harvested by 
centrifugation at 13,000 rpm for 1 min and washed 3 times in 1 ml HEBS extraction 
buffer containing varying amounts of NaCI (0.5-500mM). The beads were harvested in 
boiling mixture and either stored at -20°C or boiled for 5 min, analysed by SDS-PAGE 
Gels were either fixed, dried and autoradiographed or used for Western blotting. 
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3.0 Construction and purification of HSV -1 recombinant viruses 
3.1 Introduction 
Using a HSV-IIHSV-2 intertypic recombinant virus, RE6, Thompson et al. (1983) mapped a 
HSV -1 neurovirulence locus to a region in the long repeat sequences. A number of genes are 
encoded by the HSV-l long repeat between ICPO and the 'a' sequence (see chapter 1.15.1). 
In 1986, Chou and Roizman demonstrated that in HSV-l strain F, the "a" sequence contains 
the promoter and transcription initiation site of a gene which was subsequently identified by 
Ackennan et al. (1986). Using an antiserum directed against a synthetic peptide containing a 
Proline-Alanine-Threonine (PAT) repeat from within the putative open reading frame 
(ORF), these workers identified that this ORF expresses a protein named ICP34.5. Dolan et 
al (1992) subsequently named this ORF in HSV -1 strain 17+ RLI. Viruses which do not 
express ICP34.5 have a reduction in replication in certain cells in vitro and are avirulent 
upon intracranial inoculation in the murine model in vivo (Brown et al., 1994a; MacLean, A. 
et al., 1991; Thompson et al., 1989; Chou et al., 1990). Thus ICP34.5 appear to encodes the 
virulence locus originally identified by Thompson et al in 1983. The experiments could not 
discount the possibility that the later identified ORF 0 and P were responsible for the 
phenotype observed. 
In 1994, Lagunoff and Roizman demonstrated that there are 16 ORFs (ORFs A-P) located in 
the opposite direction to RLI within the LAT transcript in the long repeat sequences in strain 
F. Two of these ORFs (0 and P), map almost entirely antisense to RL1. However, both ORF 
o and P are not expressed from LAT but from their own promoter and associated RNA 
internal to and 3' coterminal with LAT. This transcript is known as the LIST transcript (Yeh 
and Schaffer, 1993). Binding ofICP4 to a consensus ICP4 binding site, ATCGTC, upstream 
of the ORF OIP transcription initiation site completely represses this transcript during 
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productive infection (Lagunoff and Roizman, 1995). Using a virus with a mutation in the 
ICP4 binding site of the putative ORF OIP promoter which causes repression of ORF 0 and 
P transcription, Lagunoff and Roizman in 1995 demonstrated that these two ORFs express 
proteins. 
ORFs 0 and P are not expressed during productive infection in Vero cells by HSV-l strain F 
at its permissive temprature of 37°C, but are detectable following infection of F at its non-
permissive temperature of 39.50C as ICP4 is temperature sensitive in this strain (Lagunoff 
and Roizman, 1994; Lagunoff et aI., 1996). Similarly, infection with a HSV -1 strain 17+ 
mutant (tsK) with a temperature sensitive (ts) lesion in ICP4 results in overexpression of 
ORF P at the non permissive temperature (NPT) of 38.50C. This virus is used as a control for 
expression ofORF P (chapter 4). The functions ofORFs 0 and P are not well underestood 
and are discussed in chapter 1. 
A HSV-l strain 17+ spontaneous deletion mutant, 1716, which has 759 bp ofthe long repeat 
region deleted, has been isolated and characterized (MacLean, A. et a/., 1991). In 1716 both 
copies of ICP34.5 and ORFs 0 and P in the inverted repeat sequences are deleted. The 
mutant showed major differences in behaviour both in vivo and in vitro compared to 17+ 
(see 1.15.3). To assign the phenotypes of this mutant to either ICP34.5 or ORF 0 and P, a 
number of recombinant viruses based on 1716 were constructed. In these mutants either only 
ICP34.5 or ORF P were inserted singly within 1716 or both were inserted independently. In 
most cases the site of insertion was in the non essential UL43/43.5 locus at the 5' end of 
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UL43. The site of insertion was at a unique NsiI site which had been modified to include 
SpeI and BgnJ sites in a plasmid, p35 (pac!) (Fig.3.1). 
3.2 1622 
3.2.1 Introduction 
This recombinant virus was constructed by Holman (2000) in the background of 1716 and 
expresses both ICP34.5 and LacZ in the UL43/43.5 locus (Fig.3.2). In this study 1622 was 
used for two reasons. Firstly, to analyse the role of ICP34.5 in vitro in the context of a virus 
which does not express ORF P. Secondly, to construct a further mutant, 1625, in the 1622 
background (section 3.5). 
3.2.2 Isolation and purification 
This mutant was constructed and purified by Holman (2000). Its purification was based on 
its ability to express ~-galactosidase that turns its substrate, X-Gal, blue. To check its purity, 
further plaque purification (section 2.2.17) was carried out. After several rounds of plaque 
purification, the DNA of some of the best isolated blue plaques was analysed by Southern 
blotting. 
DNA was digested with BamHI and Southern blotted with a fragment spanning the site of 
insertion (P35). The structure of 1622 is shown in Fig.3.2b and 3.3a and the resultant 
Southern blot in Fig.3.3b. Insertion of ICP34.5/LacZ introduces a new BamHI site into 
UL43/43.5 of 1622 (Fig 3.3a). Following digestion with BamHI, 17+ (and 1716) with no 
insertion gives a 6.6 kbp band (Fig.3.3b, lane!) whilst 1622 gives 2 bands of 4.5 and 7.8. 
kbp. As this figure shows, 1622 had been succesfully purified (Fig.3.3b, lanes 2 and 3). 
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NSll Bgi II SpeI NsiI 
Figure 3.1 Structure ofp3S (pael) 
p35 (pacI) containing a 5.1kbp (n.p 9161O-n.p. 96751) BamHIIEcoRI fragment spanning 
HSV-I genes UL41 to UL44. SpeI and BglII sites were inserted into the unique NsiI at 
the 5' end ofUL43. The HSV-l genes with their orientations are indicated. 
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Figure 3.2 Structure of 1622 
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a. This figure shows the structure of 1716. "a" is a direct repeat sequence present at both 
termini and in inverted orientation "a" in the internal repeat. "b" refer to the long and "c" 
to the short repeat. "X" indicates the deletion oflCP34.5/0RF P. The position of the NsiI 
site plus additional SpeI site in UL43/43.5 is shown. 
b. This line shows the structure of 1622. ICP34.5ILacZ containing an internal BamHI site 
was inserted into UL43/43.5 with ICP34.5 in the UL43 .5 and LacZ in the UL43 
orientation. The arrow heads indicate the orientation of transcription. 
Chapter. 3 Results 
a. BanrHI 3.3 kbp NsillSpel 3.3 kbp BamHI 
{ P 
BamHI NsillSpel NsillSnel 
3.3kbp 3.3kbp 
... ~ ... 
7.8 kbp ~ . Skh l' 
b. 
2 3 
7. 8 kbp 
6.6 kbp 
r.m*.~"" 4. 5 kbp 
Figure 3.3 Purification of 1622 
a. A linear diagram illustrating the BamHI fragment spanning UL43 in wild type and 
recombinant viruses, the site of insertion at the NsiIISpeJ sites, and si zes of BamHr 
fragments fo llowing digestion. 
b. A Southern blot of HSV DNA digested with BamHI and probed with e2p]dCTP 
labelled p35 and exposed to an autoradiograph for 24h at -70°C. Lane I: 17+; lane 2: the 
original 1622; Lane 3: purified 1622. The sizes of the bands are marked and determined 
from a 1 kbp ladder (not shown). Hybridising bands are indicated ( ~ ). 
Chapter. 3 Results 
Eventually, one completely purified plaque was isolated and used to prepare a viral stock. 
Previously, Holman (2000) had detennined the orientation of ICP34.S/LacZ and shown that 
ICP34.5 was transcribed in the UL43.S orientation and LacZ in the UL43 orientation. 
3.3 1624 
3.3.1 Introduction 
In order to examine the role of ORFs 0 and P in the replication of HSV-I in vitro, two 
recombinant viruses, 1624, and 1624.5 (Fig.3.4) were constructed, using 1716 as parent. The 
ORF 0 and P genes were reintroduced under the gD promoter in a novel location in 
UL43/43.5 in 1624 and 1624.5. ORFs 0 and P should be expressed with the early/late 
kinetics of gD since the ICP4 binding sequence is not present. In 1624, ORFs 0 and Pare 
transcribed in the same orientation as UL43 (Holman, 2000) and in 1624.5 the same 
orientation as UL43.5. These mutants should express only ORFs 0 and P, and not ICP34.5. 
Thus, the effect of expression of only ORFs 0 and P or any synergistic effect of ORFs 0 and 
P and ICP34.5 could be elucidated. 
3.3.2 Insertion of gDORF P in the UL43/43.5 locus 
For insertion of ORF Pinto UL43/43.S, several stages of construction were carried out. 
Firstly, two primers complementary to the N and C tennini of ORF P with tenninal EcoRi 
and BamHI sites respectively were synthesised and a 705 bp ORF P fragment generated 
(Ross Reid, personal communication). This fragment was inserted into the EcoRI/BamHI 
sites of pGEX 5Xl to generate pGEXlORF P. Using pGEXlORF P the ORF P gene was 
isolated by SmaIlBamHI digestion (Fig.3.5a) and ORF P inserted into the compatible Small 
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Figure 3.4 Structure of 1624/1624.5 
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a 
3. This line shows the structure of ] 716. "a" is a direct repeat sequence present at both 
tennini and in inverted orientation"a'" in the internal repeat. "b" refer to the long and "c" 
to the short repeat. "X" indicates the deletion oflCP34.5/0RF P. The position of the Nsf I 
site plus additional SpeJ site in UL43/43 .5 is shown. 
b. This line shows the structure of 1624. gDORF PILacZ containing an internal BamHI 
site was inserted into UL43/43.S with gDORF P in the UL43 and LacZ in the UL43 .5 
orientation. The arrow heads indicate the orientation of transcription. 
c. This line shows the structure of 1624.5. gDORF P/LacZ containing an internal BamHI 
site was inserted into UL43/43.S with gDORF P in the UL43 .S and LacZ in the UL43 
orientation. The arrow heads indicate the orientation of transcription. 
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Figure 3.5 Subcloning of gDORFP into p35 (pacl) . 
a. Diagram of the PCR generated 705bp fragment spanmg ORF P isolated from 
pGEX5X 1. There is a SmaI site at the N terminal and a BamHI site at the terminal. 
b. ORF P is inserted into the SmaIlBgilI sites ofpF14H under the gD promoter. 
c. A XbaI fragment containing gDORF P and LacZ is isolated from pF 14H/ORF P. 
d. This fragment is inserted into the SpeI site ofp35 (PacI). 
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BgnI sites in pFJ14H under the HSV-1 gD promoter and upstream of the HSV-2 immediate 
early IES poly A sequence (Holman, 2000; Fig.3.Sb). This plasmid also contains LacZ under 
the control of a SV 40 promoter and a SV 40 poly A sequence in the opposite orientation to 
the ORF P gene. 
pFJl4H was digested with XbaI and the gDORF PILacZ containing fragment isolated 
(Fig.3.5c). P35 (pacI) containing a 5.1 kbp BamHIIEcoRI fragment (n.p 91610-96751) 
spanning HSV-l genes UL4l-44 (Fig.3.5d) was digested with SpeI (in the linker) and the 
XbaI fragment containing gD/ORF P and lacZ inserted into the compatible SpeI site in 
UL43/43.5 (MacLean, A. et al., 1991; McGregor et al., 1999; Holman, 2000). Ligation 
could result in insertion in either orientation, arbitrarily called A and B. In the orientation A, 
ORF P is in the same direction as UL43 and in the orientation B, the same as UL43.5 
(Fig.3.6a, b). These plasmids were used to generate 1624 and 1624.5 respectively. 
To determine the orientation of gD/ORF P and LacZ, both plasmids were digested with 
EcoRIlBamHI and BamHIIBgfll. In the A orientation, following digestion with 
EcoRIIBamHI, bands of 5.95, 3.7, 2.7, 800bp and 450bp should be generated and in the B 
orientation bands of 7.35, 2.7, 2.2kbp, 800bp, and 450 bp. In Fig.3.6c, lanes 1 and 3 these 
bands can be seen confirming the structure of these plasmids. On BamHI/BgnI digestion, in 
the A orientation bands of 9.0, 3.3, and 1.2 kbp and in the B orientation, bands of 5.7,4.5, 
and 3.3 kbp should be generated. In Fig.3.6c, lanes 3 and 4 these bands can again be seen 
confirming the structure of these plasmids. 
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i) p35 (PacI) containing a 5.lkbp BamHI-EcoRI HSV-l fragment spanning genes UL41-
UL44 (in bold). The multicloning site in UL43 containing NsiIlBgnIlSpeI sites is shown 
ii) The 5.7 kbp gDORF P (bold) ILacZ (stiple) fragment is inserted into the Spe I site in 
p35 in either orientation. The BamHIIEcoRI sites and resultant fragments used to 
determine the orientation are marked. The arrow heads indicate the orientation of 
transcri pti on. 
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Figure 3.6b Orientation of gDORF PI LacZ in p35/0RF P 
i) p35 (Pac!) containing a 5.1kbp BamHI-EcoRl HSV-l fragment spanning genes UL41-
UL44 (in bold) . The multic\oning site in UL43 containing NsillBg/IIISpeI sites is shown. 
ii) The 5.7 kbp gDORF PILacZ (stiple) fragment is inserted into the Spe[ site in p35 
(Pac!) in either orientation. The BamHIIBgnI sites and resu ltant fragments used to 
determine the orientation are marked. The arrow heads indicate the orientation of 
transcription. 
Chapter. 3 Results 
2 3 4 5 
-.,....,..,..--9kbp 
7kbp 
Figure 3.6c The structure and orientation of P35/0RF P (A, B) 
DNA from p35/0RF P was digested with EcoRIIBamHI (lanes 1, 2) or BamHIIBglII 
(lanes 3, 4) and electrophoresed on a 0.7% (w/v) agarose gel. Orientation A is in lanes 1, 
3 and orientation B in lanes 2, 4. A I kbp ladder is shown in lane 5. The maps of these 
plasmids are shown in figure 3a (EcoRIIBamHI) and figure 3b (BamHIIBglII) . 
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A transfection with 1716 DNA and p35/0RF P (A) (Fig.3.7) had previously been performed 
by Holman (2000), but no purification had been carried out. Purification of 1624 was based 
on its ability to express ~galactosidase and turn its substrate, X-Gal, blue. After several 
rounds of plaque purification (section 2.2.17), the DNA of some of the best isolated blue 
plaques was analysed by Southern blotting. 
DNA was digested with BamHI and Southern blotted with a fragment spanning the site of 
insertion (P35) . The structure of the recombinant virus, compared with its parent, 1716, is 
shown in Fig.3.8a and the resultant Southern blot in Fig.3.8b. Insertion of gDORF P/LacZ 
introduces a new BamHI site into UL43/43.5 of 1624 (Fig.3.8a). Following digestion with 
BamHI, 17+ (and 1716) containing no insertion give a 6.6 kbp band (Fig.3.8b, lane 1) whilst 
1624 with an insertion containing a BamHI site should give 2 bands of 4.5 and 7.8. kbp 
(Fig.3.8b, lane 3). As this figure shows, during purification the wild type 6.6 kbp band 
disappears and is replaced by two bands of 4.5 and 7.8 kbp, indicating the purity of 1624. 
The profile of DNA from the original transfection to generate 1624 is shown in lane 2. Only 
the 6.6 kbp is seen, indicating a low percentage of 1624 is present in the transfection 
mixture. Eventually, one completely purified plaque was isolated and used to prepare a viral 
stock. 
3.4 1624.5 
3.4.1 Introduction: 
Holman (2000) had previously initiated construction of 1624 in which ORF P sequence 
inserted in the UL43 orientation (Fig.3.4b). After purification and during characterization, 
growth of the 1624 mutant in BHK cells was impaired compared to the growth of 17+, 1716 
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Figure 3.7 Construction of 1624 
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a. p35/0RFP (A) containing gDORF P ILacZ with ORF P in the same orientation as 
UL43 and LacZ in the same orientation as UL43.5 was digested with XbaI to isolate 
gDORF PILacZ. The arrow heads indicate the orientation of transcription. 
b. gDORF PILacZ with flanking HSV -1 DNA was recombined with 1716. 
c. The structure of 1624 is shown. The arrow heads indicate the orientation of 
transcri pti on. 
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Figure 3.8 purification of 1624 
17+/ 
1716 
1624 
a. A linear diagram illustrating the BamHI fragment spanning UL43 in wild type and 
recombinant viruses, the sites of insertion at the NsiIlSpeJ site, and size of BamHl 
fragments following digestion. 
b. A Southern blot of HSV DNA digested with BamHI and probed with e2p]dCTP 
labelled p35 and exposed to an autoradiograph for 48h at -70°C. Lane 1: J 7+; lane 2: the 
original 1624 transfection; lane 3: purified 1624. The sizes of the bands are marked and 
determined from a 1 kbp ladder (not shown). Hybridizing band are indicat d (~ ). 
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and 1622. In addition, 1624 seemed to express at best only low levels of ORF P. Based on 
Holman's (2000) preliminary finding that expression in the UL43.5 orientation is stronger 
than expression in the UL43 orientation, we decided to construct a mutant, based on 1716, 
that ORF P sequence inserted in the UL43.S orientation and named this mutant 1624.5 
(Fig.3.4c). 
3.4.2 Construction: 
Fig.3.9 shows the strategy for construction of 1624.5. P3510RF P (B) in which gD/ORF Pis 
inserted in the same orientation as UL43.5 was used to construct this mutant (Fig.3.9a). This 
plasmid was digested with XbaI to generate a linearized fragment containing gD ORF PI 
LacZ with flanking HSV DNA. This fragment was recombined with 1716 (Fig.3.9b) to 
generate 1624.5 in which gDORF PILacZ was inserted in UU3/43.5 of 1716 with ORF P 
being expressed in the UL43.5 orientation (Fig.3.9c). 
3.4.3 Isolation and purification: 
1624.5 was isolated on the basis of its ability to express ~-galactosidase and turn its 
chromatogenic substrate, X-Gal, blue. 1624.5 was purified from its parent as described in 
section 2.2.17 through several rounds of plaque purification. After several rounds of plaque 
purification, the DNA of some of the best isolated blue plaques was analysed by Southern 
blotting. 
DNA was digested with BamHI and Southern blotted with a fragment spanning the inserted 
fragment (P35). The structure of the recombinant virus, compared to its parent, 1716, is 
shown in Fig.3.10a and the resultant Southern blot in Fig.3.lOb. Insertion ofgDORF PILacZ 
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Figure 3.9 Construction of 1624.5 
a. p35/0RFP (B) containing gDORF P ILacZ with ORF P in the same orientation as 
UL43.5 and LacZ in the same orientation as UL43, was digested with XbaI to i olate 
gDORF PILacZ. The arrow heads indicate the orientation of transcription. 
b. gDORF PILacZ with flanking HSV-I DNA was recombined with 17 J 6. 
c. The structure of 1624.5 is shown. The arrow heads indicate the orientation of 
transcription. 
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Figure3.10 Purification of 1624.5 
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a. A linear diagram illustrating the BarnHI fragment spanning UL43 in wild type and 
recombinant viruses, the sites of insertion at the NsiIlSpe] site, and size of BarnHI 
fragments following digestion. 
b. A Southern blot of HSV DNA digested with BarnHI and probed with [32PJdCTP 
lablled p35(pacI) and exposed to an autoradiograph for 24h at -70°C . Lanes J -3: 
semipurified 1624.5; lanes 4-8: purified 1624.5; Lane 9: 1624.5 stock; Lane 10: 1716; 
lane 11: 17+; and lane 12: 1 kbp DNA ladder with the sizes marked. Hybridizing bands 
are indicated ( ~ ). 
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introduces a new BamHI site into the UL43/43.S locus of the recombinant virus (Fig.3.10a). 
Following digestion with BamHI, 17+ (and 1716) with no insert should give a 6.6 kbp band 
(Fig.3.IO) while 1624.5 with an insertion containing a BamHI site should give 2 bands of7.8 
and 4.5 kbp (Fig.3.1 0). 
On Southern blotting, 17+ (Fig.3.lOb, lane 11) and 1716 (lane 10) gave a 6.6 kbp band as 
expected. The initial plaques (lanes 1-3) gave a profile containing both the wild type band of 
6.6 kbp and the recombinant bands of 4.5 kbp and 7.8 kbp, indicating a mixture of virus. 
Upon further purification (lanes, 4-8), only the recombinant bands of 4.5 and 7.8 kbp could 
be detected indicating that 1624.5 was pure. One plaque was chosen as the prototype and 
used to prepare a large scale virus stock. The DNA profile of this stock was analysed and 
again only the recombinant bands of 4.5 kbp and 7.8 kbp could be detected (lane 9). 
3.5 1625 
3.5.1 Introduction: 
This mutant based on 1622 expresses both ICP34.S/LacZ and ORF P independently in the 
UL43/43.5 and USS loci respectively (Fig.3 .11). 
3.5.2 Construction: 
To construct a plasmid to generate 1625, p3S0RF P (B) and pATS.1, which contains 
BamHIIEcoRV HSV-l sequences (n.p.136289-1392S8) spanning US5, were used. A 1.2 kbp 
BglIIIBamHI fragment containing gD/ORF P was digested from p35/0RFP (B) (Fig.3.12a, 
3.13a) and purified on a 0.8% gel (Fig.3.13b). PATS.l was linearized by Bg/II (Fig.3.12a, 
86 
Chapter. 3 
a b 
a. NsillSne l 
IlL43/43 .5 
b. 
LacZ 
c. Bam HI 
LacZ 
Figure 3.11 Structure of 1625 
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a. This figure shows the structure of 1716. "a" is a direct repeat sequence present at both 
termini and in inverted orientation "a' " in the internal repeat. "b" refers to the long and 
"c" to the short repeat. "X" indicates the deletion of ICP34.5 /0RF P. The position of the 
NsiI site plus additional SpeI site in UL43/43 .5 is shown. 
b. This line shows the structure of 1622. ICP34.5/LacZ containing an internal BamHI site 
was inserted into UL43/43.5. The arrow heads indicate the orientation of transcription 
c. This line shows the structure of 1625. ICP34.5ILacZ containing an internal BamHI site 
was inserted into UL43/43.45 and gD/ORF P was inserted into US5 orientaion. The 
arrow heads indicate the orientation of transcription. 
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Figure 3.12 Construction of 1625 
a. p3510RFP (B) containing gD/ORF P in the same orientation as UL43.5 was digested 
with BgnVBamHI to isolate gD/ORFP. pAT5.1 was digested with BgnI. 
b. gD/ORFP was inserted in this plasmid to generate pAT5.1/0RF P (A+B). 
c. Linearized pAT5.1I0RF P (B) was recombined with 1622. In this recombination, 
gD/ORF P was inserted into US5, in the US5 orientation. 
d. The structure of 1625 is shown. 
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a. Lane 1: p3SIORF P (B) digested with BamH11 BgtrI . lane 2: a I kbp molecular weight 
marker. gO/ORF P is marked ( ~ ). 
b. Lane I : gel purified gOORF P; lane 2: a I kbp molecular weight. gD/ORF P i marked 
c. Lane I : pATS . I lineari zed with BgIJJ ; lane 2: a I kbp molec ular we ight marker. 
pATS. I is marked (~ ). 
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3.13c) and gD/ORF P was inserted into the BglII site of pAT5.1 (Fig.3.12a) to generate 
pATS.lIgDORF P (Fig.3.12b). Insertion of the 1.2 kbp gDIORFP fragment into USS 
generates a 7.8 kbp plasmid in which gDIORFP can insert in either orientation, A or B 
(Fig.3.12b). To construct 1625 we used the B orientation of pATS.lIgDORF P plasmid 
where gDORF P is in the same orientation as USS (Fig.3.13c, d). In the A orientation, 
gDORF P is in the opposite orientation to US5. Firstly to check for insertion of gDORF P, 
plasmid DNA was digested with XbaI (Fig.3.14). In Fig.3.l4 lane 3, pATS.l with no 
insertion gives a linear band of 6.6kbp. In lanes 1 and 2, pAT5.1 with insertion of gDORF P 
give a 7.8kbp band. To check the orientation of gDORF P in pATS.l, plasmid DNA was 
digested with BglIIlXbaI (lanes 4-6). In the A orientation digestion of this plasmid with 
BglIII XbaI generates 2 bands of 6.6+ 1.2 kbp (lane 5) whereas in the B orientation, the same 
digestion generates only 1 band of 7.8 kbp (lane 4). pATS.! with no insertion gives a linear 
band of6.6kbp (lane 6). 
3.5.3 Isolation and purification 
The parent of 1625 is 1622 (Fig.3.l1). This mutant expresses both ICP34.5 and the marker 
gene, LacZ, in the HSV-l UL43/43.S locus with only gD/ORFP being inserted into USS. To 
isolate 162S, 1622 DNA was cotransfected with linearized pATS.1I0RF P (B), progeny 
virus harvested and 10 fold serial dilutions of the transfection mixture containing both 1622 
and recombinant plated out. Individual plaques were isolated and DNA prepared and 
analysed by Southern blotting. DNA of individual plaques were digested with BamHI, 
separated on a 0.8% agarose gel, Southern blotted and probed with pATS.lIgDORF P. 
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Figure 3.14 Insertion and orientation of gDORF P in pATS.] 
Lanes 1-3: XbaI digestion; lanes 4-6: XballBg/l[ digestion . Lanes I, 4 : pAT5.I /ORF P 
(8); lanes 2, 5: PAT5.1I0RF P (A) ; lanes 3, 6: pATS. I ; lane 7 shows a I kbp molecular 
weight marker. 
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In 1622 (Fig.3.15a) the wild type 6.6 kbp band spanning US5 will be obtained, whereas in 
recombinant 1625, a 7.8 kbp band will be detected (Fig.3.l5a). In the DNA from one plaque, 
both the 6.6 kbp and 7.8 kbp bands were detected (Fig.3.15b, lane1), indicating a mixture of 
1622 and 1625. This plaque was taken through several rounds more purification and the 
DNA profile again analysed by Southern blotting. However we were unable to obtain greater 
than 90% purity (Fig.3.15b, lane 2) with 90% of the 7.8 kbp band but 10% contamination 
with the 6.6 kbp band. Rigorous attempts to further purify 1625 including 2 rounds of 
limited dilution cloning failed to produce a virus greater than 90% pure, indicating possible 
instability in the DNA structure. The frequency of 1622 contamination did not increase when 
a virus stock was prepared (Fig.3.15b, lane 3). In lanes 1-4, a band of 4.5 kbp is seen due to 
crosshybridization between the pAT5.1I0RF P probe and ICP34.5 in UL43. 
Figure 3.16 shows the sequence of the ICP34.5/0RF P genes, positions of the two ORFs, the 
promoters and the restriction sites used to cut the ORFs. 
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a. A linear diagram illustrating the BamHI fragment spaning US5 in wild type 17+ (and 
1622) and recombinant virus, 1625, and the size of Ban/HI fra gments followin g 
digestion. The 1.2 kbp gD/ORF P fragment was inserted in US5 . 
b. A Southern blot of HSV DNA prepared from recombinant virus, 1625, and its parent , 
1622. This Southern blot shows HSV DNA digested with Ball/HI , probed with [J2 P]d TP 
labelled pAT5 .1/0RF P and exposed to an autoradiograph for 48h at 
-70°C. Lane] : semipurified recombinant virus, 1625; lane 2: purified 1625; lane 3: 1625 
stock; lane 4: ]622; lane 5: 17+; lane 6: shows a I kbp molecular weight marker. 
Hybridizing bands are identified (~ ). 
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Fig 3.16 HSV-1 (17+) ICP34.5/0RF P DNA sequence 
The upper line is ICP34.5 and the lower one is the ORF P. On ICP34.5 map, 
Dra I site at 380 bp is the TATA box of the promoter, Ncol site at 512 bp is 
start codon (ATG) and TAA at 1257 bp is stop codon. On ORF P map, the 
promoter is possibly around 1300 bp but it has not been confirmed 
experimentally. The ORF P ATG is on the bottom strand at 1186 bp and the 
stop codon is at 480 bp. For expression of ICP34.5, the NcoI/ Alu I and for 
ORF P a PCR fragment spanning the ATG to the stop codon were cloned. 
, 
1600 bp. 
AGCCCGGGCCCCCCGCGGGCGCGCGCGCGCGCAAAAAAGGCGGGCGGCGGTCCGGGCGGC 
10 20 30 40 50 60 
----:----1----:----1----:----1----:----1----:----1----:----1 
TCGGGCCCGGGGGGCGCCCGCGCGCGCGCGCGTTTTTTCCGCCCGCCGCCAGGCCCGCCG 
GTGCGCGCGCGCGGCGGGCGTGGGGGGCGGGGCCGCGGGAGCGGGGGGAGGAGCGGGGGG 
70 80 90 100 110 120 
----:----1----:----1----:----1----:----1----:----1----:----1 
CACGCGCGCGCGCCGCCCGCACCCCCCGCCCCGGCGCCCTCGCCCCCCTCCTCGCCCCCC 
AGGAGCGGGGGGAGGAGCGGGGGGAGGAGCGGGGGGAGGAGCGGGGGGAGGAGCGGGGGG 
130 140 150 160 170 180 
----:----1----:----1----:----1----:----1----:----1----:----1 
TCCTCGCCCCCCTCCTCGCCCCCCTCCTCGCCCCCCTCCTCGCCCCCCTCCTCGCCCCCC 
AGGAGCGGGGGGAGGAGCGGGGGGAGGAGCGGGGGGAGGAGCGGGGGGAGGAGCGGGGGG 
190 200 210 220 230 240 
----:----1----:----1----:----1----:----1----:----1----:----1 
TCCTCGCCCCCCTCCTCGCCCCCCTCCTCGCCCCCCTCCTCGCCCCCCTCCTCGCCCCCC 
AGGAGCGGGGGGAGGAGCGGGGGGAGGAGCGGGGGGAGGAGCGGGGGGAGGAGCGGGGGG 
250 260 270 280 290 300 
----:----1----:----1----:----1----:----1----:----1----:----1 
TCCTCGCCCCCCTCCTCGCCCCCCTCCTCGCCCCCCTCCTCGCCCCCCTCCTCGCCCCCC 
AGGAGCGGGGGGAGGAGCGGCCAGACGCCGAAAACGGGCCCCCCCCAAAACACACCCCCC 
310 320 330 340 350 360 
----:----1----:----1----:----1----:----1----:----1----:----1 
TCCTCGCCCCCCTCCTCGCCGGTCTGCGGCTTTTGCCCGGGGGGGGTTTTGTGTGGGGGG 
Ora! 
\ 
GGGGGTCGCGCGCGGCCCTTTAAAGCGGTGGCGGCGGGCAGCCCGGGCCCCCCGCGGCCG 
370 380 390 400 410 420 
----:----1----:----1----:----1----:----1----:----1----:----1 
CCCCCAGCGCGCGCCGGGAAATTTCGCCACCGCCGCCCGTCGGGCCCGGGGGGCGCCGGC 
/ 
Ora! 
AGACTAGCGAGTTAGACAGGCAAGCACTACTCGCCTCTGCACGCACATGCTTGCCTGTCA 
430 440 450 460 470 480 
----:----1----:----1----:----1----:----1----:----1----:----1 
TCTGATCGCTCAATCTGTCCGTTCGTGATGAGCGGAGACGTGCGTGTACGAACGGACAGT 
Nco! 
\ 
AACTCTACCACCCCGGCACGCTCTCTGTCTCCATGGCCCGCCGCCGCCGCCATCGCGGCC 
490 500 510 520 530 540 
----:----1----:----1----:----1----:----1----:----1----:----1 
TTGAGATGGTGGGGCCGTGCGAGAGACAGAGGTACCGGGCGGCGGCGGCGGTAGCGCCGG 
/ 
Nco! 
CCCGCCGCCCCCGGCCGCCCGGGCCCACGGGCGCCGTCCCAACCGCACAGTCCCAGGTAA 
550 560 570 580 590 600 
----:----1----:----1----:----1----:----1----:----\----:----\ 
GGGCGGCGGGGGCCGGCGGGCCCGGGTGCCCGCGGCAGGGTTGGCGTGTCAGGGTCCATT 
ftle:IIN:\AIi Karimi\3 Restr.htm 
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CCTCCACGCCCAACTCGGAACCCGCGGTCAGGAGCGCGCCCGCGGCCGCCCCGCCGCCGC 
610 620 630 640 650 660 
----:----1----:----1----:----1----:----1----:----1----:----1 
GGAGGTGCGGGTTGAGCCTTGGGCGCCAGTCCTCGCGCGGGCGCCGGCGGGGCGGCGGCG 
CCCCCGCCGGTGGGCCCCCGCCTTCTTGTTCGCTGCTGCTGCGCCAGTGGCTCCACGTTC 
670 680 690 700 710 720 
----:----1----:----1----:----1----:----1----:----1----:----1 
GGGGGCGGCCACCCGGGGGCGGAAGAACAAGCGACGACGACGCGGTCACCGAGGTGCAAG 
CCGAGTCCGCGTCCGACGACGACGATGACGACGACTGGCCGGACAGCCCCCCGCCCGAGC 
730 740 750 760 770 780 
----:----1----:----1----:----1----:----1----:----1----:----1 
GGCTCAGGCGCAGGCTGCTGCTGCTACTGCTGCTGACCGGCCTGTCGGGGGGCGGGCTCG 
CGGCGCCAGAGGCCCGGCCCACCGCCGCCGCCCCCCGGCCCCGGCCCCCACCGCCCGGCG 
790 800 810 820 830 840 
----:----1----:----1----:----1----:----1----:----1----:----1 
GCCGCGGTCTCCGGGCCGGGTGGCGGCGGCGGGGGGCCGGGGCCGGGGGTGGCGGGCCGC 
TGGGCCCGGGGGGCGGGGCTGACCCCTCCCACCCCCCCTCGCGCCCCTTCCGCCTTCCGC 
850 860 870 B80 B90 900 
----:----1----:----1----:----1----:----1----:----1----:----1 
ACCCGGGCCCCCCGCCCCGACTGGGGAGGGTGGGGGGGAGCGCGGGGAAGGCGGAAGGCG 
CGCGCCTCGCCCTCCGCCTGCGCGTCACCGCGGAGCACCTGGCGCGCCTGCGCCTGCGAC 
910 920 930 940 950 960 
----:----1----:----1----:----1----:----1----:----1----:----1 
GCGCGGAGCGGGAGGCGGACGCGCAGTGGCGCCTCGTGGACCGCGCGGACGCGGACGCTG 
GCGCGGGCGGGGAGGGGGCGCCGGAGCCCCCCGCGACCCCCGCGACCCCCGCGACCCCCG 
970 980 990 1000 1010 1020 
----:----/----:----1----:----/----:----/----:----/----:----1 
CGCGCCCGCCCCTCCCCCGCGGCCTCGGGGGGCGCTGGGGGCGCTGGGGGCGCTGGGGGC 
CGACCCCCGCGACCCCCGCGCGGGTGCGCTTCTCGCCCCACGTCCGGGTGCGCCACCTGG 
1030 1040 1050 1060 1070 1080 
----:----1----:----1----:----1----:----1----:----1----:----1 
GCTGGGGGCGCTGGGGGCGCGCCCACGCGAAGAGCGGGGTGCAGGCCCACGCGGTGGACC 
TGGTCTGGGCCTCGGCCGCCCGCCTGGCGCGCCGCGGCTCGTGGGCCCGCGAGCGGGCCG 
1090 1100 1110 1120 1130 1140 
----:----1----:----1----:----1----:----1----:----1----:----1 
ACCAGACCCGGAGCCGGCGGGCGGACCGCGCGGCGCCGAGCACCCGGGCGCTCGCCCGGC 
ACCGGGCTCGGTTCCGGCGCCGGGTGGCGGAGGCCGAGGCGGTCATCGGGCCGTGCCTGG 
1150 1160 1170 1180 1190 1200 
----:----1----:----1----:----1----:----1----:----1----:----1 
TGGCCCGAGCCAAGGCCGCGGCCCACCGCCTCCGGCTCCGCCAGTAGCCCGGCACGGACC 
GGCCCGAGGCCCGTGCCCGGGCCCTGGCCCGCGGAGCCGGCCCGGCGAACTCGGTCTAAC 
1210 1220 1230 1240 1250 1260 
----:----1----:----1----:----1----:----1----:----1----:----1 
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CCGGGCTCCGGGCACGGGCCCGGGACCGGGCGCCTCGGCCGGGCCGCTTGAGCCAGATTG 
AluI AluI 
\ \ 
GTTACACCCGAGGCGGCCTGGGTCTTCCGCGGAGCTCCCGGGAGCTCCGCACCAAGCCGC 
1270 1280 1290 1300 1310 1320 
----:----1----:----1----:----1----:----1----:----1----:----1 
CAATGTGGGCTCCGCCGGACCCAGAAGGCGCCTCGAGGGCCCTCGAGGCGTGGTTCGGCG 
/ / 
AluI AluI 
TCTCCGGAGAGACGATGGCAGGAGCCGCGCATATATACGCTTGGAGCCAGCCCGCCCTCA 
1330 1340 1350 1360 1370 1380 
----:----1----:----1----:----1----:----1----:----1----:----1 
AGAGGCCTCTCTGCTACCGTCCTCGGCGCGTATATATGCGAACCTCGGTCGGGCGGGAGT 
CAGGGCGGGCCGCCTCGGGGGCGGGACTGGCCAATCGGCGGCCGCCAGCGCGGCGGGGCC 
1390 1400 1410 1420 1430 1440 
----:----1----:----1----:----1----:----1----:----1----:----1 
GTCCCGCCCGGCGGAGCCCCCGCCCTGACCGGTTAGCCGCCGGCGGTCGCGCCGCCCCGG 
CGGCCAACCAGCGTCCGCCGAGTCTTCGGGGCCCGGCCCATTGGGCGGGAGTTACCGCCC 
1450 1460 1470 1480 1490 1500 
----:----1----:----1----:----1----:----1----:----1----:----1 
GCCGGTTGGTCGCAGGCGGCTCAGAAGCCCCGGGCCGGGTAACCCGCCCTCAATGGCGGG 
AATGGGCCGGGCCGCCCACTTCCCGGTATGGTAATTAAAAACTTGCAAGAGGCCTTGTTC 
1510 1520 1530 1540 1550 1560 
----:----/----:----/----:----/----:----/----:----1----:----1 
TTACCCGGCCCGGCGGGTGAAGGGCCATACCATTAATTTTTGAACGTTCTCCGGAACAAG 
CGCTTCCCGGTATGGTAATTAGAAACTCATTAATGGGCGG 
1570 1580 1590 1600 1610 1620 
----:----1----:----1----:----1----:----/----:----/----:----1 
GCGAAGGGCCATACCATTAATCTTTGAGTAATTACCCGCC 
* Enzymes that cut Frequency Isoschizomers 
Alul 2 
Oral 1 
Nco I 1 
* Enzymes < MINCUTS Frequency Isoschizomers 
* Enzymes > MAXCUTS Frequency Isoschizomers 
* Enzymes that do not cut 
* Number of enzymes not matching SITELEN, BLUNT, STICKY, COMMERCIAL criteria 
o 
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4.0 In vitro characterization of HSV-l recombinant viruses 
4.1 Introduction: 
To investigate the role ofICP34.5 and ORF P in the HSV-l lifecycle, a number ofHSV-
1 recombinant viruses were constructed. These are described in detail in the previous 
chapter (section 3). All recombinants were made in the background of the HSV-l 
ICP34.5/0RF OIP null mutant, 1716. 1622 expresses ICP34.5 in the UL43/43.5 locus in 
the UL43.5 orientation. 1624 expresses ORF P in the UL43/43.5 locus in the UL43 
orientation. 1624.5 expresses ORF P in the UL43/43.5 locus in the UL43.5 orientation. 
1625, based on 1622, expresses ICP34.5 in the UL43/43.5 locus and also gD/ORF P in 
the US5 locus in the same orientation as US5. In addition, all recombinants express LacZ 
in the UL43/43.5 locus in the opposite orientation to that of the inserted HSV gene. In 
this chapter (i) expression of the inserted genes in these recombinants is examined; and 
(ii) the recombinants are characterised in vitro compared to both wild type, 17+, and their 
parental virus, 1716. 
4.2 Analysis of ICP34.5 expression 
Sequence analysis of ICP34.5 from several HSV -1 strains has identified variation in the 
number of copies of the DNA sequence encoding a PAT repeat within the protein. HSV-
1 strain F has 10, strain 17+ 5, and strain KOS 3 copies of this repeat. Migration of 
ICP34.5 by SDS-PAGE consequently varies between strains. Initially, an antiserum 
raised against a synthetic peptide, PATIO, was used in Western blots (McKay et al., 
1993). This antiserum strongly recognises ICP34.5 in strain F with 10 copies but only 
weakly recognises ICP34.5 in strain 17+ probably because it has only 5 PAT repeats. 
Subsequently antisera against a GSTIICP34.S fusion protein were raised and 
demonstrated equal expression of ICP34.5 in both strain F and 17+ (Brown et al., 1997). 
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Using one of these antisera, 137, ICP34.5 expression has been analysed in the 
recombinants. Using this antibody, Holman (2000) had previously reported that 1622 
overexpresses ICP34.5 compared to strain F and 17+. 
4.3 Expression of ICP34.5 in recombinant viruses 
Using BHK infected cell extracts, expression oflCP34.5 was analysed in 1622, 1624, 17+ 
and 1716 by Western blotting with antiserum, 137 (Fig.4.1). As expected ICP34.5 was 
not detected from 1716 and 1624 or mock infected extracts (Lanes 3, 4 and 5, 
respectively), but was from 17+ and 1622 (lanes 1 and 2, respectively). 1622 clearly 
expresses more ICP34.5 than 17+. By Western blotting of BHK cell extracts with 
antiserum 137, the level of expression oflCP34.5 from 1622 and 1625 was compared to 
17+ (Fig.4.2). Two-fold serial dilutions were made of 1622 and 1625 infected BHK cells 
16 h pi to ascertain a semiquantitative level of ICP34.5 expression. The level of ICP34.5 
expression in 1622 (lanes 3-6) is the same as 1625 (lanes 7-10). These two recombinants 
express nearly 8 times more ICP34.5 than 17+ (lane 1). Apparently, expression of ORF P 
in 1625 does not effect expression of ICP34.5 compared to its parent virus, 1622. As 
expected, ICP34.5 is not expressed by 1624 (lane 11), 1624.5 (lane 12) or 1716 (lanes 2 
and 13). 
4.4 Analysis of ORF P expression 
ORF P protein expressed by HSV -1 (F) is predicted to contain 248 amino acids. It 
contains a short amino terminal domain followed by an amino acid trimer of Ala-Gly-
Val repeated 10 times and a long carboxy terminal domain (Lagunoff and Roizman, 
1994). Similarly to ICP34.5, there is variation in the number oftrimers and in length of 
the protein between strains. The protein in HSV -1 (17+) contains 233 amino acids with 
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Figure 4.1 Western blotting ofICP34.S expression from recombinant viruses 
BHK cells were infected with viruses at a m.o.i of 20 pfu/cell and harvested at 24 h pi. 
Analysis of ICP34.5 expression was carried out by 12.5% SDS-PAGE and Western 
blotting with antiserum 137 (11500 dilution) and protein A-HRP, reacted with ECL and 
exposed to autoradiography. Lanel : 17+; lane 2: 1622; lane 3: 1716; lane 4: 1624; lane 5: 
MI. Molecular weight markers are indicated on the right and ICP34.5 is marked on the 
left (~). 
Chapter 4 Results 
2 3 4 5 6 7 8 9 10 II 12 13 14 
~ 46KDa 
ICP34.5 .. , 
~ 30KDa 
Figure 4.2 Semiquantitative expression of ICP34.5 by 1622 and 1625 
BHK cells were infected with viruses at a m.o.i of 20 pfu/cell, extracts prepared 24 h pi 
and serial 2-fold dilutions made of both 1622 and 1625 infected BHK cells. Analysis of 
ICP34.5 expression was carried out on a 12.5% SDS-PAGE which was Western blotted 
with 137 antiserum (11500 dilution) and protein A-HRP, reacted with ECL and exposed 
to autoradiography. Lanel: 17+; lane 2:1716; lane 3: 1622 (N); lane 4: 1622 (1:2 dilution); 
lane 5:1622 (1:4 dilution); lane 6: 1622 (1:8 dilution); lane 7: 1625 (N); lane 8:1625 (1:2 
dilution); lane 9: 1625 (1:4 dilution); lane 10: 1625 (1:8 dilution); lane 1 J: 1624; lane 
12:1624.5; lane 13: 1716; lane 14: MI. Molecular weight markers are indicated on the 
right and ICP34.5 is marked on the left ( ~ ). 
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an amino acid trimer of Ala-Gly-Val repeated 5 times. Using a aST -ORF P fusion 
protein,2 antisera, 128 and 129 had been previously raised against HSV-l (17+) ORF P 
(MacLean, A., personal communication). 
4.5 Expression of ORF P in recombinant viruses 
Western blotting of BHK infected cell extracts with two antisera against ORF P 128 and 
129 was carried out to analyse expression of ORF P in 1624/1624.5 and 1625. In 
addition, a virus with a ts mutation in ICP4 at the NPT (t8K) which overproduces ORF P 
(see 1.16) and 17+ were used as a positive control. As negative controls 1716 and the 
ICP34.5 expressing recombinant (1622) were used. Using these antibodies, it had been 
previously demonstrated in our lab that HSV -1 (17+) expresses low levels of ORF P 
during a productive infection (MacLean, A., personal communication). Therefore, ORF 
P may have a role in 17+ productive infection. Using 128, in our initial experiments 
(normal western blotting method) (Fig.4.3a) we could only detect ORF P from the 
overproducing tsK (lane 3) but from neither 17+ (lane1), 1716 (lane 2), 1622 (lane 4) nor 
any ORF P containing recombinant viruses 1624, 1624.5 and 1625 (lanes 5-7, 
respectively). Using 129, the same results were obtained (Fig.4.4a). ORF P was only 
detected from the overproducing tsK (lane 1) but from neither 17+ (lane 2), 1716 (lane 
3), 1624.5 (lane 4) nor 1625 (lane 5). This was at least partly because of the high 
background in the gel. To try to minimise the background, 1M NaCI was added to the 
antisera (Fig.4.3b). This figure shows Western blotting of BHK cell extracts with 
antiserum 128 containing 1M NaCl. Expression of ORF P was detected from both tsK 
and 17+ (lanes 1 and 2) but not from recombinants 1622, 1624, 1624.5 and 1625 (lanes 
4-7, respectively) or from 1716 (lane 2). The same results were obtained using antiserum 
129 containing 1M NaCI (Fig 4.4b). In tsK an ORF P band of 28 KDa is seen (Fig.4.3b 
and 4.4b lane 1) whereas the ORF P band in 17+ (Fig.4.3b and 4.4b lane 2) is 32 KDa 
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Figure 4.3 Western blotting of ORF P expression using antiserum 128 
BHK cells were infected with viruses at a m.o.i of 20 pfu/cell and harvested at 24 h pi. 
Analysis of ORF P expression was carried out by 12.5% SDS-PAGE and Western 
blotting with 128 antiserum and protein A-HRP, reacted with ECL and exposed to 
autoradiography. a) initial (normal western blotting method) and b) final experiments 
(using 1 molar NaCI containing antisera) . Molecular weight markers are indicated on the 
right and ORF P related bands are marked on the left t ). 
a) Lane 1: 17+; Lane 2: 1716; lane 3: tsK; lane 4: 1622; lane 5: 1624; lane 6: 1624.5; lane 
7: 1625; lane 8: MI. 
b) Lanel: tsK; lane 2: 17+; lane 3: 1716; lane 4: 1622; lane 5: 1624; lane 6: 1624.5; lane 
7: 1625; lane 8: MI. 
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Figure 4.4 Western blotting of ORF P expression using antiserum 129 
BHK cells were infected with viruses at a m.o.i of 20 pfu/cell and harvested at 24 h pi. 
Analysis of ORF P expression was carried out by 12.5% SDS-PAGE and Western 
blotting with 129 antiserum and protein A-HRP, reacted with ECL and exposed to 
autoradiography. a) initial (normal western blotting method) and b) final experiments 
(using 1 molar NaCI containing antisera) Molecular weight markers are indicated on the 
right and ORF P is marked on the left ~ ). 
a) Lane1: tsK; lane 2: 17+; lane 3: 1716; lane 4: 1624.5; lane 5: 1625; lane 6: MI. 
... 45KDa 
... 30KDa 
b) Lane1 : tsK; lane 2: 17+; lane 3: 1716; lane 4: 1622; lane 5: 1624; lane 6: 1624.5; lane 
7: 1625; lane 8: MI. 
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indicating possible processing during a productive infection. In tsK a high molecular 
weight band of 45 KDa is detected possibly due to the overproduction of ORF Pleading 
to aggregate formation. By varying conditions such as use of different dilutions of 
antisera and using 0.5-1 M NaCI in the primary antibody, we attempted to demonstrate 
expression of ORF P in the recombinants. However, no ORF P protein detected in the 
recombinants. The most probable explanation is that the antisera are not strong enough 
to detect low amounts of ORF P protein expression from the recombinants. Also it is 
possible that the viruses do not express ORF P. 
As neither 128 nor 129 detected ORF P in the recombinant viruses by Western blotting, 
immunoprecipitation of tsK, 17+ and 1716 infected BHK cell extracts was carried out 
(Fig.4.S). As there is only a small number (2) of methionines in ORF P (Lagunoff and 
Roizman, 1994) it was decided that it would label poorly with esS] methionine and 
therefore immunoprecipitations would be carried out on unlabeled extracts and detected 
by Western blotting. Immunoprecipitations were carried out at both 4°C overnight (lanes 
1-6) and at 37°C for 2 h (lanes 7-12) with both 128 (lanes 1-3 and 7-9) and 129 (lanes 4-
6 and 10-12) and Western blotted with 128. Again although the two antibodies detected 
ORF P in tsK (lanes 1, 4, 7 and 10), indicating immunoprecipitation of ORF P, they 
were not able to detectably precipitate the low amounts of ORF P in 17+ (lanes 1, 4, 7 
and 10) and 1716 (lanes 3, 6, 9 and 12). An immunoprecipitation carried out against 
ICP34.S with 137 and Western blotted with 128, as a negative control, failed to detect 
ORF P (lanes 13-15). As ORF P could not be detected from 17+ extracts, we did not 
carry out an immunoprecipitation with the recombinants 1624, 1624.5 and 1625. As 
expected the SO KDa band of the precipitated IgG heavy chain was detected by the 
protein-A-HRP in the western blots. 
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Figure 4.5 Western blotting of immunoprecipitated ORF P 
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BHK cells were infected at a m.o.i of 20 pfu/cell, harvested at 16h pi and 
immunoprecipitated with ORF P antiserum 128 (lanes 1-3; 7-9) and ORF P antiserum 
129 (lanes 4-6; 10-12) or an anti-ICP34.5 serum 137 (lanes 13-15). 
Immunoprecipitations were carried out at either 4°C (lanes 1-6) or 37°C (lanes 7-(5). 
Samples were electrophoresed on a 12.5% SDS-PAGE and Westem blotted with 128 and 
protein-A-HRP. Lanesl, 4,7,10 and 13: tsK; lanes 2, 5, 8,11 and 14: 17+; lane 3,6,9, 
12 and 15: 1716. Molecular weight markers are indicated on the right, RF P and the 
heavy chain of IgG are indicated on the left ( ~ ). 
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4.6 Analysis of ORF P RNA synthesis by recombinant viruses 
As expression of ORF P protein was not detected from the recombinants, ORF P RNA 
synthesis was analysed. Fig.4.6 shows Northern blotting of RNA extracts from the 
recombinants using GST -ORF P as probes. As ORF P is inserted in the UU3/43.5 loci, 
GST-ORF P will hybridize with and detect U143/43.5 spanning transcripts. In addition, 
it will also hybridize with and detect the ORF P (and ICP34.5) transcripts in 1624, 
1624.5 and 1625. 
Using ORF P as a probe (Fig.4.6), a number of HSV-l transcripts were detected. Based 
on a RNA size marker, the sizes of these transcripts are 1: 7.0 kbp; 2: 4.0 kbp; 3: 2.7 kbp; 
4: 2 kbp; 5: 1 kbp (Fig.4.6). These transcripts spanning UL41-44 and based on transcript 
map for this region, these transcripts are probably 1: uncharacterised; 2: UL43/44; 3: 
UL44; 4: U141; 5: U143. The uncharacterised long transcript probably arises from the 
non specific transcription detected from the HSV genome late in infection (Jacquemont 
and Roizman, 1975a, b). 
In addition to the HSV transcripts, a band with the size expected for ORF P RNA of 
about 700 bp was detected in 1624, 1624.5, and 1625 (lanes 5-7, respectively). As ORF P 
is used as the probe and there is sequence identity between ORF P and ICP34.5, the 
similarly sized ICP34.5 transcript was detected in 1622 (lane 4). As expected ORF P did 
not hybridize to the UL41-44 HSV transcripts in tsI<, 17+ and 1716 (lanes 1-3, 
respectively). Surprisingly no native ORF P RNA was detected in tsK and 17+ (lanes 1 
and 2). As expected, no hybridization was detected to mock infected RNA (lane 8). The 
ORF P probe blot has failed to detect ORF P even in positive control so no conclusion 
can be drawn. 
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Figure 4.6 ORF P RNA synthesis from recombinant viruses 
Northern blot ofHSV-l RNA probed with e2p]dCTP labelled GST-ORF P and exposed 
to an autoradiograph for 72h at -70°C. Lanel: tsK; lane 2: 17+; lane 3: 1716; lane 4: 
1622; lane 5: 1624; lane 6: 1624.5; lane 7: 1625; lane 8: MI. RNA ladder with the sizes 
marked is shown (~. Hybridizing bands ~ ) and a band with the size expected for ORF 
P are indicated (~ ). 
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To confirm that RNA was loaded in all tracks, a northern blot was carried out with a 
cellular gene, y1 actin. The membrane used for the ORF P probe was stripped and 
reprobed with y1 actin (Fig.4.7). All tracks contained RNA with a excess amount in tsK 
infected (lane 1). 
4.7 (was removed) 
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Figure 4.7 Northern blotting with y1 actin 
Northern blot ofHSV-l RNA probed with yl actin e2p]dCTP labelled and exposed to an 
autoradiograph for 72h at -70°C. Lane 1: ts K; lane 2: 17+; lane 3: 1716; lane 4: 1622; lane 
5: 1624; lane 6: 1624.5; lane 7: 1625; lane 8: MI. yl actin band is indicated (~). 
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Fig 4.8 was removed (deleted). 
Chapter.4 Results 
4.8 In vitro replication kinetics of recombinant viruses 
Having analysed expression of ICP34.5 and ORF P from the recombinant viruses, we 
then proceeded to analyse their phenotypes in vitro. It has been previously shown that 
ICP34.5 is essential for HSV-l replication in some but not all cell lines (Brown et al., 
1994a; Chou et al., 1992). Thus the replication behaviour of recombinant viruses was 
compared to 17+ (wild type) and 1716 (ICP34.5 -ve, ORF OIP -ve) in a variety of cell 
types. These recombinants were 1622 (ICP34.5+ve), 1624 (ORF P +ve), 1624.5 (ORF P 
+ve), and 1625 (lCP34.5 +ve, ORF P +ve). The cell lines used were BHK2l1C13 cells 
which are fully permissive for ICP34.5 negative viruses; 3T6 cells which are non 
permissive for ICP34.5 negative viruses; and SK-N-SH cells whose permissivity had not 
previously been fully analysed but which exhibit protein synthesis shutoff following 
infection with ICP34.5 negative viruses (Chou et ai., 1992). The multicycle growth 
kinetics of the recombinants was analysed in all 3 cell types. 
4.8.1 Multicycle replication kinetics in BHK cells 
In BHK cells, as illustrated in Fig.4.9 (a and b) all viruses with the exception of 1624 
exhibited a similar growth pattern, reaching a maximum titre of 108_109 pfulml by 48-72 
h pi. 1624 consistently grew 5 to 10 fold less well than the rest. In (c) only the growth of 
1622 and 1625 has been compared to 17+ and 1716 and again exhibited similar growth. 
4.8.2 Multicycle replication kinetics in 3T6 cells 
In stationary state 3T6 cells, FigA.10 (a, b and c) 17+ grew well reaching a maximum 
titre of 106_107 pfulml by 48-72 h pi whereas 1716, expressing neither ICP34.5 nor ORF 
OIP failed to grow. The recombinants 1624 and 1624.5 which express only ORF P, 
similarly to 1716, failed to grow whereas 1622 and 1625 expressing ICP34.5 grew. 
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Figure 4.9 Multicycle replication kinetics in BHK cells 
96 
BHK cells were infected at a m.o.i 0[0.001 pfu/cell. At 0,6, 12, 24, 48, 72, 96 and 120 
h pi, infected cells were harvested. Infected ceJls were scraped into the medium, 
sonicated and titrated onto a BHK monolayer. Three separate experiments (a, b, and c) 
are shown. 
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Figure 4.10 Multicycle replication kinetics in 3T6 cells 
3T6 cells were infected at a m,o ,i of 0,001 pfu/cell. At 0, 6, 12,24,48, 72, 96 and 120 h 
pi infected cells were harvested, Infected cells were scraped into the medium, sonicated 
and titrated onto a BHK monolayer. Three separate experiments (a, b, and c) are shown, 
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Although both 1622 and 1625 grew they plataued at a maximum titre of 101 to 102 fold 
lower than 17+ (a, b and c). In some experiments both 1622 and 1625 grew similarly 
(Fig.4.lOa) whereas in others 1625 grew 10 fold less well than 1622. Most consistently, 
1625 grew to a maximum titre 10 fold lower than 1622 (Fig.4.1 Ob and c) 
4.8.3 Multicycle replication kinetics in SK-N-SH cells 
In SK-N-SH cells, FigA.ll (a, b and c), 17+ grew well reaching a maximum titre of 107_ 
108 pfu/ml by 48-72 h pi. 1716 and 1624.5 although exhibiting some growth reached a 
maximum titre 104 lower than 17+. In agreement with its impaired growth in BHK cells, 
1624 grew consistently 10 fold poorer. Both 1622 and 1625 grew similarly to 17+ 
(Fig.4.11a). In some experiments, 1622 and 1625 grew similarly (Fig.4.11a) whilst in 
others 1625 grew about 5 fold poorer than 1622 (Fig.4.11 b and c). 
4.9 Analysis of 1625 profile at the end of the growth experiments 
As discussed in 3.5.3, we could only obtain 1625 with 90% purity. As 1625 was slightly 
impaired compared to its parent 1622, we were concerned that the growth of 1625 was 
partly due to amplification of the parental 1622 contamination. To check this a DNA 
profile analysis was carried out on the final timepoint from each of the 3 growth 
experiments. The DNA profile of 1625 from the final timepoint in each cell type was 
compared to that of the stock. Fig.4.12 represents the DNA profile from the 1st 
experiment. 
The DNA profile of 1625 at the end of the growth experiment from each cell type (lanes 
3, 4 and 5) was identical to that of the stock (lane 2) with 90% 1625 and 10% 1622. 
Thus there was no amplification of the 1622 contamination and hence the growth of 
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Figure 4.11 Multicycle replication kinetics in SK-N-SH cells 
SK-N-SH cells were infected at a m.o.i of 0.001 pfu/cel1. At 0, 6, 12, 24, 48,72, 96 and 
120 h pi infected cells were harvested. Infected cells were scraped into the medium, 
sonicated and titrated onto a BHK monolayer. Three separate experiments (a, b, and c) 
are shown. 
96 
Chapter.4 
2 3 4 5 6 7 8 9 10 
7.8 Kbp ~ 
6.6 Kbp ~ 
4.5 Kbp ~ 
(ICP34.5 
in UL43/43.5) 
Figure 4.12 DNA profile of 1625 at the end of growth curve 1 (G1) 
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Southern blot ofHSV-1 DNA digested with BamHI and probed with e2p]dCTP labelled 
pAT5.l /0RF P and exposed to an autoradiograph for 24h at -70°C. Lanel: 17+IBHK; 
lane 2: 1625 (stock); lane 3: 1625/BHK (96 h); lane 4: 1625/SK (96 h); lane 5: 1625/3T6 
(120 h); lane 6: 16221BHK; lane 7: 16241BHK; lane 8: 1624.5/BHK; lane 9: 17161BHK; 
lane 10: 1 kbp DNA ladder with the sizes marked and hybridising bands are indicated 
~ ). 
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1625 was not due to preferential growth of 1622. As expected 17+ (lane 1), 1716 (lane 9), 
1622 (lane 6), 1624 (lane 7) and 1624.5 (lane 8) taken from the final timepoint in BHK 
cells still exhibited one hundred percent purity. Hybridization to the 4.5 kbp band is due 
to hybridization of ORF P to either ICP34.5 (1622 and 1625, lanes 2, 3, 4, 5 and 6) or 
ORF P (1624 and 1624.5, lanes 7 and 8) in the UL43 locus. Similar results were 
obtained when analysing the DNA profile from all growth experiments (data not shown). 
4.10 Analysis of host protein synthesis shutoff in BHK, 3T6, and SK-N-SH cells 
One of the roles of HSV-l ICP34.5 is to maintain host and viral protein synthesis late in 
infection in certain cell types such as the human neuroblastoma cell line SK-N-SH 
(1.15.3). To determine if this phenotype had been restored in the recombinant viruses 
1622, 1624, 1624.5, and 1625, SK-N-SH, BHK, and 3T6 cells were infected at a m.o.i of 
10 pfu/cell, labelled with esS] methionine late in infection, harvested and analysed by 
SDS-PAGE. 
In Fig.4.13a the 2 varients, 1622 (lane 3) and 1625 (lane 5), expressing ICP34.5 gave a 
similar protein profile to 17+ (lane 1) whereas the recombinants expressing only ORF P, 
1624 (lane 4) and 1624.5 (lane 6), gave a protein profile similar to 1716 (lane 2) and 
protein synthesis was not restored. Thus the growth of 1622 and 1625 in SK-N-SH cells 
is most likely due to restored protein synthesis and the lack of growth of 1624/1624.5 is 
probably due to the failure to restore protein synthesis. In BHK cells (Fig.4.13b), as 
expected, all viruses showed a similar protein synthesis profile with no shutoff of protein 
synthesis. In 3T6 cells (Fig.4.13c), all viruses again also showed a similar protein 
synthesis profile with no shutoff of protein synthesis. In these cells the lack of inhibition 
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a. 
SK-N-SH CELLS 
b. 
BHK CELLS 
c. 
3T6 CELLS 
1234567 
Figure 4.13 Host cell protein synthesis shutoff in SK-N-SH, 3T6 and BHK cells 
SK-N-SH (a), BHK (b), and 3T6 (c) cells were infected with HSV-l variants at a m.o.i 
of 10 pfu/cell and pulse labelled with e5S] methionine from 14-16 h pi . The infected 
cells were harvested and analysed by 10% SDS-PAGE and exposure to an 
autoradiograph oln at -70°C. Lane 1: 17+; lane 2: 1716; lane 3: 1622; lane 4: 1624; lane 
5: 1625; lane 6: 1624.5; lane 7: MI. 
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of protein synthesis by 1716 showed that the growth defect was not due to the same 
mechanism as in SK-N-SH cells. 
ORF P expression has not been detected in our recombinants and all conclusions must be 
made with that caveat. 
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5.0 Optimization of GST -P pull down experiments 
5.1 Optimization of GST-ORF P fusion protein expression 
5.1.1 Introduction 
A pGEX based system can be used for inducible protein expression in E.coli. In this 
system target genes are cloned as a glutathione-S-transferase (GST) fusion under the 
control of the T7 promoter, which is not recognised by E.coli RNA polymerase and 
therefore virtually no expression occurs until a source of T7 RNA polymerase is 
provided. This decreases the posibility of plasmid instablility due to the production of 
proteins potentially toxic to the host cell. Once cloned, plasmids are transferred into an 
expression host containing a chromosomal copy of the T7 RNA polymerase gene under 
the control of the Lac I promoter and expression is induced by the addition of isopropyl-
~-D-thiogalactoside (lPTG) which induces expression from the Lac promoter. 
Alternatively, T7 RNA polymerase can be provided by infection of the original cloning 
host with CE6 Lambda phage which expresses T7 RNA polymerase (Smith and Johnson, 
1988). 
Routinely, the aminoterminus of a protein is fused inframe to the carboxyterminus of 
GST. During fusion protein expression, several factors can be varied to maximise the 
amount, length, and solubility of the protein. Increasing the IPTG concentration may 
increase the amount of product. Decreasing the temperature at which fusion proteins are 
expressed will decrease total yield but will also decrease the action of proteolytic 
enzymes which may degrade fusion proteins, leading to increased amounts of full length 
protein. It can also increase the solubility of the fusion protein by altering its folding. 
Increasing the time of induction will increase fusion protein expression but will also 
increase the length of time proteases have to work in and therefore may lead to a 
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decrease in the amount of full length protein. The expression of GST -ORF P where ORF 
P was cloned as a 3' GST fusion protein in a bacterial system had not been previously 
optimized. 
Using a number of E.coli strains at different temperatures, expression of the amount and 
length of GST -ORF P was optimised. 
5.1.2 Optimization of GST-ORF P expression in different E-coli strains BL21, 
C41, and Novablue. 
To choose the best expression system for GST-ORF P, E.coli strains BL21, C41, and 
Novablue were used. 
(i) BL21 
BL21 is the most widely used host backgroud and has the advantage of being deficient in 
both Ion and ompT proteases. BL21 contains a plasmid containing the T7 polymerase 
gene under the Lac Ipromoter (Fig.S.1a) which is induced by IPTG to express T7 RNA 
polymerase. This enzyme attaches to both the GST and GST -ORF P promoter and hence 
leads to expression. In this system, bacteria are grown at 37°C to midlog phase and then 
induced by IPTG for two hours. 
(ii) C41 
The principle of GST fusion protein expression in C4l is the same as that in BL2l. 
However, in C41 the lac repressor binds the Lac I promoter tighter and therefore there is 
less uninduced expression ofthe T7 polymerase and hence fusion protein (Fig.S.la). 
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Figure 5.1 Mechanism of GST/GST-ORFP expression in BL21, C41, and Novablue 
a. BL21/C41. IPTG induces the T7 polymerase promoter to express T7 polymerase and 
this enzyme attaches to the GST and GST-ORF P promoter to synthesise both GST and 
GST-ORF P. 
b. Novablue. A. CE6 phage expresses T7 polymerase in phage infected E.coli and this 
enzyme attaches to both the GST and GST-ORF P promoter to synthesise both GST and 
GST-ORF P. pTet produces the A. phage receptor on the surface of E.coli to allow phage 
entry. 
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(iii) Novablue 
Novablue is an E.coli K-12 strain ideally suited as an initial cloning host due to its high 
transfonnation efficiency which results in high yields of excellent quality plasmid DNA. 
This strain does not contain the T7 RNA polymerase gene containing plasmid and 
superinfection with CE6 A phage containing the T7 RNA polymerase gene is used to 
induce expression of fusion protein (Studier and Moffat, 1986). Novablue cells contain a 
plasmid, pTet, which encodes the phage A receptor gene and produces the phage receptor 
on the bacterial surface. This system is used when a target gene is so toxic that a plasmid 
cannot be maintained in a DE3 lysogenic host such as BL21 where there will always be 
minimal recombinant protein expression. In this system, bacteria are grown at 37°C to 
midlog phase and then superinfected with A phage for two hours (Fig.5.l b). 
Expression of both GST and GST-ORF P was detected in these 3 strains by Western 
blotting with an anti-GST serum (Fig.5.2a) and Commassie blue staining (Fig.5.2b). 
Expression of the 28 KDa GST is best in BL21 (lane 1), slightly lower in C41 (lane 3), 
and significantly lower in Novablue (lane 5). Expression of truncated GST-ORF P in 
BL21 which was detected as a 40 KDa doublet is shown in lane 2. No expression of 
GST-ORF P is detected in either C41 (lane 4) or Novablue (lane 6). Thus expression of 
GST-ORF P was best in BL21. 
5.1.3 Optimization of GST-ORF P and GST-ICP27 expression in BL21 using 
different temperatures 
The optimum temperature for expression of GST-ORF P in BL21 was investigated. As 
we were going to use GST-ICP27 in subsequent experiments (see 5.2.2), the optimum 
temperature for the expression of GST-ICP27 in BL21 was also investigated. Expression 
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Figure 5.2 Expression of GST and GST-ORF P in E.coli strains BL21, C41, and 
Novablue 
GST pulldown extracts were run on a 12.5% SDS-PAGE and analysed by a) Western 
blotting using an anti-GST serum and b) Commassie blue staining. Lanes 1 and 2: BL21; 
lanes 3 and 4: C41; lanes 5 and 6: Novablue. Lanes 1, 3, and 5: GST; lanes: 2, 4, and 6 
GST-ORF P; lane 7: molecular weight markers with sizes are shown. GST-ORF P related 
bands are indicated ~ ). 
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at different temperatures was analysed by Western blotting with an anti-OST serum 
(Fig.5.3a) and Commassie blue staining (Fig.5.3b). 
Expression of GST at all three temperatures was the same (lanes 1, 4, and 7). However, 
expression of OST-ORF P at 31°C (lane 2) was better than both RT (lane 5) and 37°C 
(lane 8). Expression ofGST-ICP27 was equally good at 31°C and 37°C (compare lanes 3, 
6, and 9). Thus we decided to use 31°C for expression of OST -ORF P and 37°C for 
expression ofGST-ICP27 in BL21 in subsequent experiments. 
5.1.4 Optimization of GST-ORF P expression in BL21 at 31°C 
GST-ORF P should theoretically be about a 55-60 KDa protein. This fusion protein like 
many HSV -1 proteins is not expressed as full length in bacterial systems (Brown et al., 
1997; Wadd et al., 1999). During these experiments, we tried to optimise expression of 
full length GST-ORF P protein. Expression of GST-ORF P was analysed by Western 
blotting with an anti GST serum (Fig.5.4a) and Commassie blue staining (Fig.5.4b). 
Expression of GST was similar in both the initial (using normal western blotting and 
Commassie blue staining) and final experiments (repetition of experiments and keeping 
everything on ice) (lanes 1 and 3). In the initial experiments, a 40 KDa GST-ORF P 
doublet was detected in both Western blotting and Commassie staining (lane 2). In the 
final experiments the 40 KDa doublet and a higher molecular weight band of 45 KDa 
was detected (lane 4). 
Expression of GST-ORF P from the final experiment was also analysed on a 5-12.5% 
gradient SDS-PAGE by Commassie staining (Fig.5.5). Again the 28 KDa OST was 
detected (lane 1). In this gel as well as detecting the 40 KDa doublet and the 45 KDa 
band, two higher molecular weight bands of SO and 60 KDa were detected (lane 2). 
These may correspond to full length GST-ORF P. 
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Figure 5.3 Expression of GST, GST-ORF P, and GST-ICP27 at RT, 31°C and 37°C 
GST pUlldown extracts were run on a 12.5% SOS-PAGE and analysed by a) Western 
blotting using an anti-GST serum and b) Commassie blue staining. Lanes 1, 2, and 3: 
room temperature; lanes 4, 5, and 6: 31°C; lanes 7, 8, and 9: 37°C; lanes 1,4, and 7: 
GST; lanes 2,5, and 8: GST-ORF P; lanes 3,6, and 9: GST-ICP27. GST-ORF P related 
bands are indicated (~. Molecular weight markers with sizes are shown ( ~ ). 
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Figure 5.4 Expression of GST -ORF P in both initial and final experiments 
GST pulldown extracts were run on a 10% SDS-PAGE and analysed by a) Western 
blotting using an anti-GST serum and b) Commassie blue staining. Lanes 1 and 3: GST; 
lanes 2 and 4: GST - ORF P; lanes 1 and 2: initial expression; lanes: 3 and 4: final 
expression. GST-ORF P related bands 40 KDa ~ ) and 45 KDa ( -+ware indicated. 
Molecular weights are marked ~ ). 
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Figure 5.5 Expression of GST -ORF P in the final experiment 
GST pulldown extracts were run on a 5-12.5 % gradient SDS-PAGE and analysed by 
Commassie blue staining. Lane 1: GST; lane 2: GST -ORF P; lane 3: molecu lar weight 
markers with sizes shown. GST-ORF P related bands of 40 KDa (~ ), 45 KDa ( + ), 50 
KDaH ) and 60 KDaW ) are indicated, Molecular weight markers are indicated on 
the right hand side (~ ). 
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5.2 GST pulJdown assays 
5.2.1 Introduction 
GST fusion proteins in which the protein of interest is cloned in frame with the carboxy 
terminus of GST are widely used to identify new protein:protein interactions or to 
confirm and investigate those identified in other systems (Meredith et al., 1994). 
The fusion protein is expressed and purified by binding to glutathione which is attached 
to agarose (Smith and Johnson, 1988). After the fusion protein is bound to the matrix, it 
is washed with buffer to remove non-specifically bound bacterial proteins and 
subsequently mixed with cellular extracts. The fusion protein containing beads serve as 
an affinity matrix which allow binding of proteins which interact. Bound proteins can be 
partially purified by a simple centrifugation step, hence the name "pull down" assay. 
Beads are washed again to remove non-specifically bound cellular proteins and proteins 
analysed by SDS-PAGE. An overview of this method can be seen in (Fig.5.6). 
GST pulldown assays have been successfully used by many workers. For example, a 
similar approach to the one used here was used to identify an interaction between the 
immediate early HSV-1 protein ICPO and a 135 KDa cellular protein (Meredith et al., 
1994). As a part of this project, this method was used to attempt to identify both cellular 
and viral proteins which interact with GST-ORF P. 
5.2.2 Control ofpuUdown assay by use of GST-ICP27. 
Using the standard conditions for a GST pull down assay, we were not able to recognize 
any ORF P interacting proteins (data not shown). This method had previously identified a 
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Figure 5.6 GST pulldown assay 
(i) GST-ORF P is transformed into E.coli. (ii) GSI-ORF P expression is induced by the 
addition of IPIG. (iii) bacteria are harvested, resuspended in a small volume and split 
open by sonication. (iv) GST -ORF P is purified from bacterial proteins by addition of 
glutathione agarose. (v) A pulldown assay was performed by the addition of e sS] 
methionine labelled cellular extracts to purified GST-ORF P bound onto beads. (vi) The 
complex is washed to remove nonspecific binding, boiled to denature the prot ins and 
break protein:protein interactions, separated by SDS-PA E and autoradiographed. 
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number of proteins interacting with GST-ICP27 (Bryant, 2000). Thus to investigate that I 
was getting the method to work, the GST-ICP27 protein was used as a positive control 
and its interaction with 17+ infected cellular proteins was investigated. A pull down of 17+ 
infected cell proteins was performed with GST, GST-ICP27 and GST-ORF P (Fig.5.7). 
GST-ICP27 (lane 1) interacted with a number of proteins compared to GST (lane 2) e.g 
previously identified bands of 66 KDa (hnRNPK) and 44 KDa (TK) (Bryant, 2000). 
Thus the pulldown procedure was working correctly. Again, GST-ORF P (lane 3) did not 
show any specific interaction with viral or cellular proteins. 
5.2.3 Optimization of the pulldown assay by varying NaCI concentration 
As with co-immunopercipitations, salt and detergent concentrations in the buffers along 
with target and interacting protein concentrations affect which proteins interact with the 
bound fusion protein. The previous experiment (Fig.5.7) showed that although the GST 
pull down method was working no ORF P interacting proteins could be identified. Thus 
we attempted to optimise the detection of interacting bands by GST -ORF P by changing 
the salt concentration of the washing buffer. The standard concentration used was 0.5 
mM NaC} and by increasing the salt concentration we would increase the stringency of 
the washing buffer and hopefully remove non specific binding bands leaving specific 
interacting bands visible. Obviously we would reach a salt concentration where both 
nonspecific and specific interacting bands were removed. Fig.5.8 shows an experiment 
when a pull down was carried out and samples were washed in either 0.5, 5, 50 or 500 
mM NaCI containing wash buffer, respectively. 
As before, washing with 0.5 mM NaCI containing wash buffer resulted in no specific 
bands being detected. (see Fig 5.7 and data not shown). Using 5 mM NaC! containing 
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Figure 5.7 GST-ICP27 pulldown 
..... 220 KDa 
..... 97 KDa 
..... 66 KDa 
..... 45KDa 
..... 30 KDa 
..... 20 KDa 
A GST pulldown was performed on a e5S] methionine labe lled 17+ infected cell extract, 
ana lysed by 12.5% SDS-PAGE and autoradiography. Lane 1 :GST-ICP27; lane 2: GST 
and lane 3: GST-ORF P. Two predominant bands which interact with JCP27, hnRNPK 
and TK are indicated ~ ). Molecular weights are marked ( ~ ). 
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Figure 5.8 Optimization of GST pulldown experiment by the use of different 
concentrations of NaCI in the washing buffer 
A GST pulldown was performed on e5S] methionine labelled 17+ infected (lanes I and 
2) and MI cell extracts (lanes 3 and 4), and analysed by SDS-PAGE and 
autoradiography. Pulldowns were washed with a) 5 mM, b) 50 mM and c) 500 mM 
NaCt. Lanes 1 and 2: 17+ infected extract; lanes 3 and 4: MI infected extracts; lanes 
and 3: GST; lanes 2 and 4: GST-ORF P. GST-ORF P interacting cellular ( ~) and viral 
(* ~ ) bands with their molecular weights are indicated. Molecular weights are marked 
( ~ ). 
Chapter. 5 Results 
wash buffer (Fig.5.8a), no specific bands were still detected. However, increasing the 
NaCl to 50 mM (Fig.5.8b) resulted in a number of specific bands being detected. These 
bands include at least two viral and possibly one cellular protein with sizes of 27, 40 
(viral) and 47 KDa (cellular) (lanes 2 and 4). However, the photograph did not reproduce 
this well. Increasing the NaCI to 500 mM, resulted in these bands being lost (Fig.5.8c). 
lOS 
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6.0 Identification of proteins which interact with ORF P 
6.1 Introduction 
Using a GST pulldown assay, it was shown in the previous chapter that ORF P interacts with 
a number of cellular proteins and also with one viral protein. The aim of the work in this 
section was to identify with which cellular and viral gene products ORF P interacts. There is 
some previous evidence indicating that ORF P interacts with a number of splicing factors 
and may playa role in splicing (Bruni and Roizman, 1996). For this reason we screened our 
GST pull downs with a range of antibodies against proteins with some role in splicing and 
posttranscriptional processing and which were of an approximate molecular weight to those 
identified in the previous chapter (Chapter 5). Western blotting of cellular extracts was 
carried out with 14 available antibodies. Of these we could only get positive results with 10 
against cellular extracts. These 10 working antibodies were used to analyse GST-ORF P 
pull downs by Western blotting to detect an interaction of ORF P with these proteins. The 
antibodies used and their characteristics are shown in table 6.1. 
6.2 Interaction of ORF P with ICP27 
It had previously been shown that ICP27 interacts with cellular posttranscriptional 
processing factors (Bryant et a/., 2000). Thus it seemed reasonable to investigate whether 
ORF P interacts with ICP27. A GST-ORF P pull down was carried out and Western blotted 
with an anti-ICP27 antibody. Both GST and GST-ORF P interact with ICP27 and its related 
bands (Fig.6. 1). To try to reduce this non specific binding, the amount of beads was reduced 
from 50 (lanes 2 and 3) to 12.5 ul (lanes 4 and 5) and 50 mM NaCI containing washing 
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PrimarY antibody Type Function References 
a CPSF (25 KDa) Mouse 3' cleavage and (Mane ley, 1995) 
polyadenylation of mRNA 
hnRNPK Rabbit Interacts with a number of (Bustello et aI., 
cellular proteins involved in 1995) 
transcription, translation and 
signal transduction 
CK II P sununit Mouse phosphorylates and (Sanz-Ezquerro et 
modulates the function of a aI., 1998) 
number of viral proteins 
Thymidine Kinase Mouse Deoxypyrimidine kinase (Evans et aI., 
(phosphorylation of 1998 
thimidine) 
P32 Mouse Involved in splicing (Krainer et aI., 
1990) 
SC35 I Mouse Splicing factor (Sandri-Goldin 
et aI., 1995) 
hnRNPJ Mouse Multifunctional protein (Bustello et aI., 
involved in posttranscriptiona 1995) 
regulation 
aASF Mouse Recognition and cleavage of (Krainer et aI., 
5' splice sites 1991) 
ICP27 Rabbit Multifunctional protein (Bryant et aI., 
involved in posttranscriptiona 2000 
regulation 
a CFI (25 KDa) Rabbit 3' cleavage and (Takagaki et aI., 
polyadenylation of mRNA 1989) 
a CFI (68 KDa) Rabbit 3' cleavage and (Takagaki et aI., 
polyadenylation ofmRNA 1989) 
a CPSF (30 KDa) Rabbit 3' cleavage and (Maneley, 1995) 
polyadenylation of mRNA 
Table 6.1: Cellular and viral proteins whose in vitro interaction with ORF P was 
investigated. Identified proteins interacting with ORF P indicated I, 
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Figure 6.1 Western blotting of a GST -ORFP pulldown with an anti ICP27 antibody 
A GST pulldown was run on a 12.5% SDS-PAGE and analysed by Western blotting 
using an anti-ICP27 antibody. Lane} : MI extract; lanes 2-6: 17+ infected cell extracts; 
lane 2: 50 ul GST beads; lane 3: 50 ul GST-ORF P beads; lane 4: 12.5 ul G T bead ; 
lane 5: 12.5 ul GST-ORF P beads and lane 6: whole 17+ infected cell extract. Full I ngth 
ICP27 is indicated (-. ). Molecular weights are marked ( ~ ). 
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buffer was used. Decreasing the amounts of beads had no effect on the nonspecific 
interaction of ICP27 with GST. As the GST-ICP27 fusion protein expressed better than 
GST-ORF P, the reverse experiment was carried out where GST-ICP27 was used to try to 
pulldown ORF P from tsK infected cell extracts and Western blotted with an anti-ORF P 
serum (Fig.6.2). In initial Western blotting, serum 128 cross reacted with the GST-ICP27 
related bands as it had been raised against a GST fusion protein (data not shown). Therefore, 
we had to pre adsorb 128 against GST to remove the GST specific bands. When this 
preadsorbed serum was used, no specific band was detected in lane 3, indicating no 
interaction of ORF P with ICP27. Also in lane 2 no specific band was detected indicating 
that no ORF P self interaction ocured. A nonspecific band of 30 KDa (presumably GST) was 
detected in lanes 1-3 and two bands of 50 KDa were detected in lane 3 presumably the 
predominant GST-ICP27 bands. These bands are detected due to incomplete adsorption of 
anti-GST antibodies and thus cross reaction with the major GST containing bands. The 
antiserum still recognized ORF P in the tsK extract (lane 4) indicating that the anti-ORF P 
antibodies were still present. 
6.3 Identification of proteins which do not interact with ORF P 
Antibodies against 10 cellular and one viral protein were used in Western blotting of GST-
ORF P pulldowns to look for specific interactions (Table 6. I). Of these, only one recognised 
an identified protein interacting with ORF P. Examples of Western blotting results from two 
of the non interacting proteins are shown in Fig.6.3 and Fig.6.4. Fig.6.3 shows Western 
blotting of pUlldown extracts with an antibody against p32. In lane 5 p32 can be detected in 
the mock infected whole cell extract, whereas no interaction can be seen in 17+ infected 
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Figure 6.2 Western blotting of a GST-ICP27 pulldown with pread orbed anti-ORF 
P serum 128 
GST pUlldowns of tsK infected cell extracts were run on a ]2.5% OS-PAGE and 
ana lysed by Western blotting using anti-ORF P serum 128. Lane I: T pulldown; lane 
2: GST-ORF P pulldown; lane 3:GST-lCP27 pulldown; lane 4: /sK infected ce ll extract. 
The ORF P band is indicated ( " ). Molecular weights are marked (" ). 
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Figure 6.3 Western blotting of a GST-ORF P pulldown with p32 antibody 
Results 
GST pulldowns were run on a 12.5% SDS-PAGE and analysed by Western blotting 
using an anti-p32 antibody. Lanes I and 2: 17+ infected cell ex tracts; lanes 3-5: MI 
extracts; lanes 1 and 3: GST pulldown ; lanes 2 and 4: GST-ORF P pulldown; lane 5: 
whole mock infected cell extract. The p32 band is indicated ( ~ ). Molecular wights are 
marked ( ~ ). 
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Figure 6.4 Western blotting of a GST-ORF P pulldown with CPSF antibody 
GST pulldowns were run on a 12.5% SDS-PAGE and analysed by Western blotting 
using an anti-CPSF antibody. Lanes 1- 3: 17+ infec ted cell extracts; lanes 4-6 : MI extract; 
lanes 1 and 4: GST pulldown; lanes 2 and 5: GST-ORF P pulldown; Ian 3: whole 17+ 
infected cell extracts and lane 6: whole MI cell extract. The CP F band is indicated ~ ). 
Molecular weights are marked ~ ). 
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(lane 1,2) or in mock infected pulldowns (lanes 3 and 4) with either GST or GST-ORF P, 
respectively. Fig.6.4 shows Western blotting of pulldown extracts with an antibody against 
CPSF. CPSF can be seen in both 17+ infected (lane 3) and MI whole cell extracts (lane 6), 
whereas no interaction can be seen in either aST or GST -ORF P pulldowns from 17+ 
infected (lanes 1 and 2) or mock infected extracts (lanes 4 and 5). 
6.4 Identification of proteins which interact with ORF P 
Using Western blotting of pulldown extracts with an antibody against CKII (~), an 
unexpected result was obtained. No specific interaction with CKII (~) was detected. CKII 
(~) is detected in both 17+ infected whole extract (Fig.6.S, lane 5) and mock infected whole 
cell extract (lane 8), whereas no specific interaction can be seen in either 17+ infected (lane 
4) or mock infected extracts (lane 7) with GST or GST-ORF P. However, a 45 KDa band is 
specifically detected in lanes 4 and 7, indicating an unidentified cellular protein, which was 
also detected by the CKII (~) antibody, interacted with ORF P. As the band detected was 
slightly lower than that detected in both 17+ (lane 5) and mock infected cell extracts (Jane 8), 
aST (Jane 1) and GST-ORF P (lane 2) extracts were used in western blotting to rule out 
cross reaction of the antibody with the GST -ORF P fusion protein. No 45 KDa protein was 
detected in either of these extracts. 
To try to identify the 40 KDa viral band interacting with GST-ORF P, Western blotting of 
pulldown extracts was carried out with an antibody against the viral thymidine kinase (TK), 
which is about 40 KDa (Fig.6.6). As expected, TK is detected in 17+ infected whole cell 
extract (lane 5) but not in mock whole cell extract (lane 6). No specific interaction can be 
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Figure 6.5 Western blotting ofa GST-ORF P pulldown with CKll (~) antibody 
OST pulldown extracts were run on a 12.5% SDS-PAOE and analy d by Western 
blotting using an anti-CKII (~) antibody. Lane I: OST; lane 2: a T-ORF P; lane 3-5 : 17+ 
infected cell extracts; lanes 6-8: MI extract; lanes 3 and 6: OST pulldown; lane 4 and 7: 
OST-ORF P pulldown; lane 5: whole 17+ infected cell extracts and lane 8: whole MI cell 
extract. CKII (~) ( ~ ) and an unidentified protein r~ ) are indicated. Molecular weights 
are marked (~ ). 
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Figure 6.6 Western blotting of GST-ORFP pull down with TK antibody 
GST pulldown extracts were run on a 12.5% SDS-PAGE and analysed by Western 
blotting using an anti-TK antibody. Lanel, 2 and 5: 17+ infected cell extract; lane 3, 4, 
and 6: MI extracts; lanes 1 and 3: GST pulldown; lanes 2 and 4: GST-ORF P pulldown; 
lane 5: whole 17+ infected cell extracts and lane 6: whole MI cell ex tract. The TK band 
~) and the unidentified protein (+-.J are indicated. Molecular w ights are mark d (~) . 
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seen in 17+ infected extract with either GST (lane 1) or GST-ORF P (lane 2), as both GST 
and GST-ORFP interacted with TK. Again the pulldown was carried out with decreasing 
amounts of GST and GST -ORF P and the interaction with TK was lost equally by GST and 
GST -ORF P indicating no specific interaction was occuring. However, a 45 KDa band was 
specifically detected in both infected (lane 2) and mock infected (lane 4) GST-ORF P 
pUlldowns and also in mock infected whole cell extract (lane 6), indicating that an 
unidentified 45 KDa cellular protein which cross reacted with the TK antibody was 
interacting with ORF P. On a long exposure, the 45 KDa band could also be identified in 17+ 
whole cell infected extracts (data not shown). 
The only identified cellular protein interacting with ORF P detected in these experiments 
was SC35. Fig.6.7 shows Western blotting ofGST and GST-ORF P pull down extracts with 
an antibody against SC35. As expected the specific 65 KDa SC35 band was detected in both 
mock infected (lane 8) and 17+ (lane 5) cell extracts. The 65 KDa SC35 band was detected 
specifically in the GST -ORF P pulldowns (lanes 2 and 5) but not in GST pulldowns (lanes 3 
and 6). 
6.5 Nuclear and cytoplasmic fractionation of SC3S/0RF P 
In section 6.4 we demonstrated that ORF P interacted in vitro with SC35. If this is 
representative of an in vivo interaction it would be expected that both proteins will be located 
in the same cellular compartment. It has been previously demonstrated that SC35 localises 
mainly to the nucleus (Boe el al., 1998) and thus we wished to confirm this and determine if 
ORF P was also located in the nucleus. To investigate the intracellular location of ORF P 
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Figure 6.7 Western blotting of GST-ORF P pulldown with SC35 antibody 
GST pulldown extracts were run on a 12.5% SOS-PAGE and analysed by We t rn 
blotting using an anti-SC35 antibody. Lanes 1 - 3: 17+ infected cell extracts; Ian s 4-6: 
MI extracts; lanes I and 4: GST pulldown; lanes 2 and 5: G T-ORF P pulldown; lane 3: 
whole 17+ infected cell extract and lane 5: whole M[ cell extract. The 35 band i 
indicated ~ ). Molecular weights are marked ( ~ ). 
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and SC35, BHK cells were infected with IsK, 17+ and 1716 or mock infected, their nuclear 
and cytoplasmic proteins separately extracted and Western blotted with both an antibody 
against SC3S and antiserum 128 against ORF P. Fig.6.8 shows a Western blot of nuclear and 
cytoplasmic extracts with the antibody against SC35. As previously published, SC3S is 
located in the nucleus of IsK (lane 1), 17+ (lane 3), 1716 (lane 5) and mock infected (lane 7) 
BHK cells with no protein being detected in the cytoplasm (lanes 2, 4, 6 and 8). 
Fig.6.9 shows a Western blot of nuclear and cytoplasmic extracts with antiserum 128. ORF 
P is located in approximately equal amounts in both the nucleus and cytoplasm of BHK cells 
infected with IsK (lanes 1 and 2) and 17+ (lanes 3 and 4). As expected no ORF P was 
detected in 1716 (lanes 5 and 6) or mock infected (lanes 7 and 8) extracts. In lane 9 a whole 
cell extract from IsK infected BHK cells was used as a positive control to show the 30 kDa 
ORF P protein. 
6.6 Coimmunoprecipitation of ORF P and SC3S 
In section 6.4 we demonstrated that ORF P interacted in vitro with SC35 and in section 6.5 
we demonstrated that both SC35 and ORF P are located in the nucleus. To investigate if 
ORF P interacts with SC35 in vivo, immunoprecipitation of BHK cell extracts infected with 
IsK, 17+ and 1716 and mock infected was carried out separately using both an antibody 
against SC35 and the anti-ORF P serum 128 and coimmunoprecipitation of the other protein 
analysed by Western blotting. 
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Figure 6.8 Western blotting of BHK nuclear and cytoplasmic extracts with SC35 
antibody 
BHK cells were infected with HSV-l at a m.o.i of 20 pfu/cell and harvested at 24 h pi. 
Analysis of SC35 distribution in both BHK cell nuclear and cytoplasmic extracts was 
carried out by 7.5% SDS-PAGE and Western blotting with SC35 antibody and anti JgG-
HRP, reacted with ECL and exposed to autoradiography. Lanes 1, 3, 5 and 7: nuclear 
extracts; lanes 2, 4, 6 and 8: cytoplasmic extracts. Lanes I and 2: tsK; lanes 3 and 4: 17+; 
lanes 5 and 6: 1716; lanes 7 and 8: MJ. Molecular weight markers are indicated on the 
right and SC35 related bands are marked on the left ( ~). 
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Figure 6.9 Western blotting of BHK nuclear and cytopla mic extracts with anti-
ORF P serum 128 
BHK cells were infected with HSV- J at a m.o.i. of 20 pfu/cell and harv ted at 24 h pi. 
Analysis of ORF P distribution in both BHK cell nuclear and cytoplasmic xtract wa 
carried out by 12.5% SDS-PAGE and Western blotting with anti erum 128 and prot in-
A-HRP, reacted with EeL and exposed to autoradiography. Lane 1, 3, 5 and 7: nucl ar 
extracts; lanes 2, 4, 6 and 8: cytoplasmic extracts. Lanes 1 and 2: tsK; lane 3 and 4: 17 ; 
lanes 5 and 6: 1716; lanes 7 and 8: MI; lane 9: tsK infected whole II e tra t. M I ular 
weight markers are indicated on the right and ORF P related band ar mark d n th I rt 
( ~). 
Chapter. 6 Results 
Initially, samples were immunoprecipitated with the ORF P antiserum and Western blotted 
with 128 and the SC35 antibody. Fig.6.l0a shows a Western blot carried out with 128 to 
confirm ORF P immunoprecipitation. Lane 5 shows that ORF P was precipitated from fsK 
infected BHK cell extracts. However, no immunoprecipitated ORF P was detected from 17+ 
infected BHK cell extracts (lane 6) or as expected from 1716 (lane 7) or mock infected 
extracts (lane 8). ORF P expression was detected from whole tsK infected BHK cell extracts 
(lane 1) but not from BHK cell extracts infected with 17+ (lane 2) or as expected from the 
negative controls infected with both 1716 (lane 3) and mock infected (lane 4). 
To investigate coimmunoprecipitation of SC35 by ORF P, Western blotting of ORF P 
immunoprecipitated samples was carried out with the SC35 antibody (Fig 6.IIa). As 
expected SC35 was detected in tsK (lane 1), 17+ (lane 2), 1716 (lane 3) and mock infected 
(lane 4) whole BHK cell extracts. This figure shows that SC35 was coimmunoprecipitated 
by ORF P from both the fsK and 17+ infected BHK cell extracts, where ORF P was present 
(lanes 5 and 6, respectively), but also from both 1716 and mock infected BHK cell extracts, 
where ORF P was not present (lanes 7 and 8, respectively). Thus there was nonspecific 
coimmunoprecipitation. 
To try to remove these non specific bands and determine if there was also specific 
coimmunoprecipitation ofSC35 by ORF P, washing of the immunoprecipitation was carried 
out with Zweig's buffer containing 1M NaCI. However, no difference was seen (data not 
shown). To further increase the stringency to attempt to remove non specific binding, 
Zweig's buffer containing 0.1% (w/v) SDS was used to prepare infected BHK cell extracts 
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Figure 6.10 Western blotting of immunoprecipitated ORF P protein with anti-ORF 
P serum 128 
BHK cells were infected with HSV -1 at a m.o.i. of 20 pfulcell , harve ted at 24 h pi and 
immunoprecipitated with ORF P antiserum 128 in a) the ab ence of OS and b) the 
presence of 0.1 % (w/v) SDS. Samples were analysed by 12.5% -PA and W t rn 
blotting with antiserum 128 and protein-A-HRP. Lane 1-4: whole cell xtract; lane 5- : 
immunoprecipitated samples. Lanes 1 and 5: IsK; lane 2 and 6: 17+; Ian 3 and 7: 1716; 
lanes 4 and 8: MI. Molecular weight markers and the heavy chain f rg ar indi at d n 
the right and ORF P on the left ~ ). 
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Figure 6.11 Western blotting of anti-ORF P immunoprecipitation with C35 
antibody 
BHK cells were infected with HSV-l at a m.o.i. of20 pfu/ce \l , harve ted at 24 h pi and 
immunoprecipitated with ORF P antiserum J 2 in a) th ab ence of and b) th 
presence of 0.1 % (w/v) SDS. Samples were analys d by 12.5% 0 -PAG and We t m 
blotting with SC35 antibody and anti IgG-HRP. Lan 1-4: whol 11 xtra l; Ian 5-8: 
immunoprecipitated samples. Lanes I and 5: IsK; lane 2 and 6: 17 ; Ian 
lanes 4 and 8: MI. Molecular weight mark r nd lh heavy hain f Jg ar indi atcd n 
the right (~ ). S 35 is indicated on th left: (~ ). 
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and carry out the immunoprecipitation with 128 followed by Western blotting with both 128 
and SC35 antibody. 
Western blotting of SDS containing ORF P immunoprecipitated samples with 128 is shown 
in Fig.6.1 Ob. The band previously seen in Fig.6.1 Oa lane 5 indicating that ORF P protein had 
been immunoprecipitated by 128 from tsK infected BHK cells was absent. As before, no 
band was immunoprecipitated from BHK cell extracts infected with 17+ (lane 6), or as 
expected from 1716 (lane 7) or mock infected (lane 8). As before, ORF P expression was 
detected from whole tsK infected BHK cell extracts (lane 1) but not from 17+ (lane 2) or as 
expected from either 1716 (lane 3) or mock infected (lane 4) cells. Thus the presence of 
0.1% (w/v) SDS prevented the immunoprecipitation ofORF P by 128 and we will not expect 
SC35 to coimmuoprecipitate. 
However, we decided to carry out Western blotting of SDS containing ORF P 
immunoprecipitated samples with the SC35 antibody (Fig.6.11 b). Again SC35 was detected 
in tsK, 17+, 1716 and mock infected immunoprecipitations (lanes 5, 6, 7 and 8, respectively), 
indicating that SC35 is being nonspecifically immunoprecipitated. Whole BHK cell extracts 
infected with ts K (lane 1), 17+ (lane 2), 1716 (lane 3) and mock (lane 4) were used as 
positive controls for the Western blot. 
We then proceeded to carry out the reverse experiment by immmunoprecipitating SC35 and 
looking for coimmunoprecipitation of ORF P. Immunoprecipitation of SC35 was carried out 
both at 4°C overnight and at 37°C for 2 h and the samples Western blotted with the SC35 
antibody. Fig.6.12 shows the result of the immunoprecipitation carried out at 4°C. Whole 
112 
Chapter 6 Resu lts 
2345678 
SC35 ~ 
~1fi~~~~'I${J~}oIII IgO 
45 KDn 
;:",."",..,._ 30 KDo 
Figure 6.12 Western blotting of immunoprecipitated SC35 with C35 antibody 
BHK cells were infected with HSV -1 at a m.o. i of 20 pfulce ll , harvested at 24 h pi and 
immunoprecipitated with SC35 antibody. Samples were electrophore ed on a 12.5% 
SDS-PAGE and Western blotted with SC35 antibody and anti-IgG-HRP. Lanes 1-4: 
whole cell extracts; lanes 5-8: immunoprecipitated samples. Lane 1 and 5: tsK; lane 2 
and 6: 17+; lanes 3 and 7: 1716; lanes 4 and 8: mock infected. Mol ular wight mark r 
and the heavy chain ofIgG are indicated on the right and 35 on th I ft: ( ~) . 
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tsK (lane 1), 17+ (lane 2),1716 (lane 3) and mock (lane 4) infected BHK cell extracts were 
used as positive controls and the 65 KDa SC35 protein was detected in all extracts. 
However, no SC35 protein was detected in the tsK, 17+, 1716 or mock infected 
immunoprecipitations (lanes 5, 6, 7 and 8, respectively) indicating no immunoprecipitation 
of SC35 by SC35 antibody had occurred. An identical result was obtained with the 
immunoprecipitation carried out at 37°C (data not shown). As we were unable to precipitate 
SC35, it was not possible to determine ifSC35 coimmunoprecipitated ORF P. 
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7.0 Discussion 
The work carried out in this project comprises two main sections: i) characterisation of 
the role of ICP34.5 and ORF P in HSV -1 replication; and ii) identification of cellular and 
viral proteins which interact with ORF P. These two areas will be discussed separately. 
7.1 Characterisation ofthe role oflCP34.5 and ORF P in HSV-l replication 
A complication in the analysis of the role of ICP34.5 in the virus lifecycle is the 
presence of overlapping antisense genes, ORF OIP, which are also deleted in ICP34.5 
negative mutants. In 1991, MacLean, A. et al. isolated 1716, a HSV-l 17+ ICP34.510RF 
OIP deletion mutant. This mutant has been demonstrated to have specific characteristics 
both in vitro and in vivo. Following intracranial inoculation, 1716 is unable to replicate 
in the CNS of mice and is totally avirulent with a LDso of 106 pfu/mouse higher than 
wild type or rescued virus (MacLean, A. et al., 1991). Following peripheral inoculation 
via the eye, 1716 does not appear to replicate in the cornea or trigeminal ganglia (TG) 
and although establishing latency in TG does so at a significantly lower frequency than 
wild type virus. Following footpad or vaginal inoculation, virus may undergo limited 
replication at the initial site of inoculation but no replication takes place in the dorsal 
rout ganglia (DRG) and latency is established although not as inefficiently as in the TG 
and can be reactivated in vitro following explantation (Roberston et al.,1992; Spivack et 
al., 1995). 
In tissue culture, 1716 replicates normally in many non neuronal cell types such as Vero 
and BHK 211C13 cells, but is restricted in 3T6 cells (Brown et al., 1994a). In general, in 
nonpermissive cells the growth defect of ICP34.5 null mutants is greater when they are in 
the stationary phase (Brown et al., 1994a). In certain cell types such as SK-N-SH cells 
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infected with ICP34.5 null mutants, PKR is activated, eIF-2a is phosphorylated and 
protein synthesis is shutoff (Chou and Roizman, 1992; Chou et al., 1995). 
Both the in vitro and in vivo phenotypes of 1716 were demonstrated to be due to the 
absence of the deleted sequences by the wild type growth characteristics of two 
independently constructed rescuants of 1716 (MacLean, A. et al., 1991; McKie et al., 
1994; Spivack et al., 1995). 
To attribute characteristics which were originally attributed solely to ICP34.5 to each of 
the two genes, a number of HSV-l recombinant viruses that express ICP34.5 and ORF 
OIP independently were constructed, purified and characterised. 
The basic design of all recombinant viruses was that an expression cassette was inserted 
into the 1716 UL431UL43.510cus. In this cassette the gene of interest was inserted under 
a HSV -1 gD promoter with a HSV -2 IE4/5 polyadenylation signal. In the opposite 
orientation, the lacZ gene was inserted under a SV 40 promoter with its own 
polyadenylation signal. Construction of these recombinants is described in Section 3. 
The delayed early HSV -1 gD promoter (Everett, 1984) was used to express both 
ICP34.5 and ORF P as it was believed that it would express both genes strongly, and 
ICP34.5 with similar kinetics to those of the wild type. As UL43/43.5 are non essential 
genes and it had previously been shown that deletion and insertional inactivation of 
these genes has no effect on virus replication either in vitro or in vivo (MacLean, C. et 
aI., 1991), this locus was selected as the site of insertion. Disruption of these two genes 
should have no effect on the phenotype of the recombinants. ICP34.5 and lacZ were 
inserted at the 5' end ofUL43 and thus this insertion should inactivate UL43. However, 
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these two genes were inserted at the 3' end of UL43.5 and thus this insertion might not 
inactivate UL43.5. By this method, 1622 expressing ICP34.5 and 1624, 1624.5 and 1625 
,in which ORF P sequence were inserted, constructed. 
To construct 1625, gD/ORF P was inserted in the middle of the non essential gene US5 
which encodes glycoprotein J (McGeoch et al., 1985). As it had been demonstrated that 
insertion of LacZ in this position inactivated US5 (Balan et al., 1994), insertion of ORF 
P should also inactivate this gene. Although US5 is also not essential for HSV-I 
replication in vitro or in vivo (Longnecker and Roizman, 1987; Balan et al., 1994), we 
were not able to completely purify 1625 from its parent, 1622 with a level of about 10% 
contamination. It seems unlikely that 1625 is non viable and requires 1622 as a helper 
virus. The contamination is more likely to be due to instability of 1625 DNA with 
deletion of the inserted sequences. This deletion is unlikely to be precisely limited to the 
inserted sequence and could either leave some of the inserted sequences or remove some 
of the adjacent viral DNA with the deletion being within 100 bp of the size of the insert 
as no size alteration was detected by Southern blotting. To address this possibility, PCR 
could be carried out across the insertion site followed by sequence analysis. Also, the 
instability may be due to mUltiple insertion of gO promoter. 
The recombinants need to properly characterised to conclude if they actually 
contain/express ORF P by using specific ORF P fragment with no extra sequences. 
Western blotting analysis of 1622 and 1625 infected BHK cells demonstrated at least an 
eight-fold increase in ICP34.5 levels compared with wild type 17+. Both 1622 and 1625 
express ICP34.5 under the gD promoter and in the UL43.5 orientation. 1625 also contain 
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gO/ORF P inserted in US5. The most probable explanation is that the gO promoter is 
stronger than the ICP34.5 native promoter. Alternatively, as there is a ATG in the 5' 
untranslated leader of the natural ICP34.5 gene and this ATG is absent in the 5' 
untranslated leader of gD/ICP34.5, this ATG might be having a negative effect on 
ICP34.5 translation in wild type virus. The higher level of ICP34.5 expression might also 
be due to an orientation effect in the UL43/43.S locus (see below). Analysis of ICP34.5 
RNA levels might allow determination of the reason for this overexpression. 
Expression of USTs and their protein products, ORF P and ORF 0, has not been 
detected during productive infection by HSV-l strain F (Lagunoff et al., 1996). 
However, it had been previously demonstrated in our laboratory (McKie and MacLean, 
personal communication) that in BHK2l1C13 cells RLI and ORF P transcripts and 
proteins were simultaneously expressed during a productive infection by HSV-l (17+) in 
the presence of functional ICP4. My work also confirmed that HSV-l (17+) produces 
ORF P during a productive infection. Thus, ORF P may have a role in 17+ productive 
infection. It has been suggested that ORF 0 specifically binds to and inhibits in vitro 
binding ofICP4 to its recognition sites in DNA (Randall et al., 1997). Thus, the higher 
production of ORF P in 17+ than strain F may be due to higher production of ORF 0 in 
17+ than in strain (F). Alternatively, ORF 0 of 17+ might bind to ICP4 stronger than that 
of strain F and thus allow more expression of USTs and hence ORF OIP in strain 17+. 
Evidence to support the different function between ORF 0 protein in strains 17+, F and 
KOS is their different length. ORF 0 consists of 245 amino acids in 17+ whilst in strains 
F and KOS consists of 105 amino acids (Randall et al., 1997; Yea and Schaffer, 1998). 
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In the recombinants 1624, 1624.5 and 1625 no ORF P protein was detected. This would 
suggest that these recombinants express low levels of ORF P. In 1624 ORF P sequence 
inserted in the UL43 orientation, in 1624.5 in the UL43.5 orientation and in 1625 in US5. 
The antibodies used, 128 and 129, were rabbit polyc1onal sera raised against a GST-ORF 
P fusion protein. Use of GST fusion proteins tends to generate rabbit polyclonal sera with 
high background as evidenced by the antisera against ICP34.5 and ICP27 used in this 
thesis. Also, as evidenced from our results the GST fusion protein produces a truncated 
protein. Therefore, this antiserum will be against a limited number of epitopes from the 
aminoterminus of the protein. These antisera exhibited problems of detection with low 
amount of ORF P protein from the recombinants and to a lesser extent from 17+ but not 
from the overproducing ts mutant in ICP4 (tsK) at the nonpermissive temperature (NPT). 
If monoclonal antibodies were raised against ORF P these might produce less 
background and thus the Western blots could be exposed longer to detect low levels of 
ORFP. 
When gD/ORF P was originally cloned, it was thought that ORF 0 was translated from a 
different initiating methionine codon upstream from that of ORF P (Lagunoff et al., 
1996; Yeh and Schaffer, 1993) and thus only ORF P would be expressed. Subsequently, 
it was shown that both ORF 0 and P share the same initiating methionine codon and 
ORF 0 then frameshifts to the ORF 0 frame after amino acid 35 of ORF P (Randall et 
al., 1997). If the normal (LIST) RNA 5' untranslated leader is required for the correct 
RNA structure to allow this frameshifting from the ORF P to ORF 0 reading frame, then 
the recombinants will not express ORF O. However, if the sequence determining 
frameshifting is in the 5' part of the ORF they will express both ORFs 0 and P. Without 
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experimental evidence of ORF 0 expression by antibody detection, it is not possible to 
conclusively say whether or not ORF 0 is expressed from our recombinants. 
As neither antisera 128 nor 129 detected ORF P in the recombinant viruses by Western 
blotting, immunoprecipitation of tsK, 17+ and 1716 infected BRK cell extracts was 
carried out. As there is only a small number (2) of methionines in ORF P it was decided 
that it would label poorly with esS] methionine and therefore immunoprecipitation was 
carried out on unlabelled extracts and detected by Western blotting. Again although both 
antibodies immunoprecipitated ORF P in tsK at the NPT, they were not able to 
detectably precipitate the lower amounts of ORF P expressed in 17+' As ORF P could 
not be detected from 17+ extracts, we did not carry out an immunoprecipitation with the 
recombinants 1624, 1624.5 and 1625. 
As we were not able to detect ORF P protein from our recombinant viruses, we 
proceeded to look for the RNA. As ORF P is inserted in the UL43/43.5 loci, the GST-
ORF P probe will detect the HSV UL43/43.S spanning transcripts. The size of transcripts 
were 7.0 kbp; 4.0 kbp; 2.7 kbp; 2 kbp; 1 kbp and are probably respectively 
uncharacterised; UL43/44; UL44; UL41; and UL43. The uncharacterised long transcript 
probably arises from the non specific transcription detected from the HSV genome late in 
infection (Jacquemont and Roizman, 1975a, b). In addition, the GST-ORF P probe also 
detects a band with the size expected for ORF P RNA of about 700 bp in 1624, 1624.5, 
and 1625. As ORF P is used as the probe and there is sequence identity between ORF P 
and ICP34.5, a 700 bp ICP34.5 transcript was detected in 1622. As expected ORF P did 
not hybridise to the UL41-44 HSV transcripts in tsK, 17+ and 1716. Surprisingly no 
native ORF P RNA was detected in tsK or 17+ and thus the ORF P probe blot has failed 
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to detect ORF P even in positive control so no conclusion can be drawn. Although we did 
confirm the presence of RNA using a yl actin probe. 
No Southern blotting definitely showing ORF P had been performed. Neither ORF P 
protein nor RNA was detected from the recombinants. Using a specific ORF P fragment 
with no extrasequence as a probe both Southern and northern blotting should be carried 
out to detect ORF P gene and ORF P RNA synthesis, respectively in the recombinants. 
Alternatively, PCR could be carried out across the insertion site followed by sequence 
analysis. 
As previously stated, in tissue culture ICP34.5 null mutants replicate nonnally in many 
non neuronal cell types such as Vero and BHK2l1C13 cells, but are restricted in SK-N-
SH neuroblastoma cells, human foreskin fibroblasts (HFF), murine 10T1I2 cells, 
stationary phase primary mouse embryo cells, and 3T6 cells (Chou et al., 1990, 1994; 
Chou and Roizman, 1992; Bolovan et al., 1994; Brown et al., 1994a). In some cell types 
such as SK-N-SH cells infected with ICP34.5 null mutants, PKR is activated, eIF-2a. is 
phosphorylated and protein synthesis is shutoff (Chou et al., 1995). 
It had been previously shown that neither ICP34.5 nor ORFOIP are essential for 
replication of HSV-l (17+) in BHK cells (MacLean, A. et al., 1991). Therefore as 
expected, in these cells all our recombinant viruses with the exception of 1624 exhibited 
a similar growth pattern to wild type virus, confirming that neither ICP34.5 nor ORF OIP 
are essential for replication of HSV -1 (17+) in BHK cells. 1624 seems to be impaired in 
growth in BHK cells compared with the other viruses, indicating a probable secondary 
mutation elsewhere in the genome. 
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In stationary state 3T6 cells, 17+ grew well reaching a maximum titre of 106_107 pfu/ 106 
cells whereas 1716, expressing neither ICP34.5 nor ORF OIP failed to grow. The 
recombinants 1624 and 1624.5 which express only ORF OIP also failed to grow whereas 
1622 and 1625 expressing ICP34.5 grew. However, 1622 and 1625 plataued at a 
maximum titre of 101 to 102 fold lower than 17+. Previous work (Adams, 1999) had 
demonstrated that an insertion into UU3/43.5 did not affect growth in 3T6 cells. There 
are at least two possible explanations for the poorer growth of the recombinants 
compared to 17+. Either the higher levels of expression of ICP34.5 in 1622 than in 17+ or 
different kinetics of ICP34.5 expression in 1622 compared with 17+ might be deleterious 
to growth. In some experiments both 1622 and 1625 grew similarly whereas in others 
1625 grew 5-10 fold less well than 1622. Most consistently, 1625 grew to a maximum 
titre 5-10 fold lower than 1622. Thus, in 3T6 cells, expression of ICP34.5 partially 
restored 1716 growth to 17+ levels. Expression of ORF OIP either by itself or in 
conjunction with ICP34.5 has no positive effect on 1716 growth. 
In SK-N-SH cells, 17+ grew well reaching a maximum titre of 107_108 pfu/106 cells. The 
growth of 1716 in SK-N-SH cells had not been previously characterised. As expected 
based on the host protein synthesis shutoff phenotype, SK-N-SH cells are not fully 
permissive for 1716. However, our results showed that this cell line is semi permissive 
for 1716, exhibiting limited growth with a maximum titre 104 fold lower than 17+. There 
are at least two possibilities to explain this semi rather than non permissive phenotype. 
As SK-N-SH cells are a heterogenous cell line and a small percentage of cells have 
dedifferentiated and reverted to fibroblasts, these dedifferentiated cells might fully 
support 1716 replication whilst the differentiated cells are nonpermissive. Alternatively, 
host protein synthesis shutoff might not completely inhibit growth of 1716 in infected 
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SK-N-SH cells allowing limited growth of 1716 in these cells. 1624.5 grew similarly to 
1716 and thus expression of ORF OIP has no positive effect on 1716 growth. In 
agreement with its impaired growth in BHK cells, 1624 grew consistently 10 fold poorer 
than 1716. Both 1622 and 1625 grew similarly to 17+. Although in some experiments 
1625 grew about 5 fold poorer than 1622. In SK-N-SH cells, expression of ICP34.5 
restores 1716 growth to nearly 17+ levels. 
One role of ICP34.5 is to maintain host and viral protein synthesis late in infection in 
some cell lines such as SK-N-SH (Chou et al., 1995). In HSV-l infected cells, 
transcription of the complementary DNA strands results in the formation of double 
stranded RNA, induction of IFN and activation of the PKR pathway and eIF-2a 
phosphorylation which results in premature shutoff of host protein synthesis. However, 
the HSV encoded ICP34.5 blocks this shutoff of host protein synthesis (Chou and 
Roizman, 1994) by forming a cytoplasmic complex containing protein phosphatase la 
(PPla) to redirect PPlcx to dephosphorylate eIF-2a (He et al., 1997a, 1998) and thus 
prevent premature shutoff of host protein synthesis induced after the onset of viral DNA 
synthesis (Chou et al., 1995). In cells infected with ICP34.5 null mutants, PKR is 
activated, eIF-2a is phosphorylated and protein synthesis is shutoff (Chou et al., 1995). 
Restoration of ICP34.5 function in both 1622 and 1625 infection was confirmed in vitro 
by the maintenance of host cell and viral protein synthesis in SK-N-SH cells. Thus, 
expression of this gene in 1716 prevents host cell protein synthesis shutoff. However, 
expression of ORF OIP fails to prevent host cell protein synthesis shutoff in 1716. 
Brown et al. (1994a) demonstrated that the growth ofICP34.5 null mutants was impaired 
in mouse embryo fibroblasts (3T6) with the impairment amplified in the stationary state. 
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In 3T6 cells, expression ofICP34.5 restored growth of 1716 to nearly 17+ growth levels. 
In 3T6 cells, the mechanism of lack of growth seems to be different from that in SK-N-
SH cells in that I have demonstrated that lack of ICP34.5 has no effect on host protein 
synthesis in these cells. Brown et al. (1994b) demonstrated that the impairment in growth 
in 3T6 cells was due to a defect in envelopement and egress of virus particles with an 
accumulation of unenvelopped capsids in the nucleus of infected 3T6 cells with little or 
no effect on the behaviour of the virus in BRK cells. 
ICP34.5 seems to confer two functions: growth and maintenance of protein synthesis. 
The relationship between these is not clear. In SK-N-SH cells, these are linked but in 3T6 
cells they are not. The relationship of host shutoff to the in vivo phenotype may be 
complicated (1.15.3). 
ORF P insertion into the viruses has not been conclusively proven and there is no 
evidence of expression at all. Therefore the conclusions made with regard to growth 
curves etc. may be incorrect. 
7.2 Analysis of ORF P interacting proteins 
As mentioned in the previous section of this chapter, ORFOIP overlap and are antisense 
to ICP34.5. As determined by characterisation of mutants in these genes, these two genes 
seem to have little if any role in the HSV lifecycle (this thesis; section 1.16). An 
alternative way to analyse their function is to determine those cellular and viral proteins 
which interact with ORF P and O. This was carried out for ORF P. There are a number of 
methods such as GST pulldown, the yeast two-hybrid system and coimmunoprecipitation 
which can be used to determine protein-protein interactions both in vitro and in vivo. 
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Using GST-ICP27 and GST-ICP34.S, it was previously shown in our laboratory that 
GST pulldown is useful for detennining protein-protein interactions in vitro (Brown et 
al., 1997; Bryant et al., 2000) and thus this method was used in this work to detennine 
the interaction of ORF P with cellular and viral proteins. The principle of the GST 
pulldown assay is shown in Fig.6.6. 
Expression of the GST -ORF P fusion protein where ORF P was cloned as a 3' GST 
fusion protein in a bacterial system had not been previously optimised. Using a number 
of E.coli strains and different temperatures of induction, I attempted to optimize 
expression of both the amount and length of GST-ORF P. 
Firstly, expression of both GST and GST-ORF P was investigated in 3 different E.coli 
strains BL21, C41 and Novablue. BL 21 is the most widely used host backgroud and has 
the advantage of being deficient in both Ion and ompT proteases. BL21 contains a 
plasmid containing the T7 polymerase gene under the Lac I promoter which is induced 
by IPTG to express T7 RNA polymerase. The principle of GST fusion protein expression 
in C41 is the same as that in BL21. However, in C41 the lac repressor binds the LacI 
promoter for the T7 gene tighter and therefore there is less uninduced expression of T7 
polymerase and hence the fusion protein. This promotes plasmid stability if the fusion 
protein is toxic. Novablue does not contain the T7 RNA polymerase gene containing 
plasmid and superinfection with CE6 A. phage containing the T7 RNA polymerase gene is 
required to induce expression of the fusion protein (Studier and Moffat, 1986). This 
system is used when a target gene is so toxic that a plasmid cannot be maintained in a 
DE3 lysogenic host such as BL21 where there will always be minimal recombinant 
protein expression. 
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Expression of OST was similar in all 3 strains although slightly higher in BL2!. 
Expression of GST -ORF P which was initially detected as a truncated 40 KDa doublet 
was only detected in BL21. No expression of GST-ORF P was detected in either C41 or 
Novablue. Thus BL2! was the strain used for future analysis. 
The optimum temperature for expression of GST -ORF P in BL21 was investigated. 
Expression of GST at all three temperatures was similar. However, expression of GST-
ORF P at 31 DC was better than at either RT or 37°C. Thus we decided to use 31°C for 
expression of GST -ORF P in BL21 in subsequent experiments. 
The main problem faced in carrying out the pulldown experiments was the lack of 
expression of full length GST -ORF P fusion protein. This could either be a problem of 
protease degradation or lack of expression of full length protein. This fusion protein like 
many HSV-I proteins does not express as full length in bacterial systems (Brown et al., 
1997; Wadd et al., 1999). As most HSV genes, unlike bacterial genes, consist ofa high G 
+ C content, bacterial cells wilJ not favour expression of these proteins. By repeated 
experiments, we tried to optimise expression and harvesting to obtain full length OST-
ORF P. In the initial experiments, only a 40 KDa GST -ORF P doublet was detected. In 
the final experiments the 40 KDa doublet, a higher molecular weight band of 45 KDa and 
two higher molecular weight bands of 50 and 60 KDa were detected. ORF P in 17+ 
contains 233 amino acids (Lagunoff and Roizman, 1994). As the molecular weight of 
each amino acid is approximately 110 Dalton ORF P is about 28 KDa. As GST is about 
28 KDa, GST -ORF P should theoretically be about a 55-60 KDa protein. Thus the higher 
molecular weight products may correspond to full length GST-ORF P. Our results show 
at the end, some nearly full length GST -ORF P was expressed and this preparation was 
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used for our pulldown assays. Purification of some full length OST -ORF P might be due 
to a number of factors, such as taking greater care during the harvesting procedure, 
obtaining more experience and better skills enabling the experiment to be carried out 
quicker and keeping everything on ice. All these would give proteases less opportunity to 
work. 
In our initial experiments, using the standard conditions for a GST pulldown assay, we 
were not able to recognize any ORF P interacting proteins. This method had previously 
identified a number of cellular proteins interacting with GST-ICP27 (Bryant, 1999) and 
GST-ICP34.S (Brown et al., 1997). As a positive control, a OST-ICP27 pull down was 
carried out with HSV -1 17+ infected cellular proteins. OST ·ICP27 interacted with a 
number of proteins, for example hnRNP and HSV -1 TK, previously shown to interact 
with ICP27 (Bryant, 1999). This result showed that the pulldown procedure was working 
correctly. As with coimmunopercipitations, salt and detergent concentrations in the 
buffers along with target and interacting protein concentrations affect which proteins are 
pulled down. As we had shown that, although the OST pulldown method was working, 
no ORF P interacting proteins could be identified, we attempted to optimise the detection 
of proteins interacting with GST -ORF P by changing the salt concentration of the 
washing buffer. The standard buffer used contained 0.5 mM NaCI and by increasing the 
salt concentration we would increase the stringency of the washing buffer and hopefully 
remove non specific binding proteins leaving specific interacting proteins visible. 
Obviously we would reach a salt concentration where both non specific and specific 
interacting proteins were removed. NaCI concentrations of O.S, S, 50 and 500 mM NaCI 
were used. 
Washing with 0.5 and SmM NaCI containing wash buffer resulted in no specifically 
bound proteins being detected. However, increasing the NaCI to SO mM resulted in 
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binding by a number of specific proteins being detected. These proteins include at least 
two viral proteins with sizes of 27 and 40 KDa and one cellular protein of 47 KDa. 
Although the photograph did not reproduce this well. Increasing the NaCI to 500 mM, 
resulted in these protein interactions being lost. 
As ORF P was cloned as a 3' GST fusion protein and different lengths of GST-ORF P 
fusion protein were expressed, all the fusion proteins will include the aminoterminus but 
be truncated at the carboxyterminus which will thus be underrepresentated. Thus the 
protein identified might interact with the amino terminus of ORF P. 
We then proceeded to try to identify these interacting proteins. There is some previous 
evidence indicating that ORF P interacts with a number of splicing factors and may play 
a role in splicing (Bruni and Roizman, 1996). Thus we chose to look at proteins involved 
in posttranscriptional regulation. It had previously been shown that ICP27 interacts with 
a number of proteins involved in posttranscriptional gene regulation (Bryant et al., 2000). 
Thus it seemed reasonable to investigate whether ORF P interacts with ICP27. A GST-
ORF P pulldown was carried out and Western blotted with an anti-ICP27 antibody. Both 
GST and GST-ORF P interact with ICP27 and its related bands. Despite attempts to 
reduce non specific binding by decreasing the amount of beads, we were unable to do so 
without losing binding to both aST and GST- ICP27. Thus we could not screen for an 
interaction. Non-specific binding could be either because GST binds non-specifically to 
ICP27, or that ICP27 is trapped between the GST beads. Reducing the amount of beads 
trends to rule out the possibility of capture of the protein by GST beads and the second 
idea that ICP27 binds non-specifically to GST is more acceptable. 
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As the GST-ICP27 fusion protein is expressed better than GST-ORF P, the reverse 
experiment was carried out where GST -ICP27 was used to try to pulldown ORF P from 
tsK infected cell extracts and Western blotted with an anti ORF P serum. In initial 
Western blotting, serum 128 cross reacted with the GST-ICP27 related bands as it had 
been raised against a GST fusion protein. Therefore, we had to preadsorb 128 against 
GST to remove the GST specific bands. When this preadsorbed serum was used, no 
specific bands were detected binding to GST-ICP27 or GST-ORF P. This indicated that 
no interaction of ORF P with ICP27 or self interaction was occurring. 
We next screened our GST-ORF P pulldowns with a range of antibodies against proteins 
with a role in posttranscriptional regulation and which were of an approximate molecular 
weight to those previously identified. Western blotting of GST -ORF P pulldowns was 
carried out with 10 available cellular antibodies (table 6.1). Of these, only one recognised 
an identified protein interacting with ORF P. In addition, two unidentified proteins were 
demonstrated to interact specifically with ORF P. 
Using an antibody against CKII (P), an unexpected result was obtained. No specific 
interaction of GST-ORF P with CKII (3) was detected. However, a 45 KDa band was 
detected both in cell extracts and from the GST pulldown, indicating an unidentified 
cellular protein was interacting with ORF P. 
To try to identify the 40 KDa viral band interacting with GST-ORF P, Western blotting 
of pull down extracts was carried out with an antibody against HSV -1 TK, which is about 
40 KDa. Both GST and GST -ORFP interacted with TK. Again the pulldown was carried 
out with decreasing amounts of GST and GST -ORF P and the interaction with TK was 
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lost equally by GST and GST -ORF P indicating no specicfic interaction was occuring. 
However, a 45 KDa cellular band was specifically detected, indicating that an 
unidentified 45 KDa cellular protein which cross reacted with the TK antibody was 
interacting with ORF P. 
The only characterized cellular protein interacting with ORF P detected in these 
experiments was SC35. SC35 is an essential component of small non nuclear 
ribonucleoprotein particles (snRNPs) and is a splicing factor (Sandri-Goldin et al.,1995; 
Zahler et al., 1992). 
Having demonstrated that ORF P interacted in vitro with SC35, we wished to detennine 
if this was representative of an in vivo interaction. For this to occur, it would be expected 
that both proteins would be located in the same cellular compartment. It has been 
previously demonstrated that SC35 localises mainly to the nucleus (Boe et ai., 1998) and 
thus we wished to confinn this and detennine if ORF P was also located in the nucleus. 
To investigate the intracellular location of ORF P and SC35, BHK cells were infected 
with tsK and 17+, their nuclear and cytoplasmic proteins separately extracted and 
Western blotted with antisera against SC35 and ORF P. 
As previously published, SC35 is located in the cell nucleus with no protein being 
detected in the cytoplasm. ORF P is located in approximately equal amounts in both the 
nucleus and cytoplasm of infected BRK cells. This agrees with the finding of Lagunoff et 
ai. (1995) who detected ORF P in the nucleus of cells infected with a mutant which 
overproduced ORF P by using immunofluorescence and Western blotting of fractionated 
cell extracts. 
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Having demonstrated that ORF P interacted in vitro with SC35 and that both SC35 and 
ORF P are located in the nucleus, we investigated if ORF P interacts with SC35 in vivo 
by carrying out an immunoprecipitation of BHK cell extracts infected with tsK and 17+. 
Immunoprecipitation was carried out separately with antibodies against both SC35 and 
ORF P and coimmunoprecipitation of the other protein analysed by Western blotting. 
Initially, samples were immunoprecipitated with the ORF P antiserum and Western 
blotted with anti-ORF P which confirmed succesful immunoprecipitation of ORF P from 
tsK but not from 17+ infected BRK cell extracts. To investigate coimmunoprecipitation 
of SC35 by ORF P, Western blotting of ORF P immunoprecipitated samples was carried 
out with the SC35 antibody. SC35 was coimmunoprecipitated by the ORF P antisera 
non-specifically as it was detected when both ORF P was present (tsKlI7+) and absent 
(1716/mock infected). To try to remove these non specific bands and determine if there 
was also specific coimmunoprecipitation of SC35 by ORF P, the immunoprecipitated 
samples were washed with high salt. However, no difference was seen. To further 
increase the stringency to attempt to remove non specific bands, SDS was added to the 
buffers. However, the presence of SDS prevented the immunoprecipitation of ORF P by 
the anti-ORF P serum and we could not look for coimmunoprecipitation ofSC35. 
We then proceeded to carry out the reverse experiment by immmunoprecipitating SC35 
and looking for coimmunoprecipitation of ORF P. However, we were unable to 
immunoprecipitate SC35 under a number of conditions. As we were unable to precipitate 
SC35, it was not possible to determine ifSC35 coimmunoprecipitated ORF P. 
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Antisera 128 and 129 do not work in immunofluorescence due to their high background 
(MacLean, A, personal communication) and thus we did not try to investigate 
colocalization ofORF P and SC35 by immunofluorescecne. 
Overall, these results show that ORF P interacts with SC35 in vitro and also both are in 
the nucleus of infected cells. However, due to technical difficulties we were unable to 
detennine if an in vivo interaction was occurring. This data is in agreement with 
previously published work. Previous workers using immunofluorescense had 
demonstrated that ORF P colocalises with SM antigens and with SC35 in the nuclei of 
infected cells, interacts with SM components in a GST pulldown assay and interacts with 
p32 by in a yeast-two-hybrid system (Brunei and Roizman, 1996). 
Conclusively, the work in this project in addition to confinnation (previously shown) that 
17+ expresses ORF P in productive infection showed that i); if the recombinants express 
ORF P, this protein seems to have no role in the HSV -1 17+ replication in vitro; ii) SK-
N-SH cells are semi pennissive (rather than non pennissive) for 1716; iii) over 
expression of ICP34.5 protein might have deleterious effect on growth of 17+; iv) 
expression of ORF P in a GST fusion protein is optimized and an ORF P protein ranging 
of 40-60 KDa was detected; v) ORF P interacts with at least two viral and one cellular 
protein. 
7.3 Methods for analysis of protein-protein interactions 
To investigate if any cellular or viral proteins interact with ORF P in vitro, a GST 
pulldown assay was carried out. In this method, the fusion protein is expressed and 
purified by binding to glutathione which is attached to agarose (Smith and Johnson, 
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1988). After the fusion protein is bound to the matrix, it is washed with buffer to remove 
nonspecifically bound bacterial proteins and subsequently mixed with cellular extracts. 
The fusion protein containing beads serve as an affinity matrix to allow binding of 
proteins which interact with the protein fused to GST. Beads are washed again to remove 
nonspecific ally bound cellular proteins and proteins analysed by SDS-PAGE. Non 
specific proteins are eliminated as they also bind to a GST control. Bound proteins can be 
partially purified by a simple centrifugation step, hence the name "pulldown" assay. An 
overview of this method can be seen in Fig.5.6. A disadvantage of this method is that 
interacting proteins are not identified directly and the GST pull downs need to be 
screened by Western blotting to identify the protein or proteins eluted from the gel and 
sequenced. Using this method, a number of ORF P interacting proteins were detected. 
However we were able to identify only one of these proteins by Western blotting. 
An alternative method to identify interacting proteins is the yeast two-hybrid system. 
This method exploits the ability of a pair of interacting proteins to bring the activation 
domain (AD) of a transcription factor in close proximity with the DNA-binding domain 
(BD) of the same transcription factor which can bind to a cis-acting regulatory element 
and thus stimulate the expression of adjacent reporter genes, LacZ and HIS3 (reviewed in 
Mendelsohn and Brent, 1999). In this system two different cloning vectors are used to 
generate fusions of the AD and the genes encoding the target proteins to construct a 
library and the BD and the gene encoding the protein used to screen the library. The 
hybrid proteins are coexpressed in a strain of yeast that lacks the HIS3, TRPl, LEU2 and 
LacZ genes. Since the cloning vector that encodes the activation domain/target protein 
also carries the TRPI gene and the vector that encodes the DNA-binding domainlbait 
protein encodes the LEU2 gene, yeast colonies containing two plasmids encoding 
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interacting proteins can be selected for by culture on a medium lacking tryptophan, 
leucine and histidine. An assay for fJ-galactosidase activity confinns that colonies 
contain two interacting proteins. 
The two-hybrid system is a very sensitive method for detecting protein-protein 
interactions and can detect binding that is often beyond the limits of other detection 
methods such as immunoprecipitation. As the two-hybrid system is perfonned in vivo, 
conditions are similar to those in which protein interactions nonnally occur. A major 
advantage is that as positive plasmids are identified, a portion of the gene encoding the 
interacting protein is immediately available for sequencing and the identity of interacting 
proteins can be detennined very quickly. Purified target protein or antibody against the 
protein is not required for this system. However, the high sensitivity of the two-hybrid 
system can create a large number of false positives, especially if the bait protein encodes 
a transcriptional activator. Also, some hybrid proteins may not be stably expressed in 
yeast cells (Estojak et al., 1995). 
Coimmunoprecipitation has been used to investigate protein:protein interactions in vivo 
and for example the interaction of the HSV -1 glycoproteins gH and gL was discovered 
by this method (Hutchinson et al., 1992). Due to their high specificity, antibodies may be 
used to isolate specifically interacting proteins from a complex such as cell lysates. 
Identification of the immunoprecipitated protein and proteins which 
coimmunoprecipitate with it can be achieved by separation of the complex on a SDS-
PAGE gel, followed by detection of radio labelled proteins by autoradiography or non-
labelled proteins by Western blotting. However, there are a number of limitations. An 
antibody may mask an interaction site or a protein:protein interaction may mask the 
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antibody binding site. Thus polyclonal antisera are better than monoclonal antibodies, 
although in general the latter give a cleaner result with low background. Salt and 
detergent concentrations in the buffer used to immunoprecipitate and wash the 
antibody:antigen complex will effect the ability of the proteins to maintain their 
interaction and this may affect the stringency of the immunoprecipitation. 
Another method used to identify co localization of two proteins in the same cellular 
compartment is confocal microscopy. Here antibodies labeled with different fluors for 
example, fluorescene and rhodamine are directed against the two proteins whose 
interaction is being analysed allowing the location of both proteins and hence potential 
colocalization to be examined (Lagunoff and Roiman, 1995). These latter two methods 
are more useful for confirming suspected interactions. 
7.4 Future work 
To further analysis the recombinant viruses generated in this thesis, in vivo 
characterization in terms of LDso and establishment/reactivation from latency should be 
carried out. This would allow investigation into the possible roles of both ICP34.5 and 
ORF P in HSV -1 latency and virulence. 
To further investigate the role of ORF 0 and P, new recombinant viruses expressing 
either ORF 0 and ORF P separately should be constructed and characterized both in vitro 
and in vivo. Monoclonal antibodies raised against both ORF 0 and ORF P proteins 
should be used to detect expression of these two proteins from the recombinants (see 
below). 
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To determine which region of ORF P is involved in the interactions identified, 3 GST 
fusion proteins which express the aminoterminus, carboxyterminus and middle region of 
ORF P should be constructed and used in GST pulldwns. To identify further interacting 
proteins, a yeast-two-hybrid screen should be carried out with both intact and truncated 
versions ofORF P. 
ORF 0 and ORF P are overlapping genes. The GST ORF P fusion protein used in this 
thesis, did not allow investigation into possible interactions of ORF 0 with both cellular 
and viral proteins. Thus either a GST -ORF 0 fusion protein which expresses only ORF 
o should be used in the GST pulldown assay or alternatively ORF 0 should be used in a 
yeast-2-hybrid screen. It would be good idea to compare both the ORF 0 and ORF P 
interacting proteins. 
The antisera used in this study, 128 and 129, were rabbit polyclonal sera raised against a 
GST -ORF P fusion protein. Use of GST fusion proteins tends to generate rabbit 
polyclonal sera with high background. If monoclonal antibodies were raised against ORF 
P these higher specific antibodies might produce less background on Western blots 
allowing detection of low levels of ORF P. Similarly monoclonal antibodies against an 
ORF 0 fusion protein could be raised. 
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